Cancer in Australia: an overview 2014 by unknown
Australasian Association 
of Cancer Registries
in AustrAliA an overview 2014
CA
n
Cer in
 Au
strA
liA
 an overview
 2014
A
IH
W
Cancer in Australia: an overview 2014 presents the latest 
available information on national population screening 
programs, cancer incidence, hospitalisations, survival, 
prevalence and mortality. It is estimated that the most 
commonly diagnosed cancers in 2014 will be prostate 
cancer, colorectal cancer and breast cancer (excluding basal 
and squamous cell carcinoma of the skin, as these cancers 
are not notifiable diseases in Australia). For all cancers 
combined, the incidence rate is expected to increase by 
22% from 1982 to 2014, but the mortality rate is estimated 
to decrease by 20%. Cancer survival has improved over 
time. Cancer outcomes differ by Aboriginal and Torres Strait 
Islander status and remoteness area.
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Summary 
Cancer in Australia: an overview 2014 was prepared by the Australian Institute of Health and 
Welfare with support from state and territory members of the Australasian Association of 
Cancer Registries. It provides comprehensive national information and statistics on cancer, 
including the latest available data and projections, as well as trends over time. Information 
by Aboriginal and Torres Strait Islander status, state and territory, remoteness area, life 
stages and socioeconomic disadvantage are also presented. 
Cancer is a major cause of illness in Australia 
In 2014, it is estimated that 123,920 Australians will be diagnosed with cancer (excluding 
basal and squamous cell carcinoma of the skin, as these cancers are not notifiable diseases in 
Australia). More than half (55%) of the cancer cases diagnosed in Australia are expected to be 
for males. The most commonly reported cancers in 2014 are expected to be prostate cancer, 
followed by colorectal (bowel) cancer, breast cancer in females, melanoma of the skin, and 
lung cancer. 
Between 1982 and 2014, the number of new cancer cases diagnosed more than doubled—
from 47,417 to 123,920. This increase can be largely attributed to the rise in the incidence of 
prostate cancer, colorectal cancer, breast cancer in females and lung cancer. The increase can 
also be partly explained by the ageing and increasing size of the population, improved 
diagnoses through population health screening programs, and improvements in 
technologies and techniques used to identify and diagnose cancer. 
Mortality rate due to cancer has fallen  
In 2014, it is estimated that nearly 45,780 Australians will die from cancer. Cancer accounted 
for about 3 in 10 deaths in Australia. For all cancers combined, the age-standardised 
mortality rate is estimated to decrease by 20%, from 209 per 100,000 in 1982 to 168 per 
100,000 in 2014. 
Survival improved over time, but not consistent across all cancers 
Five-year survival from all cancers combined increased from 46% in 1982–1986 to 67% in 
2007–2011. The cancers with the largest survival gains over this time were prostate cancer, 
kidney cancer and non-Hodgkin lymphoma. 
People living in Australia who were diagnosed with cancer generally had better survival 
prospects compared with people living in other countries and regions who were diagnosed 
with cancer. 
Cancer outcomes differ across population groups 
Cancer outcomes differ by Aboriginal and Torres Strait Islander status and remoteness area. 
In 2008–2012, for all cancers combined, Indigenous Australians experienced higher mortality 
rates than non-Indigenous Australians. In 2005–2009, incidence rates were highest for those 
living in Inner regional areas of Australia; in 2008–2012, mortality rates were highest for those 
living in Very remote areas. 
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Data at a glance 
Estimated incidence of cancer in 2014 
Table 1: Estimated 20 most commonly diagnosed cancers, Australia, 2014(a) 
Males  Females 
Site/type (ICD-10 codes) Cases ASR(b)  Site/type (ICD-10 codes) Cases ASR(b) 
Prostate (C61) 17,050  128.7  Breast (C50) 15,270  114.5 
Colorectal (C18–C20) 9,290  73.9  Colorectal (C18–C20) 7,340  51.5 
Melanoma of the skin (C43) 7,440  59.7  Melanoma of the skin (C43) 5,210  39.4 
Lung (C33–C34) 6,860  54.8  Lung (C33–C34) 4,720  33.2 
Head and neck (C00–C14,  
C30–C32) 3,260  25.9  
Uterus (C54–C55) 2,490  17.9 
Lymphoma (C81–C85) 3,110  25.2  Lymphoma (C81–C85) 2,430  17.9 
Leukaemia (C91–C95) 2,110  17.0  Thyroid (C73) 1,890  15.4 
Bladder (C67) 2,060  16.7  Leukaemia (C91–C95) 1,440  10.4 
Kidney (C64) 2,000  15.9  Ovary (C56) 1,430  10.5 
Pancreas (C25) 1,530  12.2  Pancreas (C25) 1,410  9.7 
Stomach (C16)  1,460  11.7  Unknown primary site (C80)  1,210  7.8 
Unknown primary site (C80)  1,430  11.7 
 
Head and neck (C00–C14,  
C30–C32)  1,160  8.4 
Liver (C22)  1,260  10.1  Kidney (C64)  1,060  7.8 
Oesophagus (C15)  1,070  8.5  Cervix (C53)  865  7.0 
Brain (C71)  1,060  8.6  Stomach (C16)  785  5.4 
Myeloma (C90)  975  7.8  Brain (C71)  740  5.6 
Myelodysplastic syndromes (D46)  910  7.5  Myeloma (C90)  700  4.9 
Testis (C62)  770  6.7  Bladder (C67)  675  4.5 
Mesothelioma (C45)  640  5.1  Myelodysplastic syndromes (D46)  490  3.3 
Thyroid (C73)  630  5.2  Oesophagus (C15)  455  3.1 
All cancers combined(c) 68,260 540.4  All cancers combined(c) 55,660 406.2 
(a) The 2014 estimates are based on 2002–2011 incidence data (see Appendix G). The estimates are rounded to the nearest 10. Estimates 
less than 1,000 are rounded to the nearest 5. 
(b) The rates were standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population. 
(c) Includes cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate a basal or squamous 
cell carcinoma of the skin. 
Source: AIHW Australian Cancer Database 2011. 
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Estimated mortality from cancer in 2014 
Table 2: Estimated 20 most common causes of death from cancers, Australia, 2014(a) 
Males  Females 
Site/type (ICD-10 codes) Deaths ASR(b)  Site/type (ICD-10 codes) Deaths ASR(b) 
Lung (C33–C34) 5,150 41.5  Lung (C33–C34)  3,480 24.1 
Prostate (C61) 3,390 28.2  Breast (C50) 3,000 20.9 
Colorectal (C18–C20) 2,210 17.9  Colorectal (C18–C20) 1,910 12.6 
Pancreas (C25) 1,360 10.9  Pancreas (C25) 1,280 8.6 
Unknown primary site (C80) 1,160 9.4  Unknown primary site (C80) 1,180 7.6 
Melanoma of the skin (C43) 1,120 9.1  Ovary (C56) 1,000 6.9 
Liver (C22) 1,080 8.7  Leukaemia (C91–C95) 695 4.6 
Leukaemia (C91–C95) 1,040 8.5  Other digestive organs (C26) 680 4.3 
Oesophagus (C15) 975 7.7  Lymphoma (C81–C85) 640 4.2 
Lymphoma (C81–C85) 855 7.0  Brain (C71) 540 4.0 
Brain (C71)  790  6.3  Liver (C22)  535  3.7 
Bladder (C67)  780  6.5  Melanoma of the skin (C43)  505  3.5 
Other digestive organs (C26)  740  6.0  Stomach (C16)  415  2.8 
Stomach (C16)  700  5.7  Uterus (C54–C55)  405  2.8 
Kidney (C64)  625  5.0  Myeloma (C90)  405  2.7 
Mesothelioma (C45)  575  4.7  Oesophagus (C15)  380  2.5 
Myeloma (C90)  535  4.3  Kidney (C64)  355  2.4 
Multiple primary cancers (C97)  415  3.4  Bladder (C67)  335  2.1 
Non-Melanoma skin cancer (C44)  345  2.8  Cervix (C53)  245  1.8 
Myelodysplastic syndromes (D46)  275  2.3  Multiple primary cancers (C97) 230 1.5 
All cancers combined(c) 26,010 211.5  All cancers combined(c) 19,770 133.7 
(a) The 2014 estimates are based on 2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 
1,000 are rounded to the nearest 5. 
(b) The rates were standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population. 
(c) Includes cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Source: AIHW National Mortality Database. 
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1 Introduction 
Cancer is a major cause of illness in Australia and has a substantial social and economic 
impact on individuals, families and the community. In 2014, it is estimated that 123,920 
people will be diagnosed with cancer and 45,780 people will die from cancer. Findings from 
recent global burden of disease studies (World Health Organization [WHO] Global Health 
Estimates [GHE] 2012 and Global Burden of Diseases [GBD] 2010) show that cancer 
contributed between 16% and 19% of the total disease burden in Australia (The Lancet 2012; 
WHO 2014). In 2008–09, it was estimated that the total health system expenditure in 
Australia on cancer and non-cancerous tumours (neoplasms) was $4,526 million  
(AIHW 2013b). 
Box 1.1: Defining cancer 
Cancer, also called malignancy, is a term used for diseases in which abnormal cells divide 
without control and can invade nearby tissues. Cancer cells can also spread to other parts of 
the body through the blood and lymph systems. There are several main types of cancer: 
Carcinoma—is a cancer that begins in the skin or in tissues that line or cover internal organs 
Sarcoma—is a cancer that begins in bone, cartilage, fat, muscle, blood vessels or other 
connective or supportive tissue 
Leukaemia—is a cancer that starts in blood-forming tissue, such as the bone marrow, and 
causes large numbers of abnormal blood cells to be produced and enter the blood 
Lymphoma and multiple myeloma—are cancers that begin in the cells of the immune 
system  
Central nervous system cancers—are cancers that begin in the tissues of the brain and 
spinal cord. 
Source: National Cancer Institute 2014. 
Purpose and structure of this report 
Cancer in Australia: an overview 2014 is the seventeenth in a series and provides a 
comprehensive overview of national statistics on cancer (see Box 1.1 for a list of terminology 
in this report). The report presents estimates for 2014 for all cancers combined, as well as for 
individual cancer sites/types (location of the body in which the cancer began). Estimates for 
2014 provide the most up-to-date and current statistics and information possible. Actual 
cancer incidence data are presented for the period 1982–2011—except for New South Wales 
and the Australian Capital Territory, where data were available to 2009 and estimated for 
2010 and 2011. Further information on data availability is in the Data sources section  
(page 3) and at Appendix I. 
Information and statistics are presented on national population screening programs, cancer 
incidence, hospitalisations, survival, prevalence and mortality. The report is targeted at a 
wide audience, including health professionals, policy makers, health planners, educators, 
researchers, consumers and the general public. 
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The report is structured according to the general chronological ‘journey through the health 
system’ of people diagnosed with cancer. It is acknowledged, however, that this 
chronological order can vary widely for individuals diagnosed with cancer. 
Box 1.2 Breast cancer in females 
Both males and females can develop breast cancer. However, the proportion of females who 
develop breast cancer is much greater than the proportion of males who do so. To present 
the proportion across the entire population (males and females) would not accurately reflect 
the burden of breast cancer in females. For this reason, breast cancer data presented in this 
report refers to breast cancer in females, unless otherwise stated. 
Supplementary data for each chapter are available as online Excel tables at 
<www.aihw.gov.au>. Throughout the report, these online tables are referred to with the 
prefix ‘D’; for example, see online Table D2.1. 
Data interpretation 
A number of different classifications are referred to in this report, such as the International 
Statistical Classification of Disease and Related Health Problems (ICD) and the International 
Classification of Disease for Oncology (ICD-O). Information about these classifications is at 
Appendix E. 
The report includes information on the number of cancer cases and deaths, as well as age-
specific and age-standardised rates (ASRs). 
Age-specific rates  
Age-specific rates provide information on the incidence of a particular event in an age group 
relative to the total number of people at risk of that event in the same age group (see 
Appendix H for further information on age-specific rates). 
Age-standardised rates 
The use of ASRs is important when making comparisons between and within groups over 
time in order to take account of differences in the age structure and size of the population. 
This is especially important for cancer, since the risk of many cancers increases with age. 
Rates have been standardised to the Australian population as at 30 June 2001 and are 
generally expressed per 100,000 population (see Appendix H for further information on  
age-standardisation). 
International comparisons 
International comparisons are provided for cancer incidence, mortality and survival. Take 
care when comparing cancer data from different countries as observed differences may be 
influenced not only by the underlying number of cancer cases (or number of cancer deaths 
when considering mortality data), but by differences in age distribution and composition of 
populations, cancer detection and screening, types of treatment provided and access to 
treatment services, characteristics of the cancer (such as stage at diagnosis and histology 
type), coding practices and cancer registration methods, as well as the accuracy and 
completeness of recording of cancer cases. 
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Care must be exercised when interpreting differences in rates based on small counts and/or 
population groups as such rates may be volatile.   
Data sources 
The primary data sets used to produce this report are the Australian Cancer Database (ACD) 
and the National Mortality Database (NMD). 
Australian Cancer Database 
The ACD contains information on all new cases of primary invasive cancer (excluding basal 
cell and squamous cell carcinoma of the skin) diagnosed in Australia since 1982. Data are 
collected by state and territory cancer registries from a number of sources and are supplied 
annually to the Australian Institute of Health and Welfare (AIHW). The AIHW is responsible 
for compiling the ACD through the National Cancer Statistics Clearing House—a 
collaboration with the Australasian Association of Cancer Registries. The ACD includes 
actual data for the period 1982–2011—except for New South Wales and the Australian 
Capital Territory, where data were available to 2009 and estimated for 2010 and 2011 (see 
Appendix F). 
National Mortality Database 
The NMD is a national collection of information for all deaths in Australia from 1968 to 2012 
and is maintained by the AIHW. Information on the characteristics and causes of death of the 
deceased is provided by the Registrars of Births, Deaths and Marriages and coded nationally 
by the Australian Bureau of Statistics (ABS). 
In the NMD, both the year of occurrence of the death and the year in which the death was 
registered are provided. In this report, actual mortality data are shown based on the year of 
occurrence of the death, except for the most recent year (namely 2012) where the number of 
people whose death was registered is used. Previous investigation has shown that, due to a 
lag in processing of deaths, year of death information for the latest available year generally 
underestimates the true number of deaths, whereas the number of deaths registered in that 
year is closer to the true value. Note that deaths registered in 2010 and earlier are based on 
the final version of cause of death data; deaths registered in 2011 and 2012 are based on 
revised and preliminary versions, respectively, and are subject to further revision by the 
ABS. 
Several other data sources—including the National Death Index (NDI), the National Hospital 
Morbidity Database (NHMD) and the 2012 GLOBOCAN database—have also been used to 
present a broad picture of cancer statistics in Australia. 
Additional information about each of the data sources used in this report is at Appendix I. 
What is missing from the picture? 
Detailed reliable data are not available on many aspects of cancer, so have not been included 
in this report. Reasons include difficulty in collecting some data and the associated resource 
implications. 
 4 Cancer in Australia: an overview 2014 
Staging data 
Cancer stage at diagnosis refers to the extent or spread of cancer at the time of diagnosis. The 
stage at cancer diagnosis and subsequent treatment outcomes are important determinants of 
cancer survival. They can also reflect the extent to which improvements in survival are a 
result of earlier detection or better treatment. 
Although some cancer registries collect information on the stage of cancer at diagnosis, these 
data are not currently collected nationally. Further, no information is available on the 
treatments applied to cancers, complications with cancer treatment, or the frequency of 
recurrence of cancer after treatment. However, there are comprehensive national data on 
treatments provided through admitted patient hospitalisations—for example, surgery and 
non-surgical care. 
Work is currently underway to enable the collection of national cancer staging data. 
Primary health-care information 
The primary health-care sector in Australia includes a wide range of professionals, such as 
general practitioners, pharmacists, ambulance officers, many different types of allied health 
professionals, community health workers, practice nurses, midwives, Aboriginal health 
workers and dentists, just to name a few. 
The Australian health system collects vast amounts of clinical and administrative data that 
can yield valuable information that is useful for health policy development and evaluation. 
These data can also lead to enhanced clinical care and subsequently health outcomes through 
evidence-based practice, and to safety and quality monitoring (O’Keefe & Connolly 2010). 
These data are often collected by individual clinicians for the purpose of recording the 
encounter with the patient; however, they are often not collected in a standardised format. 
In effect, there is very little information publicly available on why an individual attended a 
primary health-care professional, what intervention the health professional provided to the 
individual, or the outcome of the visit. This situation causes inefficiencies for those reporting 
and collecting data. It also severely hampers evidence-based decision making and limits the 
self-improving capacity of the health system. 
For more information on primary health care in Australia, see the feature article in Australia’s 
health 2014 at <http://www.aihw.gov.au/publication-detail/?id=60129547205>. 
Burden of disease due to cancer 
To ensure that a health system is aligned to a country’s health challenges, policy makers 
must be able to compare the effects of different conditions that cause ill-health and 
premature death. Burden of disease analysis simultaneously compares the non-fatal burden 
(impact of ill-health) and fatal burden (impact of premature death) of a comprehensive list of 
diseases and injuries. This list, which includes cancers, quantifies the contribution of various 
risk factors to the total burden as well as to individual diseases and injuries. 
The most recent global estimates come from the GBD 2010 and the WHO GHE for 2000–2012. 
The GBD 2010 covered 241 diseases and injuries and 57 risk factors for 187 countries for 1990, 
2005 and 2010 (The Lancet 2012). The WHO GHE for 2000–2012 (WHO 2014) draw on many 
aspects of GBD 2010, but with different data and methods for some components (WHO 
2013). 
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The last Australian national burden of disease report was published in 2007, based on 2003 
data. The AIHW is updating these estimates using the GBD 2010 methodology where 
possible, with some enhancements to better suit the Australian contexts, and using more 
recent and detailed Australian data. The revised estimates are expected to be finalised in 
2015. 
Non-hospital palliative care 
This report does not cover palliative care provided in settings other than in admitted patient 
care. The importance of having a comprehensive national data collection on community-
based palliative care services is well recognised (AIHW 2004), but such a collection does not 
currently exist. Thus, the data in this report describe a subset of all palliative care services 
delivered in Australia. The relative balance between providing palliative care services in the 
admitted patient setting and in other settings is unknown, and is likely to vary across the 
jurisdictions. However, available data suggest that a substantial proportion of palliative care 
provided in Australia occurs within the admitted patient setting (PCOC 2010). 
Health system expenditure on cancer 
The most recent data on health system expenditure on cancer are for 2008–09. The AIHW is 
currently updating disease expenditure estimates to better reflect the current health system 
environment. 
For more information on health system expenditure on cancer in Australia, see Health system 
expenditure on cancer and other neoplasms in Australia 2008–09 at 
<http://www.aihw.gov.au/publication-detail/?id=60129545611>. 
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2 Risk factors, early detection and 
prevention 
Known risk factors for cancer 
A risk factor is any factor associated with an increased likelihood of a person developing a 
health disorder or health condition, such as cancer. Understanding what causes cancer is 
essential in setting processes and policies designed to successfully prevent, detect and treat 
the disease. For most cancers the causes are not fully understood. However, some factors 
that place individuals at a greater risk for cancer are well recognised and are outlined below. 
These risk factors were sourced from World cancer report 2014 (IARC 2014) and Food, nutrition, 
physical activity and the prevention of cancer: a global perspective (WCRF & AICR 2007). 
There has been increasing interest in the life course approach to reducing the incidence of 
chronic diseases, such as cancer. Studies suggest that exposure to risks during childhood, 
adolescence and early adult life influence the risk of adult incidence and mortality due to 
chronic disease (Uauy & Solomons 2005). Preventing death from cancer has often focused on 
early detection and treatment rather than on modifying long-term behaviour and exposure 
to risk factors. 
It should be noted that exposure to a risk factor does not mean that a person will develop 
cancer. Many people are exposed to at least one cancer risk factor but will never get cancer. 
 
Smoking/passive smoking, and smokeless tobacco use 
Smoking is the major cause of cancer in humans. Evidence suggests that 
active and, for some cases, passive smoking can cause cancers of the: 
• bladder  
• bone marrow (myeloid 
leukaemia) 
• cervix 
• kidney 
• larynx 
• liver 
• lung  
• nasal cavity and nasal sinuses 
• oral cavity (lip, mouth, tongue) 
• oesophagus 
• pancreas 
• pharynx 
• stomach. 
 
 
Alcohol consumption 
Alcohol consumption is an important risk factor for cancer. The risk of 
cancer increases with the amount of alcohol consumed. Cancers 
associated with alcohol consumption include those of the: 
• breast (females) 
• colon and rectum 
• larynx 
• liver 
• oesophagus 
• oral cavity (lip, mouth, tongue) 
• pharynx. 
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Diet 
Evidence suggests that high intake of particular foods (such as 
processed meat, and foods that are high in fat) may be associated with 
an increased risk of cancers of the: 
• breast 
• colon and rectum 
• kidney 
• oesophagus 
• pancreas 
• prostate 
• stomach  
• uterus. 
 
 
Obesity and physical inactivity 
Obesity is defined as abnormal or excessive fat accumulations that may 
impair health, and a body mass index of 30 and over. 
Physical activity is an important part of a healthy lifestyle. Doing little 
or no physical activity increases an individual’s risk of being 
overweight or obese, and is associated with a higher risk of developing 
cancer. Obesity and lack of physical activity increase the risk of cancers 
of the: 
• breast (females) 
• colon and rectum 
• endometrium 
• gallbladder 
• kidney 
• oesophagus 
• ovary 
• pancreas. 
 
 
Chronic infections 
Cancer associated with chronic infections (such as viruses, bacteria and 
parasites) include those of the: 
• bladder 
• blood or bone marrow 
(leukaemias) 
• cervix 
• gallbladder 
• liver 
• lung 
• lymphatic system (lymphomas) 
• nasopharynx and oropharynx 
• oral cavity (lip, month, tongue) 
• stomach. 
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Family history and genetic susceptibility 
Some gene mutations increase the risk of cancer being passed from 
parent to child. Genetic inheritance increases the risk of cancers of the: 
• bladder 
• blood or bone marrow 
(leukaemias) 
• breast 
• colon and rectum 
• gallbladder 
• ovary 
• pancreas 
• prostate 
• testis 
• thyroid. 
 
 
Occupational exposures 
Occupational exposures include exposures to chemicals, dust, radiation 
and industrial processes. Cancers that have been found to be caused by 
occupational exposures include those of the: 
• bladder 
• blood or bone marrow 
(leukaemias) 
• kidney 
• liver 
• lung 
• lymphatic system 
(lymphomas) 
• mesothelium 
• nasal cavity 
• nasopharynx 
• non-melanoma of the skin 
• oesophagus 
• oral cavity (lip, mouth, tongue) 
• pharynx 
• stomach. 
 
 
Sunlight 
Excessive exposure to the ultraviolet rays of the sun is a risk factor for 
some cancers. The risk of cancer due to excessive exposure to sunlight is 
highest for people who have fair skin, blond or red hair, freckles, 
and/or a tendency to burn easily. Sunlight is a risk factor for: 
• melanoma of the skin 
• non-melanoma skin cancer. 
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Radiation 
Ionising radiation from natural sources, from nuclear accidents and 
explosions, and from diagnostic X-rays can be risk factors for cancer. 
The most common source of radiation for the average person is 
diagnostic X-rays; however, the risk of developing a cancer after an  
X-ray is minimal and the benefits nearly always outweigh the risk. 
Ionising radiation can increase the risk of cancers of the:  
• blood or bone marrow 
(leukaemias) 
• breast 
• lung 
• thyroid. 
 
 
Medical and iatrogenic factors 
Medical and iatrogenic factors relate to the inadvertent adverse effect 
of, or complication resulting from, medical treatment or advice. For 
example, drugs or treatment used for one disease can potentially lead to 
the development of a secondary condition. Cancers relating to medical 
and iatrogenic factors include those of the: 
• bladder 
• colon and rectum 
• kidney 
• liver 
• lung 
• mesothelium 
• oesophagus 
• pancreas. 
 
 
Reproductive and hormonal factors 
Reproductive hormones are thought to influence the risk of developing 
some cancers. For women, the risk can be related to reproductive 
history, endogenous and exogenous hormone exposures and 
child-bearing. Cancers associated with reproductive and hormonal 
factors include those of the: 
• breast 
• endometrium 
• ovary 
• testis. 
 
 
Environmental pollution 
There are many pollutants in the environment that may cause cancer. 
People are exposed to these pollutants through the air, drinking water, 
food, soil, sediments, surface waters and groundwater. Pollution can 
contribute to cancers of the: 
• bladder 
• kidney 
• liver 
• lung 
• skin 
• stomach. 
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Early detection through organised population 
screening 
Population-based cancer screening is an organised, systematic and integrated process of 
testing for signs of cancer or pre-cancerous conditions in asymptomatic populations. In 
Australia, there are three national population-based screening programs: for breast, cervical 
and bowel cancers. The three programs—BreastScreen Australia, the National Cervical 
Screening Program and the National Bowel Cancer Screening Program—are run through 
partnerships between the Australian Government and state and territory governments. 
These programs aim to reduce illness and death from these cancers through early detection 
of cancer and pre-cancerous abnormalities and through effective follow-up treatment. 
The programs target specific populations and age groups where evidence shows screening is 
most effective at reducing cancer-related morbidity and mortality. 
BreastScreen Australia 
BreastScreen Australia, established in 1991, led to a rapid increase in the number of breast 
cancers diagnosed in women. This was due largely to increased detection of breast cancers 
that were too small to be felt. Screening led to increases in the incidence rate as a result of 
these cancers being diagnosed earlier than they would have been had they continued to 
grow until symptoms developed. The mortality rate for breast cancer decreased after 
BreastScreen Australia was introduced as detection of breast cancer at an earlier stage—
when the tumour is often smaller—is associated with increased treatment options and 
improved treatment outcomes (AIHW 2013a). Additional mortality reductions are attributed 
to independent treatment advances, including the advent of new systemic therapies. 
The program provides free 2-yearly screening mammograms to women aged 40 and over, 
and actively invites women aged 50–69 to participate. 
Key statistics 
• In the 2-year period 2011–2012, more than 1.4 million women aged 50–69 had a screening 
mammogram—a participation rate of 55%. Participation rates were highest for women 
aged 60–64 (60%) and lowest for those aged 50–54 (49%). 
• Participation rates were lower among: 
– Aboriginal and Torres Strait Islander women (38%) than non-Indigenous women 
(54%) 
– women living in Very remote areas (46%) than women living in other regions 
– women who reported speaking a language other than English at home (50%) than 
women who spoke English at home (55%). 
• The ASR of participation for women aged 50–69 was 52% in 1996–1997 when reporting 
began. This increased to a peak of 57% in 2001–2002 and thereafter remained steady at 
55–57%, although the total number of women participating in screening increased 
(Figure 2.1). 
• In 2012, there were 104 invasive breast cancers and 23 ductal carcinomas in situ detected 
for every 10,000 women screened for the first time. The detection rate was lower among 
women attending a subsequent screening, with 44 invasive breast cancers and 11 DCISs 
per 10,000. 
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Notes:  
1. The ASR is the number of women aged 50–69 screened in each reporting period as a percentage of the ABS estimated resident population 
for women aged 50–69, and age-standardised to the Australian population as at 30 June 2001. 
2. Data for this figure are in online Table D2.1. 
Source: AIHW analysis of BreastScreen Australia data. 
Figure 2.1: Participation number and age-standardised participation rate, BreastScreen Australia, 
Australia, 1996–1997 to 2011–2012 
National Cervical Screening Program 
The National Cervical Screening Program was established in 1991. It has led to falls in both 
cervical cancer incidence and mortality due to its ability to detect pre-cancerous 
abnormalities that may, if left, progress to cancer. With opportunistic cervical screening 
occurring in Australia since 1960, falls in incidence and mortality of cervical cancer were also 
evident before this program was introduced (in 1991). 
The program targets women aged 20–69 for a 2-yearly Papanicolau (Pap) smear, or ‘Pap test’. 
Key statistics 
• In the 2-year period 2011–2012, more than 3.7 million women aged 20–69 had a screening 
Pap test—a participation rate of 58% of women in the target population. Participation 
was highest for women aged 45–49 (64%) and lowest for those aged 20–24 (43%). 
• Participation was lower among women living in Very remote areas than in other regions, 
and rose with increasing socioeconomic status—from 52% in areas of lowest 
socioeconomic status to 64% in areas of highest status. 
• The participation rate was 58% in 2011–2012. This has remained relatively stable over 
time, although the total number of women participating in screening has increased 
(Figure 2.2). 
• In 2012, a high-grade abnormality (pre-cancerous condition) was detected in 
16,808 women aged 20–69, at a rate of 8 per 1,000 women screened. Detection presents an 
opportunity for treatment before possible progression to cancer. 
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Notes:  
1. The ASR is the number of women aged 20–69 screened in each reporting period as a percentage of the ABS estimated resident population 
for women aged 20–69, adjusted to include only women with an intact cervix, and age-standardised to the Australian population as at 30 
June 2001. 
2. Data for this figure are in online Table D3.2. 
Source: AIHW analysis of state and territory cervical cytology register data. 
Figure 2.2: Participation number and age-standardised participation rate, National Cervical 
Screening Program, Australia, 1996–1997 to 2011–2012 
National Bowel Cancer Screening Program 
The National Bowel Cancer Screening Program was established in 2006. It is expected to lead 
to decreases in both cancer incidence and mortality as it has the ability to detect 
pre-cancerous abnormalities. However, it is likely to take some time for the effect of the 
program on incidence and mortality to become apparent. The bowel cancer screening 
program currently offers free screening, using a faecal occult blood test (FOBT), to people 
turning 50, 55, 60 and 65 years of age. The program is scheduled to be expanded from 
July 2015, with the phasing in of biennial screening for those aged 50 to 74 by 2020. 
Key statistics 
Of those people invited to participate in the National Bowel Cancer Screening Program in 
2012–13: 
• 321,413 returned a completed bowel cancer screening kit for analysis—a participation 
rate of 33.4%. Participation was higher among women (35.7%) than men (31.1%) 
• 23,671 (7.5%) returned a valid screening test and had a positive screening result and 
70.4% of those (16,670 ) had a follow-up colonoscopy recorded 
• 404 participants (1 in 32) who underwent a colonoscopy were diagnosed with a 
confirmed or suspected bowel cancer, and 728 (1 in 17) were diagnosed with an 
advanced adenoma (pre-cancerous tumour). 
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What is missing from the picture? 
National cancer data do not include whether a new case of cancer was identified through 
screening, or if cancers identified through screening are diagnosed at an earlier stage than for 
those that present naturally. 
There is no national mechanism for reporting Aboriginal or Torres Strait Islander 
identification on pathology forms. As a result, state and territory cervical cytology (Pap test) 
registers are unable to report Indigenous status. Hence, the reporting of cervical screening 
indicators is not possible nationally for Indigenous women. 
Outcome data for the National Bowel Cancer Screening Program—such as follow-up of a 
positive FOBT result by a primary practitioner, colonoscopy follow-up, histopathology 
follow-up, and bowel abnormality detected at colonoscopy—are under-reported. The 
Department of Health is working on a number of steps to improve reporting of outcomes. 
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3 Incidence of cancer 
Key findings 
In 2014 in Australia, it is estimated that: 
• 123,920 new cases of cancer will be diagnosed 
• more than half (55%) of all cancers will be diagnosed in males 
• 75% of new cancer cases in males and 65% in females will be diagnosed among those 
aged 60 and over 
• the most commonly diagnosed cancers in males will be prostate cancer (17,050 cases), 
colorectal cancer (9,290), melanoma of the skin (7,440), lung cancer (6,860) and head 
and neck cancers (3,260) 
• the most commonly diagnosed cancers in females will be breast cancer (15,270 cases), 
colorectal cancer (7,340), melanoma of the skin (5,210), lung cancer (4,720) and uterine 
cancer (2,490) 
• the age-standardised incidence rate will be 467 per 100,000 
• the risk of being diagnosed with cancer before the age of 85 will be 1 in 2 for males and 
1 in 3 for females. 
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About incidence 
Incidence data refer to the number of new cases of cancers diagnosed in 1 year. It does not refer 
to the number of people newly diagnosed (because one person can be diagnosed with more 
than one cancer in a year), although the two numbers are likely to be similar. 
Cancer incidence data come from the AIHW Australian Cancer Database (ACD) 2011, which 
contains information on Australians diagnosed since 1982 with primary invasive cancer 
(excluding basal cell and squamous cell carcinomas of the skin) (see Box 3.1 and Appendix 
F). 
This chapter focuses on the estimated cancer incidence for 2014 and cancer trends from 1982 
to 2014. Actual incidence data cover the period 1982–2011—except for New South Wales and 
the Australian Capital Territory, where data were available to 2009 and estimated for 2010 
and 2011 (see Appendix F). Incidence data for 2012–2016 were estimated based on 2002–2011 
national cancer incidence data (see Appendix G). The 2012–2016 estimates are only indicative 
of future trends and the actual incidence may be different from these estimates. They are not 
forecasts and do not attempt to allow for future changes in cancer detection methods, 
changes in cancer risk factors or for non-demographic factors (such as government policy 
changes and economic differences) that may affect future cancer incidence rates. 
Summary pages for selected cancers on latest incidence data (2011) and estimates for  
2014–2016 are at Appendix B. An overview of incidence statistics for all cancers is at 
Appendix C. 
Box 3.1: Cancer registration in Australia 
Registration of all cancers, excluding basal and squamous cell carcinomas of the skin, is 
required by law in each state and territory. Information on newly diagnosed cancers is 
collected by each state and territory cancer registry and provided to the AIHW annually to 
be compiled to form the ACD. Since basal and squamous cell carcinomas of the skin are not 
notifiable, data on these cancers are not included in the ACD and therefore not in this 
report. However, past research has shown that basal and squamous cell carcinomas of the 
skin are by far the most frequently diagnosed cancers in Australia (AIHW & CA 2008). 
Estimated number of cases diagnosed 
It is estimated that 123,920 new cases of cancer will be diagnosed in Australia in 2014 
(excluding basal and squamous cell carcinoma of the skin, as these cancers are not notifiable 
diseases and hence are not reported to cancer registries). More than half (55%) of these cases 
are expected to be diagnosed in males (Table 3.1). 
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Table 3.1: Estimated incidence of all cancers combined(a), Australia, 2014(b) 
 Males Females Persons 
Number of cases 68,260 55,660 123,920 
Crude rate 582.9 471.1 526.8 
ASR(c) 540.4 406.2 467.3 
Per cent (%) of all cancer cases 55.1 44.9 100.0 
(a) Cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate a basal or  
squamous cell carcinoma of the skin. 
(b) The 2014 estimates are based on 2002–2011 incidence data (see Appendix G). The estimated numbers of cancer cases  
diagnosed are rounded to the nearest 10. The estimates for males and females may not add up to the estimates for  
persons due to rounding. 
(c) The rates were standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population. 
Source: AIHW ACD 2011. 
Most commonly diagnosed cancers 
In 2014 (excluding basal and squamous cell carcinoma of the skin), prostate cancer is 
estimated to be the most commonly diagnosed cancer in Australia (17,050 cases), followed by 
colorectal cancer (16,640), breast cancer (15,410), melanoma of the skin (12,640) and lung 
cancer (11,580). These cancers are expected to account for about 60% of all cancers estimated 
to be diagnosed in 2014. 
Males 
Prostate cancer is estimated to be the most commonly diagnosed cancer (17,050 cases), 
followed by colorectal cancer (9,290), melanoma of the skin (7,440), lung cancer (6,860) and 
head and neck cancers (3,260) (Table 3.2). Head and neck cancers incorporate cancer of the 
lip, tongue, mouth, salivary glands, pharynx, nasal cavity sinuses and larynx. These 5 most 
commonly diagnosed cancers account for around 64% of all cancers estimated to be 
diagnosed in males in 2014. 
Females 
Breast cancer is estimated to be the most commonly diagnosed cancer (15,270 cases). This is 
followed by colorectal cancer (7,340), melanoma of the skin (5,210), lung cancer (4,720) and 
uterine cancer (2,490) (Table 3.2). These 5 cancers account for around 63% of all cancers 
estimated to be diagnosed in females in 2014. 
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Table 3.2: Estimated 10 most commonly diagnosed cancers, Australia, 2014(a) 
Males  Females 
Cancer site/type 
(ICD-10 codes) Cases 
Crude 
rate ASR(b)  
Cancer site/type 
(ICD-10 codes) Cases 
Crude 
rate ASR(b) 
Prostate (C61) 17,050  145.6 128.7  Breast (C50) 15,270  129.2 114.5 
Colorectal  
(C18–C20) 9,290  79.4 73.9  
Colorectal  
(C18–C20) 7,340  62.1 51.5 
Melanoma of the 
skin (C43) 7,440  63.5 59.7  
Melanoma of the 
skin (C43) 5,210  44.1 39.4 
Lung (C33–C34) 6,860  58.5 54.8  Lung (C33–C34) 4,720  40.0 33.2 
Head and neck 
(C00–C14,  
C30–C32) 3,260  27.9 25.9  
Uterus (C54–C55) 2,490  21.0 17.9 
Lymphoma  
(C81–C85) 3,110  26.6 25.2  
Lymphoma  
(C81–C85) 2,430  20.6 17.9 
Leukaemia  
(C91–C95) 2,110  18.0 17.0  
Thyroid (C73) 1,890  16.0 15.4 
Bladder (C67) 2,060  17.6 16.7 
 
Leukaemia  
(C91–C95) 1,440  12.2 10.4 
Kidney (C64) 2,000  17.1 15.9  Ovary (C56) 1,430  12.1 10.5 
Pancreas (C25) 1,530  13.1 12.2  Pancreas (C25) 1,410  12.0 9.7 
All cancers 
combined(c) 68,260 582.9 540.4  
All cancers 
combined(c) 55,660 471.1 406.2 
(a) The 2014 estimates are based on 2002–2011 incidence data (see Appendix G). The estimated numbers of cancer cases diagnosed  
are rounded to the nearest 10. The estimates for males and females may not add up to the estimates for persons due to rounding. 
(b) The rates were standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population.  
(c) Cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate a basal or squamous  
cell carcinoma of the skin. 
Source: AIHW ACD 2011. 
Differences by age 
The incidence of cancer increases with age (Figure 3.1). In 2014, it is estimated that 75% of 
new cancer cases diagnosed in males and 65% in females will occur in those aged 60 and 
over. 
For those aged under 30, the estimated age-specific incidence rate is expected to be similar in 
males and females. For those aged 30–54, females have a higher estimated age-specific 
incidence rate than males. 
The high incidence of cancer in females in this age group could be partly attributed to the 
estimated high incidence of breast cancer. After the age of 55, the age-specific incidence rate 
is then higher for males. Incidence of prostate cancer, colorectal cancer, melanoma of the skin 
and lung cancer contributes to the high incidence rate in males aged over 55. 
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Notes 
1. The 2014 estimates are based on 2002–2011 incidence data (see Appendix G). 
2. Data pertain to cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate a  
basal or squamous cell carcinoma of the skin. 
3. Data for this figure are in online Table D3.1. 
Source: AIHW ACD 2011. 
Figure 3.1: Estimated incidence rates of all cancers combined by age at diagnosis, Australia,  
2014 
Risk of being diagnosed with cancer 
In 2014, it is estimated that 1 in 3 males and 1 in 4 females will be diagnosed with cancer by 
the age of 75. By the age of 85, the risk is estimated to increase to 1 in 2 for males and 1 in 3 
for females (see Appendix H for an explanation of how these risks are calculated). 
Table 3.3: Estimated risk of being diagnosed with cancer(a), by sex, Australia, 2014 
Sex Risk to age 75  Risk to age 85 
Males 1 in 3 1 in 2 
Females  1 in 4 1 in 3 
Persons  1 in 3 1 in 2 
(a) The 2014 estimates are based on 2002–2011 incidence data (see Appendix G). 
Source: AIHW ACD 2011. 
Males 
For males, the risk of being diagnosed with cancer is estimated to be highest for prostate 
cancer, at 1 in 9 before the age of 75 and 1 in 6 before the age of 85. The risk is also expected 
to be high for colorectal cancer at 1 in 19 before the age of 75 and 1 in 10 before the age of 85. 
For lung cancer, the risk is expected to be at 1 in 28 before the age of 75 and 1 in 13 before the 
age of 85. 
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Females 
For females, the risk of being diagnosed with cancer is estimated to be highest for breast 
cancer with a risk of 1 in 11 before the age of 75 and 1 in 8 before the age of 85. In 
comparison, the risk of a female being diagnosed with colorectal cancer is estimated to be 
1 in 28 before the age of 75 and 1 in 15 before the age of 85. For lung cancer, the risk is 
expected to be 1 in 38 before the age of 75 and 1 in 22 before the age of 85. 
Change over time 
In this section, trends in incidence for all cancers combined and selected cancer sites are 
presented for actual data for 1982–2011 and estimated data for 2012–2014. 
Trends for all cancers combined 
The number of new cancer cases expected to be diagnosed in 2014 is 2.6 times as high as in 
1982—from 47,417 in 1982 to 123,920 in 2014. The age-standardised incidence rate of all 
cancers combined is expected to increase by 22%, from 383 per 100,000 in 1982 to 467 per 
100,000 in 2014 (Figure 3.2). This suggests that the increase in the absolute number of cancer 
cases over the years can only be partly explained by the ageing and increasing size of the 
population. This increasing trend can be largely attributed to the rise in the number of 
prostate cancers, breast cancers in females and colorectal cancers diagnosed, as well as to 
improved diagnoses through population health screening programs and improvements in 
technologies and techniques used to identify and diagnose cancer. 
 
Notes 
1. The graph presents actual data for 1982–2011 and estimates for 2012–2014. Estimates for 2015 and 2016 are also available at  
Appendix B.  
2. The 2012–2014 estimates are based on 2002–2011 incidence data (see Appendix G). Estimates are displayed on the graph as a dotted 
line or as bars in a lighter shade. 
3. Data pertain to cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate a basal or 
squamous cell carcinoma of the skin. 
4. The rates were age-standardised to the Australian population as at 30 June 2001. 
5. The data for this figure are in online Table D3.2. 
Source: AIHW ACD 2011. 
Figure 3.2: Trends in incidence of all cancers combined, Australia, 1982 to 2014 
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The trend in the incidence rate of all cancers combined was markedly different for males and 
females (online Table D3.2). For males, it increased steadily until 1994, where it peaked at 
613 per 100,000. This was followed by a decline until the late 1990s when it began to increase 
again, reaching a rate of 612 per 100,000 in 2008. It then fell gradually to 580 per 100,000 in 
2011. 
It is expected to continue to fall to 540 per 100,000 in 2014. The trend in the rate for males is 
strongly influenced by changes in the incidence rate of prostate cancer—the most common 
cancer in males—as a result of initiatives such as Prostate-specific Antigen (PSA) testing. 
For females, the incidence rate of all cancers combined rose steadily during the early 1990s, 
reaching 398 per 100,000 in 1995. Since then, it has been fairly stable, ranging from 390 to 410 
per 100,000. 
The incidence rate for all cancers in females is estimated to be 406 per 100,000 in 2014. The 
rate for females has been strongly influenced by the trend in the incidence rate of breast 
cancer. The development of new technologies, such as Magnetic Resonance Imaging (MRI), 
and the introduction of population screening programs, including BreastScreen Australia, 
contribute to the increased diagnosis of breast cancer. 
Trends for specific cancers 
Between 1982 and 2014, there were increases in the age-standardised incidence rates for 
some cancers, including:  
• thyroid cancer (from 2.7 to 10.3 per 100,000 persons) 
• liver cancer (from 1.8 to 6.4 per 100,000) 
• mesothelioma (from 1.2 to 2.9 per 100,000) 
• kidney cancer (from 6.2 to 11.7 per 100,000) 
• melanoma of the skin (from 26.7 to 48.8 per 100,000) 
• prostate cancer (from 79.5 to 128.7 per 100,000). 
Of these cancers, thyroid cancer had the greatest increase of 281% between 1982 and 2014. 
The cancers that show the greatest percentage-point decreases between 1982 and 2014 are: 
• cervical cancer (from 14.2 to 7.0 per 100,000) 
• stomach cancer (from 15.8 to 8.3 per 100,000) 
• cancer of unknown primary site (from 18.0 to 9.6 per 100,000) 
• bladder cancer (from 17.8 to 10.0 per 100,000) 
• larynx cancer (from 4.3 to 2.5 per 100,000) (Figure 3.3). 
The incidence rate of each of these cancers decreased by at least 40 per cent.   
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Notes 
1. The bars indicate the percentage change in incidence rates between1982 and 2014. 
2. The 2014 estimates are based on 2002–2011 incidence data (see Appendix G). 
3. The percentage change between 1982 and 2014 is a summary measure that allows the use of a single number to describe the change  
over a period of multiple years. However, it is not always reasonable to expect that a single measure can accurately describe the trend 
over the entire period. 
4. The rates were age-standardised to the Australian population as at 30 June 2001. 
5. The data for this figure are in online Table D3.3. 
Source: AIHW ACD 2011. 
Figure 3.3: Estimated percentage change in age-standardised incidence rates between 1982 and 
2014, Australia 
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4 Hospitalisations and admitted patient 
palliative care for cancer 
Key findings  
In 2012–13 in Australia:  
• cancer was the main reason (principal diagnosis) for 1 in 10 hospitalisations, 
accounting for 2.31 million bed days 
• about three-quarters (76%) of cancer-related hospitalisations were for same-day care 
• the average length of stay (ALOS) for all cancer-related hospitalisations was 2.5 days. 
When same-day hospitalisations were excluded, the ALOS was 7.3 days 
• non-melanoma skin cancer was the most common cancer type recorded as principal 
diagnosis, with about 99,000 hospitalisations 
• chemotherapy was the most common cancer-related treatment or service recorded as 
the principal diagnosis, with about 370,000 hospitalisations 
• of all hospitalisations that involved palliative care, 56% (34,379) were cancer-related. 
From 2001–02 to 2012–13: 
• the number of cancer-related hospitalisations increased by 41% from 649,353 to 914,993 
• the age-standardised cancer-related hospitalisation rate increased by 9%, from 337 per 
10,000 to 367 per 10,000. 
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About hospitalisations 
Hospitalisation data include information on admitted patient services provided for people 
with cancer in Australian hospitals. 
This chapter presents the total number of cancer-related hospitalisations and provides 
information on cancer-related palliative care hospitalisations. The data source for this 
chapter was the NHMD, which contains data on admitted patient hospitalisations (Box 4.1). 
Box 4.1: Interpreting cancer hospitalisations 
National Hospital Morbidity Database 
The NHMD 2012–13 is a comprehensive data set containing records for all episodes of 
admitted patient care from public and private hospitals in Australia during 2012–13. 
Admitted patients are those who undergo a hospital’s formal admission process  
(AIHW 2014e). 
A hospitalisation (also known as a ‘separation’) is an episode of care either that starts with 
admission and ends with discharge, transfer or death, or that is defined by a change in care 
type, such as from acute care to rehabilitation. Hospitalisations (or separations) refer to 
admitted patients only. 
As the NHMD is episode based, the data presented in this chapter do not refer to 
individuals. An individual may be counted in the database multiple times in a reference 
year for each episode of care they receive as an admitted patient. 
Diagnosis information recorded in the NHMD is coded according to the International 
Statistical Classification of Diseases and Related Health Problems, Tenth Revision, 
Australian Modification (ICD-10-AM) (NCCH 2010). 
In this report, cancer-related hospitalisations are defined as those where: 
• the principal diagnosis (the diagnosis chiefly responsible for the episode of care) is 
cancer (ICD-10-AM codes C00-C97, D45, D46, D47.1 and D47.3) 
• the principal diagnosis is related to the treatment or management of cancer  
• the principal diagnosis is a non-cancer-specific treatment or service and cancer is 
recorded as an additional diagnosis (a diagnosis that coexists with the principal 
diagnosis or arises during the episode of care) for that hospitalisation. 
Data of cancer-related hospitalisations include those where palliative care was provided. 
Chemotherapy 
Not all cancer-related chemotherapy is provided on an admitted patient basis. Some 
jurisdictions provide a substantial amount of chemotherapy on a non-admitted basis, and 
this activity is therefore not reported to the NHMD. 
For more information on the NHMD, see Australian hospital statistics at 
<http://www.aihw.gov.au/publication-detail/?id=60129546922>  
and  
National Hospital Morbidity Database Data Quality Statement: 2012–13 at  
<http://meteor.aihw.gov.au/content/index.phtml/itemId/568730>. 
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Box 4.2 Summary of terms used in the hospitalisation chapter 
A same-day hospitalisation occurs when a patient is admitted to and separated from the 
hospital on the same date. An overnight hospitalisation occurs when a patient is admitted 
to and separated from the hospital on different dates. 
Additional diagnosis is a condition or complaint that either co-exists with the principal 
diagnosis or arises during the episode of care. An additional diagnosis is reported if the 
condition affects patient management. 
Average length of stay is the average number of patient days for admitted patient episodes. 
A same-day patient is allocated a length of stay of 1 day. 
Care type defines the overall nature of a clinical service provided to an admitted patient 
during an admitted care, or the type of service provided by the hospital for boarders or 
posthumous organ procurement (care other than admitted care). Admitted patient care 
consists of acute care, rehabilitation care, palliative care, geriatric evaluation and management, 
psychogeriatric care, maintenance care, newborn care and other admitted patient care. 
Palliative care hospitalisations in this report are defined as those where the care type is 
palliative care, and/or palliative care is recorded as an additional diagnosis, for admitted 
patients only (ICD-10-AM code Z51.5).  
Principal diagnosis is the diagnosis established after study to be chiefly responsible for 
occasioning the patient’s episode of admitted patient care. 
Hospitalisations in 2012–13 
In 2012–13, there were 914,993 cancer-related hospitalisations, accounting for 1 in 10 
hospitalisations in Australia. Less than half (45%) of all cancer-related hospitalisations had a 
principal diagnosis of cancer (Table 4.1). The remainder had a principal diagnosis related to 
the treatment or management of cancer. 
Table 4.1: Cancer-related hospitalisations(a), persons, Australia, 2012–13 
 Number Per cent ASR(b) 
Principal diagnosis of cancer(c) 415,130 45.4 165.1 
Principal diagnosis of a cancer-related treatment or service(d) 499,863 54.6 201.9 
Cancer specific treatment or services 491,947 53.8 198.7 
Non-cancer specific treatment or services with an additional diagnosis of cancer 7,916 0.9 3.2 
All cancer-related hospitalisations 914,993 100.0 367.0 
(a) Hospitalisation for which the care type was reported as Newborn with no qualified days and records for ‘Hospital boarders’ and ‘Posthumous 
organ procurement’ have been excluded from the analysis. 
(b) The rates were age-standardised to the Australian population as at 30 June 2001 and are expressed per 10,000 population. 
(c) Hospitalisations in which the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D47.1 and D47.3). 
(d) Hospitalisations in which the principal diagnosis is a health service or treatment that may be related to the treatment of cancer (see 
Appendix J). 
Source: AIHW NHMD. 
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Length of stay 
In 2012–13, cancer-related hospitalisations totalled 2.31 million bed days; 76% were same-day 
hospitalisations and 24% were overnight hospitalisations. 
The average length of stay (ALOS) for overnight cancer-related hospitalisations was 7.3 days 
(Table 4.2). This is longer than the overnight ALOS for all hospitalisations (5.6 days). 
More than half (52%) of hospitalisations in which the principal diagnosis was cancer were 
overnight, with an ALOS of 7.5 days. In contrast, the majority (99%) of hospitalisations with 
a principal diagnosis related to the treatment or management of cancer were same-day 
(Table 4.2). 
Table 4.2: Average length of stay (days) for cancer-related hospitalisations(a), Australia, 2012–13 
 Same-day  Overnight  Total 
 Number 
Per cent 
of total 
 
Number 
Per cent 
of total ALOS 
 
Number ALOS 
Principal diagnosis of cancer(b) 199,837 48.1  215,293 51.9 7.5  415,130 4.3 
Principal diagnosis of a cancer-related 
treatment or service(c) 494,364 98.9  5,499 1.1 2.2  499,863 1.0 
Cancer specific treatment or 
    services 486,916 99.0  5,031 1.0 2.1  491,947 1.0 
Non-cancer specific treatment or 
    services with an additional diagnosis 
    of cancer 7,448 94.1  468 5.9 3.0  7,916 1.1 
All cancer-related hospitalisations 694,201 75.9  220,792 24.1 7.3  914,993 2.5 
(a) Hospitalisation for which the care type was reported as Newborn with no qualified days and records for ‘Hospital boarders’ and ‘Posthumous 
organ procurement’ have been excluded from the analysis. 
(b) Hospitalisations in which the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D47.1 and D47.3),  
(c) Hospitalisations in which the principal diagnosis is a health service or treatment that may be related to the treatment of cancer (see 
Appendix J). 
Source: AIHW NHMD. 
In 2012–13, for hospitalisations where the principal diagnosis was cancer, the five cancer 
types with the longest ALOS (excluding same-day hospitalisations) were acute myeloid 
leukaemia (16.8 days), Kaposi sarcoma (13.5 days), hypopharyngeal cancer (13.0 days), anal 
cancer (11.5 days) and cancer of the small intestine (11.3 days). 
Hospitalisations for cancers and for cancer-related treatments  
Data on hospitalisations include cancer as a principal diagnosis and cancer-related 
treatments and services (see Appendix J for more information). Note that some treatments 
and services (such as Z51.0 ‘Radiotherapy session’) included in the data are not entirely 
cancer specific; that is, they may be provided to a small number of non-cancer patients. 
However, the proportion of these over counts is less than 0.01% of the data presented in this 
report. 
Cancer as a principal diagnosis 
In 2012–13, there were 415,130 hospitalisations where the principal diagnosis was cancer. 
Non-melanoma skin cancer was the most common principal diagnosis in this group (24%), 
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followed by cancer of secondary site (10%), prostate cancer (9%), colorectal cancer (7%) and 
breast cancer (6%). 
The 10 most common cancers as a principal diagnosis accounted for 77% of all 
hospitalisations with a principal diagnosis of cancer (Table 4.3). 
Table 4.3: Ten most common cancers as principal diagnosis(a), Australia, 2012–13 
Principal diagnosis (ICD-10-AM codes) Number Per cent 
Cancer site/type   
Non-melanoma of the skin (C44) 99,300 23.9 
Secondary site (C77–C79) 41,080 9.9 
Prostate (C61) 35,740 8.6 
Colorectal (C18–C20) 28,213 6.8 
Breast (C50) 25,117 6.1 
Leukaemia (C91–C95)  21,782  5.2 
Lymphoma (C81–C85)  20,496 4.9 
Lung (C33–C34)  18,878  4.5 
Bladder (C67)  14,051  3.4 
Myelodysplastic syndromes (D46)  13,829  3.3 
Total 10 most common cancers as a principal diagnosis 318,486 76.7 
Total hospitalisations with a principal diagnosis of cancer(b) 415,130 100.0 
(a) Hospitalisation for which the care type was reported as Newborn with no qualified days and records for ‘Hospital boarders’  
and ‘Posthumous organ procurement’ have been excluded from the analysis. 
(b) Hospitalisations in which the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D47.1 and D47.3 
(see Appendix J). 
Source: AIHW NHMD. 
In 2012–13, non-melanoma skin cancer was the most common cancer type recorded as 
principal diagnosis for both males (25%) and females (23%). 
The second most common cancer types recorded as principal diagnosis was prostate cancer 
in males (15%) and breast cancer in females (14%). These were followed by cancer of 
secondary site (9% males, 11% females), colorectal cancer (7% males, 7% females) and 
leukaemia (5% males, 5% females) (Table 4.4). 
The 10 most common cancer types accounted for around 80% of all cancers recorded as 
principal diagnoses in both males and females. 
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Table 4.4: Ten most common cancers as principal diagnosis(a), by sex, Australia, 2012–13 
Males  Females 
Principal diagnosis (ICD-10-AM codes) Number  Principal diagnosis (ICD-10-AM codes) Number 
Cancer site/type   Cancer site/type  
Non-melanoma of the skin (C44) 59,119  Non-melanoma of the skin (C44) 40,180 
Prostate (C61) 35,740  Breast (C50)  24,940  
Secondary site (C77–C79) 21,166  Secondary site (C77–C79)  19,914  
Colorectal (C18–C20) 15,617  Colorectal (C18–C20)  12,596  
Leukaemia (C91–C95) 12,846  Leukaemia (C91–C95)  8,936  
Lymphoma (C81–C85) 12,308  Lymphoma (C81–C85)  8,188 
Lung (C33–C34) 11,089  Lung (C33–C34)  7,789  
Bladder (C67) 10,794  Myelodysplastic syndromes (D46)  5,367  
Myelodysplastic syndromes (D46) 8,462  Melanoma of the skin (C43)  4,608  
Melanoma of the skin (C43) 6,344  Myeloma (C90)  4,391  
Total 10 most common cancers as a 
principal diagnosis 193,485  
Total 10 most common cancers as a 
principal diagnosis 136,909 
Total hospitalisations with a principal 
diagnosis of cancer(b) 239,518  
Total hospitalisations with a principal 
diagnosis of cancer(b) 175,611 
(a) Hospitalisation for which the care type was reported as Newborn with no qualified days and records for ‘Hospital boarders’ and 
‘Posthumous organ procurement’ have been excluded from the analysis. 
(b) Hospitalisations in which the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D47.1 and D47.3 (see Appendix J). 
Source: AIHW NHMD. 
Cancer-related treatments and services 
In 2012–13, there were 499,863 hospitalisations where the principal diagnosis was a 
cancer-related treatment or service. The 5 most common principal diagnoses were: 
• pharmacotherapy session for neoplasm (Z51.1 ‘Chemotherapy’) was the most common 
principal diagnosis in this group (75%) 
• special screening examination for neoplasm of intestinal tract (11%) 
• follow-up after surgery for cancer (8%) 
• adjustment and management of vascular access device (1%) 
• follow-up examination after combined treatment for malignant neoplasm (1%)  
(Table 4.5). 
These 5 most common reasons for hospitalisation when the principal diagnosis was a  
cancer-related treatment or service accounted for 96% of all hospitalisations with a principal 
diagnosis of a cancer-related treatment or service. 
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Table 4.5: Five most common reasons for hospitalisation(a), when the principal diagnosis is a 
cancer-related treatment or service, Australia, 2012–13 
Principal diagnosis (ICD-10-AM codes) Number Per cent 
Pharmacotherapy session for neoplasm (Chemotherapy [Z51.1])  374,824  75.0 
Special screening examination for neoplasm of intestinal tract (Z12.1)  54,480  10.9 
Follow-up after surgery for cancer (Z08.0)  42,110  8.4 
Adjustment and management of vascular access device (Z45.2)  5,838  1.2 
Follow-up examination after combined treatment for malignant neoplasm (Z08.7)  4,758  1.0 
Total 5 most common reasons for hospitalisation when the principal diagnosis 
was a cancer-related treatment or service 482,010 96.4 
Total hospitalisations with a principal diagnosis of a cancer-related 
treatment or service(b) 499,863 100.0 
(a) Hospitalisation for which the care type was reported as Newborn with no qualified days and records for ‘Hospital boarders’ and  
‘Posthumous organ procurement’ have been excluded from the analysis. 
(b) Hospitalisations in which the principal diagnosis is a health service or treatment that may be related to treatment of cancer  
(see Appendix J). 
Source: AIHW NHMD. 
In 2012–13, the most common reasons by sex for hospitalisation when the principal diagnosis 
was a cancer-related treatment or service were: 
• pharmacotherapy session for neoplasm in both males (72%) and females (78%) 
• follow-up after surgery for cancer in males (12%) and special screening examination for 
neoplasm of intestinal tract in females (12%) (Table 4.6). 
Table 4.6: Five most common reasons for hospitalisation(a), when the principal diagnosis is a 
cancer-related treatment or service, by sex, Australia, 2012–13 
Males  Females 
Principal diagnosis (ICD-10-AM codes) Number  Principal diagnosis (ICD-10-AM codes) Number 
Pharmacotherapy session for neoplasm 
(Chemotherapy [Z51.1])  170,926   
Pharmacotherapy session for neoplasm 
(Chemotherapy [Z51.1])  203,898  
Follow-up after surgery for cancer (Z08.0)  27,738  
 
Special screening examination for neoplasm 
of intestinal tract (Z12.1)  30,313  
Special screening examination for neoplasm 
of intestinal tract (Z12.1)  24,167  
 Follow-up after surgery for cancer (Z08.0)  14,372  
Follow-up examination after combined 
treatment for malignant neoplasm (Z08.7)  3,426   
Adjustment and management of vascular 
access device (Z45.2)  3,831  
Follow-up examination after unspecified 
treatment for malignant neoplasm (Z08.9)  2,416   
Family history of malignant neoplasm of 
digestive organs (Z80.0)  1,436  
Total 5 most common reasons for 
hospitalisation when the principal diagnosis 
was a cancer-related treatment or service 228,673  
Total 5 most common reasons for 
hospitalisation when the principal diagnosis 
was a cancer-related treatment or service 253,850 
Total hospitalisations with a principal 
diagnosis of a cancer-related treatment 
or service(b) 237,285  
Total hospitalisations with a principal 
diagnosis of a cancer-related treatment 
or service(b) 262,578 
(a) Hospitalisation for which the care type was reported as Newborn with no qualified days and records for ‘Hospital boarders’ and 
‘Posthumous organ procurement’ have been excluded from the analysis. 
(b) Hospitalisations in which the principal diagnosis is a health service or treatment that may be related to treatment of cancer (see Appendix J). 
Source: AIHW NHMD. 
Most hospitalisations where the principal diagnosis was a cancer-related treatment or service 
were for same-day services (99%). The 5 leading treatments, as detailed in Table 4.6, 
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accounted for the majority (97%) of all same-day hospitalisations for cancer-related 
treatments and services in 2012–13. 
Hospitalisations by age 
In 2012–13, people were more likely to be hospitalised for a cancer-related condition with 
increasing age (Figure 4.1). 
The hospitalisation rates for patients with cancer were low for those aged under 30, at 42 per 
10,000 persons or below. The hospitalisation rate then increased for each age group, peaking 
for those aged 75–79, at 1,741 per 10,000. The hospitalisation rate then decreased to 1,352 per 
10,000 for those aged 85 and over. 
The cancer-related hospitalisation rate was similar for males and females aged under 30. 
Females 
Females aged 30–59 had a higher rate of hospitalisation than males of the same age. In 
particular, the hospitalisation rate for females aged 40–44 was 1.9 times as high as that for 
males (261 compared with 135, respectively, per 10,000). This may be partly attributed to the 
high number of breast cancer hospitalisations in females within this age group. 
Males 
Males aged 60 and over had a higher hospitalisation rate than females of the same age. In 
particular, the hospitalisation rate for males aged 85 and over was 2.4 times as high as that 
for females (2,177 compared with 909, respectively, per 10,000). This may be partly attributed 
to the high number of prostate cancer hospitalisations among males within this age group. 
 
Notes 
1. Hospitalisation for which the care type was reported as Newborn with no qualified days and records for ‘Hospital boarders’ and  
‘Posthumous organ procurement’ have been excluded from the analysis. 
2. Hospitalisations in which (i) the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D47.1 and D47.3) or (ii) the  
principal diagnosis is a health service or treatment that may be related to treatment of cancer (see Appendix J). 
3. Data for this figure are in online Table D4.1. 
Source: AIHW NHMD. 
Figure 4.1: Age-specific rates for all cancer-related hospitalisations, Australia, 2012–13 
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Cancer-related hospitalisations over time 
Between 2001–02 and 2012–13, the total number of cancer-related hospitalisations increased 
by 41% from 649,353 to 914,993 hospitalisations. Much of this can be attributed to a 49% 
increase in the number of same-day hospitalisations, from 465,440 in 2001–02 to 694,201 in 
2012–13. 
In the same period, the age-standardised cancer-related hospitalisation rate increased 
slightly from 337 per 10,000 to 367 per 10,000. 
Between 2001–02 and 2012–13, there was a slight increase in the hospitalisation rate for 
same-day hospitalisation, from 241 per 10,000 to 279 per 10,000. Over the same period, the 
hospitalisation rate for overnight hospitalisation fell from 96 per 10,000 to 88 per 10,000 
(Figure 4.2). 
The trend in the rate of all cancer-related hospitalisations is mostly due to changes in the rate 
of same-day hospitalisations, which is affected by changes in admission practices in some 
jurisdictions. 
 
Notes 
1. Hospitalisation for which the care type was reported as Newborn with no qualified days and records for ‘Hospital boarders’ and 
‘Posthumous organ procurement’ have been excluded from the analysis. 
2. Hospitalisations in which (i) the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D47.1 and D47.3) or (ii) the 
principal diagnosis is a health service or treatment that may be related to treatment of cancer (see Appendix J). 
3. Rates were age-standardised to the Australian population as at 30 June 2001 and expressed per 10,000 population. 
4. Data for this figure are in online Table D4.2. 
Source: AIHW NHMD. 
Figure 4.2: All cancer-related hospitalisations by same-day and overnight status, Australia,  
2001–02 to 2012–13 
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Palliative care for cancer in the hospital setting 
Admitted hospital care commonly focuses on the treatment and care of disease. Palliative 
care, sometimes referred to as ‘hospice’ or ‘end-of-life’ care, is care in which the clinical 
intent or treatment goal is primarily quality of life for a patient with an active, progressive 
disease with little or no prospect of cure. It is usually evidenced by an interdisciplinary 
assessment and/or management of the physical, psychological, emotional and spiritual 
needs of the patient; and a grief and bereavement support service for the patient and their 
carers/family. Research has shown that cancer patients comprise the majority of those using 
palliative care services. This may be due to the difficulties in predicting the disease pathway 
and estimating prognosis of decline for non-cancer patients compared with cancer patients 
(AIHW 2011). 
This section presents a summary of cancer-related hospitalisations where palliative care was 
provided within an admitted patient setting in 2012–13 (see Box 4.1).  
In 2012–13, nearly 61,600 hospitalisations involved palliative care in Australia (0.7% of all 
hospitalisations). Of these, 56% (34,379) were cancer related. For most of these 
hospitalisations (74%), palliative care was the intended mode of clinical care; that is, the care 
type was recorded as palliative care. For the remaining 26%, palliative care was recorded as an 
additional diagnosis and provided as part of the hospitalisation where the intended care 
type was acute care, rehabilitation care or other modes of care. 
The most common type of cancer recorded for palliative care hospitalisation was secondary 
site cancer, which refers to a malignant tumour that originated elsewhere in the body; this 
principal diagnosis was reported in 23% of all cancer-related hospitalisations where 
palliative care was provided in 2012–13 (Table 4.7). 
Table 4.7: Ten most common cancers as principal diagnosis of the hospitalisation(a) where  
palliative care was provided, persons, Australia, 2012–13 
Principal diagnosis (ICD-10-AM codes) Number Per cent 
Cancer site/type   
Secondary site (C77–C79)  7,859  22.9 
Lung (C33–C34)  5,658  16.5 
Colorectal (C18–C20)  2,716  7.9 
Pancreas (C25)  1,874  5.5 
Prostate (C61)  1,618  4.7 
Breast (C50)  1,554  4.5 
Brain (C71)  1,187  3.5 
Stomach (C16)  973  2.8 
Liver (C22)  914  2.7 
Leukaemia (C91–C95)  803  2.3 
All cancer-related hospitalisations where palliative care was provided(b) 34,379 100.0 
(a) Hospitalisation for which the care type was reported as Newborn with no qualified days and records for ‘Hospital boarders’ and 
‘Posthumous organ procurement’ have been excluded from the analysis. 
(b) Palliative care hospitalisations in which (i) the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D47.1 and D47.3)  
or (ii) the principal diagnosis is a health service or treatment that may be related to treatment of cancer (see Appendix J). 
Source: AIHW NHMD. 
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Palliative care and deaths in hospital 
In 2012–13, among those cancer-related hospitalisations that ended in death, 75% included 
palliative care. Around 27% of non-cancer-related hospitalisations that ended in death 
included palliative care. The lower proportion of non-cancer-related hospitalisations that 
ended in death that included palliative care may be a result of some non-cancer-related 
conditions not fitting the criteria for palliative care or the progression of these conditions was 
difficult to predict. 
Over the same period, 51% (17,582) of cancer-related hospitalisations involving palliative 
care ended in death. Of the remaining hospitalisations, 13% (4,380) transferred to another 
facility and 31% (10,771) were sent to where they usually live, which could be a person’s own 
home or welfare institution.  
The proportion of cancer-related hospitalisations involving palliative care that ended in 
death was similar to that for all hospitalisations involving palliative care. 
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5 Survival after a diagnosis of cancer 
Key findings 
In 2007–2011 in Australia: 
• 5-year relative survival was 67% for all cancers combined  
• females had slightly higher survival than males (5-year relative survival of 68% and 
66%, respectively)  
• for males diagnosed with cancer, 5-year relative survival was highest for testicular 
cancer (98%), lip cancer (93%) and prostate cancer (93%) 
• for females diagnosed with cancer, 5-year relative survival was highest for thyroid 
cancer (97%), lip cancer (94%) and melanoma of the skin (94%) 
• for all cancers combined, 5-year relative survival decreased with age. 
From 1982–1986 to 2007–2011: 
• 5-year relative survival increased significantly from 40% to 66% for males and 52% to 
68% for females for all cancers combined. 
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About survival 
Information on survival from cancer provides an indication of cancer prognosis and the 
effectiveness of treatments available. A range of factors influence survival from cancer, 
including the demographic characteristics of the patient (such as age, sex and genetics), the 
nature of the tumour (such as site, stage at diagnosis and histology type) and the health-care 
system (such as availability of health-care services, screening, diagnostic and treatment 
facilities, and follow-up services) (Black et al. 1998; WCRF & AICR 2007). 
Survival in this report refers to ‘relative survival’; that is, all survival probabilities presented 
are relative to those of the general population. It refers to the probability of being alive for a 
given amount of time after diagnosis compared with the general population, and reflects the 
impact of a cancer diagnosis. For more information, see Box 5.1 and Appendix H. 
This chapter focuses on 5-year survival based on the 2011 ACD (see Appendix F). Data from 
the National Death Index (NDI) on deaths (from any cause) that occurred up to 31 December 
2011 were used to determine which people with cancer had died and when this occurred. 
Summary pages for selected cancers are at Appendix B. 
Box 5.1: Period survival  
In this report, relative survival was calculated using the period method for all reported time 
periods (Brenner & Gefeller 1996). This method calculates survival from a given follow-up 
or at-risk period. Survival estimates are based on the survival experience of people who 
were diagnosed before or during this period, and who were at risk of dying during this 
period. More information about the period method is at Appendix H. 
Note that the period method is an alternative to the traditional cohort method, which 
focuses on a group of people diagnosed with cancer in the past time period, and follows 
these people over time. By its nature, the period method produces more up-to-date 
estimates of survival than the cohort method. In this report, all year spans presented were 
calculated using the period method. As the cohort method was used in previous Cancer in 
Australia reports (for example, AIHW & AACR 2010), survival estimates in this report 
should not be directly compared with those in earlier reports. 
Five-year relative survival 
In 2007–2011, 5-year survival was 67% for all cancers combined. This means that people 
diagnosed with cancer had a 67% chance of surviving for at least 5 years compared with 
their counterparts in the general population. Females had slightly higher 5-year survival 
than males, at 68% compared with 66% for males (Table 5.1). 
Table 5.1: Five-year relative survival from all cancers combined(a), Australia, 2007–2011  
Sex 5-year relative survival (%) 95% confidence interval 
Males 66.1 65.9–66.3 
Females 67.5 67.3–67.7 
Persons  66.7 66.5–66.8 
(a) Cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate a basal or  
squamous cell carcinoma of the skin. 
Source: AIHW ACD 2011. 
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Cancer site 
In 2007–2011, 5-year survival was highest for people diagnosed with testicular cancer (98%), 
thyroid cancer (96%), lip cancer (93%), prostate cancer (93%) and melanoma of the skin (90%) 
and lowest for those diagnosed with pancreatic cancer (6%) and mesothelioma (6%)  
(Figure 5.1). 
For males, 5-year survival was highest for those diagnosed with testicular cancer (98%), lip 
cancer (93%) and prostate cancer (93%). For females, it was highest for those diagnosed with 
thyroid cancer (97%), lip cancer (94%) and melanoma of the skin (94%) (online Table D5.1). 
Pancreatic cancer (males 6% and females 6%) and mesothelioma (males 5% and females 8%) 
accounted for the lowest survival in both males and females.  
In 2007–2011, 5-year survival was significantly higher for males than for females for cancer of 
unknown primary site (1.5 times that for females) and bladder cancer (1.2 times). Five-year 
survival was significantly higher for females than for males for lung cancer (1.4 times that for 
males), anal cancer (1.2 times), melanoma of the skin (1.1 times), thyroid cancer (1.1 times), 
chronic lymphocytic leukaemia (1.1 times), myeloproliferative cancers excluding CML (1.1 
times) and mouth cancer (1.1 times). 
 
Notes 
1. All cancers combined include cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that  
indicate a basal or squamous cell carcinoma of the skin. Non-melanoma skin cancer does not include C44 codes that indicate  
a basal or squamous cell carcinoma of the skin. 
2.  HL=Hodgkin lymphoma, CLL=Chronic lymphocytic leukaemia, NHL=Non-Hodgkin lymphoma, MDS= Myelodysplastic syndromes, 
AML=Acute myeloid leukaemia, UPS=Cancer of unknown primary site. 
3. Data for this figure are in online Table D5.1. 
Source: AIHW ACD 2011. 
Figure 5.1: Five-year relative survival from selected cancers, Australia, 2007–2011 
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Difference by age 
In 2007–2011 for all cancers combined, 5-year survival was highest for those aged 15–24 
(87%); it decreased with age and was lowest (48%) for those aged 75 and over (Figure 5.2). 
The difference in survival by age may be due to a number of reasons, including the stage at 
diagnosis of tumours, a greater likelihood of co-morbidity among those diagnosed at an 
older age, differences in treatments received and inclusion in clinical trials (Brenner & Arndt 
2004; Ellison & Gibbons 2006; NCRI & WHC 2006). 
Females had a survival advantage up to the 55–64-year age group. The difference was most 
noticeable for those aged 45–54, where 5-year survival was 82% for females and 74% for 
males. From the age of 65–74, survival was slightly but significantly higher for males (online 
table D5.2). The difference in the age-related pattern of survival by sex may be partly due to 
the age distributions and survival outcomes for prostate cancer and breast cancer. 
 
Note: Data for this figure are in online Table D5.2. 
Source: AIHW ACD 2011. 
Figure 5.2: Five-year relative survival from all cancers combined by age at diagnosis, Australia, 
2007–2011 
The age-related pattern of survival for all cancers combined was characteristic of most 
individual cancer types. The reduction in survival with age was more pronounced in the 
second half of the lifespan; however, the pattern of decline varied across cancer types. 
For example, 5-year survival for colorectal cancer did not vary considerably for those aged 
under 75 (69% to 72%), but it dropped significantly to 60% for those aged 75 and over.  
Five-year survival for prostate cancer had a similar pattern. For those aged under 75, 5-year 
survival was 96% to 97%; it reduced to 82% for those aged 75 and over. 
For breast cancer in females, 5-year survival was highest in those aged between 45 and 74 
(91% to 92%). This may be related to the population-based BreastScreen program, which 
targets females in the age group of 50–69. 
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In contrast, 5-year survival for lung cancer fell sharply, earlier than for other selected cancers. 
For those aged 15–24, 5-year survival was 76%; it quickly declined to 29% for those aged  
25–44. A more gradual decline continued, to 8.7%, for those aged 75 and over (Figure 5.3). 
 
Notes 
1. Data on the age group 0–14 for these cancers and the age group 15–24 for prostate cancer cannot be released due to the small  
number of cases. 
2. Data for this figure are presented in online Table D5.2. 
Source: AIHW ACD 2011. 
Figure 5.3: Five-year relative survival from selected cancers by age at diagnosis, Australia,  
2007–2011 
Change over time 
Five-year survival for people diagnosed with cancer increased significantly over time, from 
46% in 1982–1986 to 67% in 2007–2011 (Figure 5.4). 
The increase in 5-year survival over time is evident in both males and females, although the 
increase was greater for males. For all cancers combined, 5-year survival for males increased 
from 40% in 1982–1986 to 66% in 2007–2011, compared with 52% to 68% for females. These 
gains can be partly attributed to better diagnostic methods, earlier detection and 
improvements in treatment (Dickman & Adami 2006). 
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Note: Data for this figure are in online Table D5.3. 
Source: AIHW ACD 2011. 
Figure 5.4: Five-year relative survival from all cancers combined, Australia, 1982–1986 to 2007–2011 
Between 1982–1986 and 2007–2011, survival from most cancers improved, but the change 
was not uniform over time or across cancer types (Figure 5.5). 
The cancers that had the largest absolute increase in survival were prostate cancer, kidney 
cancer, non-Hodgkin lymphoma, colorectal cancer, myeloma, Hodgkin lymphoma and anal 
cancer, where 5-year survival increased by 18 percentage points or more.  
Many of the cancers that had low survival in 1982–1986 showed only small improvements, 
such as cancer of other digestive organs (from 10% to 12%), pancreatic cancer (from 4% to 
6%) and lung cancer (from 9% to 14%). 
Some cancers had a decrease in survival over time. Cancer of the bladder showed a 
statistically significant decrease in 5-year survival (67% to 53%). The negative trend in 
bladder cancer survival may be partly attributed to changes in coding practices and changes 
in the age at diagnosis over time (Duncombe et al. 2009; English et al. 2007; Luke et al. 2010). 
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Notes 
1. Arrow positions indicate survival estimates and arrow lengths indicate the change in survival between the periods 1982–1986 and  
2007–2011. Cancers labelled with an asterisk (*) indicate changes that were not statistically significant. 
2. Data for 1987–1991, instead of 1982–1986, are used for liver cancer, mesothelioma and cancer of other digestive organs due to  
the small number of cases from the earlier time period. 
3. All cancers combined include cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that  
indicate a basal or squamous cell carcinoma of the skin. Non-melanoma skin cancer does not include C44 codes that indicate a  
basal or squamous cell carcinoma of the skin. 
4. Data for this figure are in online Table D5.4. 
Source: AIHW ACD 2011. 
Figure 5.5: Survival trends for selected cancers, Australia, between 1982–1986 and 2007–2011 
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Conditional survival  
Conditional survival estimates show the probability of surviving a given number of years 
provided that an individual has already survived a specified amount of time after diagnosis. 
Ordinary relative survival shows the probability of survival at diagnosis. 
Note that all conditional survival estimates in this report are conditional relative survival 
estimates. That is, they have been derived from relative survival but are referred to simply as 
‘conditional survival’. 
For all cancers combined, the prospect of surviving for at least 5 more years after having 
already survived for 1, 5, 10 or 15 years, increased markedly. At diagnosis, the probability of 
surviving for at least 5 years was 67%. However, by 1 year after diagnosis, individuals with 
cancer had an 80% chance of surviving at least 5 more years (Table 5.2). This increased 
further to 97% by 15 years after diagnosis, at which survival prospects were almost the same 
as for the general population. 
Table 5.2: Summary of conditional survival from all cancers combined(a), Australia, 2007–2011 
Years already survived 5-year conditional relative survival (%) 95% confidence interval 
At diagnosis 66.7 66.5–66.3 
Already survived 1 year after diagnosis 80.4 80.3–80.6 
Already survived 5 years after diagnosis 91.0 90.8–91.2 
Already survived 10 years after diagnosis 93.8 93.6–94.0 
Already survived 15 years after diagnosis 96.5 96.2–96.7 
(a) Cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate basal cell and squamous  
cell carcinoma of the skin. 
Source: AIHW ACD 2011. 
The relationship between conditional survival and survival at diagnosis varied for different 
cancer sites. Some cancers that had poor survival prospects at diagnosis were observed to 
have substantial increases in conditional survival with the number of additional years 
survived. These included stomach cancer, cancer of the gallbladder and extrahepatic bile 
ducts, cancer of unknown primary site and acute myeloid leukaemia. All of these had a  
5-year relative survival at diagnosis of less than 30%. However, 5 years after diagnosis, 
survival for an additional 5 years was more than 80%. 
Some cancers that had relatively high survival at diagnosis were observed to have little 
increase in conditional survival by 5 years after diagnosis. For example, survival from 
testicular cancer, thyroid cancer, melanoma of the skin, lip cancer and prostate cancer was 
comparatively high at diagnosis (more than 90%), with only marginal gains in conditional 
survival after having already survived for 1 or 5 years (Figure 5.6). 
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Notes 
1. The three columns for each cancer are overlapping, such that the area for Already survived 5 years after diagnosis includes those  
for Already survived 1 year after diagnosis and At diagnosis. 
2. All cancers combined include cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that 
 indicate a basal or squamous cell carcinoma of the skin. Non-melanoma skin cancer does not include C44 codes that indicate a  
basal or squamous cell carcinoma of the skin. 
3. HL= Hodgkin lymphoma, AML=Acute myeloid leukaemia, NHL=Non-Hodgkin lymphoma, UPS=Cancer of unknown primary site, 
CLL=Chronic lymphocytic leukaemia, MDS= Myelodysplastic syndromes. 
4. Data for this figure are in online Table D5.5. 
Source: AIHW ACD 2011. 
Figure 5.6: Five-year survival by number of years already survived, Australia, 2007–2011 
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6 Prevalence of cancer 
Key findings 
At the end of 2009 in Australia: 
• 465,016 people were alive who had been diagnosed with cancer within the previous  
5 years; this represented 2.1% of the Australian population 
• 5-year prevalence was higher in males than in females (56% and 44% of all prevalent 
cases, respectively) 
• 5-year prevalence increased with age, with the highest prevalence among those aged 
85 and over  
• among males, 5-year prevalence was highest for prostate cancer (40% of total male  
5-year prevalence), followed by melanoma of the skin (13%) and colorectal cancer (8%)  
• among females, 5-year prevalence was highest for breast cancer (35% of total female  
5-year prevalence), followed by melanoma of the skin (12%) and colorectal cancer 
(10%). 
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About prevalence 
Prevalence, or survivorship population, refers to the number of people alive who have ever 
been diagnosed with cancer. The combined effect of several factors—increasing incidence, 
decreasing mortality, improving survival, and developments in treatment—is leading to an 
increase in the population who have ever been diagnosed with cancer (see Box 6.1). 
Prevalence is a direct product of incidence and survival. Cancers with high incidence and 
high survival (such as melanoma of the skin) tend to have high prevalence, whereas cancers 
with low incidence and low survival (such as pancreatic cancer) tend to have low prevalence. 
In other cases, prevalence may represent a balance between conflicting incidence and 
survival patterns. For example, lung cancer has high incidence but low survival and 
therefore has low prevalence (AIHW & CA 2011). 
This chapter presents limited-duration prevalence with an index date of 31 December 2009, 
based on the 2011 ACD, which contains actual national cancer data from 1982 to 2009 (see 
Appendix F). Data from the National Death Index (NDI) on deaths (from any cause) that 
occurred up to 31 December 2011 were used to determine which people with cancer had died 
and when this occurred. Note that a person who was diagnosed with two separate cancers 
contributed separately to the prevalence of each cancer. However, this person would 
contribute only once towards prevalence of all cancers combined. 
Box 6.1: Survivorship experience 
Survivorship is increasingly recognised as starting at diagnosis and, in some cases, 
continuing long after treatment ends. It is more than simply not dying from cancer; it 
focuses on living with (and after) a cancer diagnosis (Jackson et al. 2013). Cancer survivors 
often face emotional, physical and financial challenges as a result of the detection, diagnosis 
and treatment of cancer. These factors—and the associated stressors and reduced quality of 
life for cancer survivors and their family, friends and caregivers—highlight the importance 
of follow-up health care and of survivorship as part of the cancer control continuum 
(Hawkins et al. 2010; Jackson et al. 2013). 
A summary of prevalence data is provided in this chapter. Summary pages for selected 
cancers are at Appendix B. 
Cancer prevalence  
At the end of 2009, 465,016 people were alive who had been diagnosed with cancer in the 
previous 5 years (Table 6.1). This represented 2.1% of the Australian population. Males made 
up 56% of the 5-year prevalent cases. At the end of 2009, the 10-year prevalence of cancer 
was 662,645 and the 28-year prevalence was 919,622 (Table 6.1). 
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Table 6.1: Limited-duration prevalence of all cancers combined(a), by sex, Australia, as at  
end of 2009 
 Number(b) Per cent of prevalent cases Per cent of population(c) 
 5-year prevalence 
Males 258,639 55.6 2.4 
Females 206,377 44.4 1.9 
Persons 465,016 100.0 2.1 
 10-year prevalence 
Males 354,184 53.5 3.3 
Females 308,461 46.5 2.8 
Persons 662,645 100.0 3.0 
 28-year prevalence 
Males 462,356 50.3 4.2 
Females 457,266 49.7 4.2 
Persons 919,622 100.0 4.2 
(a) Cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate  
basal cell and squamous cell carcinoma of the skin. 
(b) Prevalence refers to number of living people previously diagnosed with cancer, not the number of cancer cases. 
(c) Based on the Australian population at 31 December 2009. 
Source: AIHW ACD 2011. 
Differences by age 
Five-year prevalence for all cancers combined increased with age. Note that in these 
prevalence statistics, age refers to the age of a person on the index date of 31 December 2009. 
At the end of 2009, one-tenth (10%) of all Australians aged 75 and over had a diagnosis of 
cancer within the previous 5 years. 
Five-year prevalence was highest for those aged 85 and over (10,386 per 100,000) and lowest 
for those under 14 (62 per 100,000) (Figure 6.1). 
  
  Cancer in Australia: an overview 2014 45 
 
Notes 
1. Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
2. Data for this figure are in online Table D6.1. 
Source: AIHW ACD 2011. 
Figure 6.1: Five-year prevalence of all cancers combined by age group, Australia, as at end of 2009 
Cancer sites 
Among males, prostate cancer had the highest 5-year prevalence of 102,220 males at the end 
of 2009. This was followed by melanoma of the skin (33,138) and colorectal cancer (20,709). 
Prostate cancer accounted for 40% of the total 5-year prevalence in males, while melanoma of 
the skin contributed 13% and colorectal cancer contributed 8%. 
Among females, breast cancer had the highest 5-year prevalence (71,145 females), followed 
by melanoma of the skin (25,309) and colorectal cancer (19,654). Breast cancer accounted for 
35% of the total 5-year prevalence in females, while melanoma of the skin contributed 12% 
and colorectal cancer contributed 10%. 
Of the selected cancer sites, the lowest 5-year prevalence was observed for bladder cancer. 
Prevalence of lung cancer represented a balance between its high incidence and low survival, 
which was 13,704 males and 9,834 females (Figure 6.2). 
For the majority of cancer sites, 5-year prevalence was higher in males than in females. Of the 
selected cancers, the trend was most pronounced for bladder cancer, where 5-year 
prevalence was more than 3 times as high in males as in females (6,880 males and 2,068 
females). For liver cancer and lip cancer, 5-year prevalence was 2.7 times as high in males as 
in females and for oesophagus cancer and kidney cancer was twice as high in males as in 
females. In contrast, the 5-year prevalence for thyroid cancer was more than 3 times as high 
in females as in males (2,445 males and 7,630 females). 
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Notes 
1. Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
2. NHL=Non-Hodgkin lymphoma. Melanoma refers to melanoma of the skin. 
3.  Data for this figure are in Online Table D6.2. 
Source: AIHW ACD 2011. 
Figure 6.2: Five-year prevalence of selected cancers, Australia, as at the end of 2009 
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7 Mortality from cancer 
Key findings 
In Australia, it is estimated that in 2014: 
• 45,780 people will die from cancer, an average of 125 deaths every day  
• males will account for more than half of all deaths from cancer (57%)  
• lung cancer will be the leading cause of cancer death among males (5,150 deaths), 
followed by prostate cancer (3,390), colorectal cancer (2,210), pancreatic cancer (1,360) 
and cancer of unknown primary site (1,160)  
• the most common cancers causing death in females will be lung cancer (3,480 deaths), 
breast cancer (3,000), colorectal cancer (1,910), pancreatic cancer (1,280) and cancer of 
unknown primary site (1,180)  
• the age-standardised mortality rate for all cancers combined will be 168 per 100,000, a 
fall of 20% from 1982 (209 per 100,000).  
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About mortality 
In this report, mortality refers to the number of deaths for which the underlying cause was a 
primary cancer. The cancer that led to the death of the person may have been diagnosed 
many years previously, in the same year in which the person died or, in some cases, after 
death (for example at autopsy). Information on the underlying cause of death is derived 
from the medical certificate of cause of death, which is usually completed by a medical 
practitioner. 
The main data source used in this chapter was the AIHW National Mortality Database 
(NMD), which contains information about all deaths registered in Australia (see Appendix I 
for more information).  
This chapter focuses on the estimated deaths from cancer for 2014 and mortality trends from 
1982 to 2014. It should be noted that the estimates are only indicative of the future trends, 
and the actual numbers may differ from these estimates. They are not forecasts and do not 
attempt to allow for future changes in cancer treatments. Actual mortality data from 1982 to 
2011 are based on the year of occurrence of the death, and data for 2012 are based on the year of 
registration of the death (see Appendix I). 
Summary pages for selected cancers on latest mortality data (2012) and estimates for  
2014–2016 are at Appendix B. An overview of mortality statistics for all cancers is at 
Appendix C. 
Estimated number of deaths from cancer  
It is estimated that cancer will account for about 3 of every 10 deaths (30%) registered in 
Australia in 2014. 
In 2014, it is estimated that 45,780 people will die from cancer in Australia, an average of 
125 deaths every day. More males (57%) than females (43%) are expected to die from cancer 
in 2014, with cancer accounting for 33% of all male deaths and 27% of all female deaths. 
The age-standardised mortality rate for all cancers combined is estimated to be 168 per 
100,000 in 2014. The mortality rate of males (212 per 100,000) is estimated to be considerably 
higher than that of females (134 per 100,000) (Table 7.1). 
Table 7.1: Estimated deaths from all cancers combined(a), Australia, 2014(b)  
 Males Females Persons 
Number of deaths 26,010 19,770 45,780 
ASR(c) 211.5 133.7 167.7 
Per cent of all cancer deaths (%) 56.8 43.2 100.0 
Per cent of all deaths (%) 32.6 26.7 30.2 
(a) Cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
(b) The 2014 estimates are based on 2002–2012 mortality data (see appendixes G and I). They are rounded to the 
 nearest 10. The estimates for males and females may not add to the estimates for persons due to rounding. 
(c) The rates were standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population. 
Source: AIHW NMD. 
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Most common causes of death from cancer 
In 2014, it is estimated that the most common causes of death from cancer in Australia were: 
• lung cancer (8,630 deaths) 
• colorectal cancer (4,120) 
• prostate cancer (3,390) 
• breast cancer (3,030) 
• pancreatic cancer (2,640). 
Together, these five cancers represent just under half (48%) of the total mortality from cancer, 
with lung cancer alone accounting for 1 in every 5 deaths due to cancer (19%).  
Males 
For males, lung cancer is estimated to be the leading cause of death from cancer, with 
5,150 deaths in 2014 (Table 7.2). It is estimated that prostate cancer (3,390) and colorectal 
cancer (2,210) will be the second and third leading cause of cancer deaths in males, 
respectively, followed by pancreatic cancer (1,360) and cancer of unknown primary site 
(1,160). These five cancers account for around 51% of all cancer deaths in males. 
Females 
For females, lung cancer is estimated to be the most common cause of death from cancer in 
2014 (3,480 deaths) (Table 7.2). This is followed by breast cancer (3,000), colorectal cancer 
(1,910), pancreatic cancer (1,280) and cancer of unknown primary site (1,180). These five 
cancers account for around 55% of all cancer deaths in females (Table 7.2). 
Table 7.2: Estimated 10 most common causes of death from cancer, Australia, 2014(a) 
Males  Females 
Cancer site/type  
(ICD-10 codes) Deaths 
Crude 
rate ASR(b)  
Cancer site/type  
(ICD-10 codes) Deaths 
Crude 
rate ASR(b) 
Lung (C33–C34) 5,150  44.0  41.5  Lung (C33–C34)  3,480 29.5 24.1 
Prostate (C61) 3,390  28.9  28.2  Breast (C50) 3,000 25.4 20.9 
Colorectal (C18–C20) 2,210  18.9  17.9  Colorectal (C18–C20) 1,910 16.2 12.6 
Pancreas (C25) 1,360  11.6  10.9  Pancreas (C25) 1,280 10.8 8.6 
Unknown primary site 
(C80) 1,160  9.9  9.4  
Unknown primary site 
(C80) 1,180 10.0 7.6 
Melanoma of the skin 
(C43) 1,120  9.6  9.1  
Ovary (C56) 1,000 8.5 6.9 
Liver (C22) 1,080  9.2  8.7  Leukaemia (C91–C95) 695 5.9 4.6 
Leukaemia (C91–C95) 1,040  8.9  8.5 
 
Other digestive organs 
(C26) 680 5.8 4.3 
Oesophagus (C15) 975  8.3  7.7  Lymphoma (C81–C85) 640 5.4 4.2 
Lymphoma (C81–C85) 855  7.3  7.0  Brain (C71) 540 4.6 4.0 
All cancers(c) 26,010 222.1 211.5  All cancers(c) 19,770 167.3 133.7 
(a) The 2014 estimates are based on 2002–2012 mortality data (see appendixes G and I). They are rounded to the nearest 10. Estimates less 
than 1,000 are rounded to nearest 5. 
(b) The rates were standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population. 
(c) Cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Source: AIHW NMD. 
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Mortality by age  
The age-specific mortality rate of all cancers combined increases with age (Figure 7.1). In 
2014, it is estimated that 87% of all cancer deaths in males and 84% of all cancer deaths in 
females occurred in people aged over 60. 
For those aged under 50, the estimated age-specific mortality rate is similar for males and 
females. After 55, the mortality rate increased more steeply for males. Mortality from lung 
cancer, prostate cancer and colorectal cancer may be attributed to the high cancer mortality 
rate in older males. 
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Notes 
1. The 2014 estimates are based on 2002–2012 mortality data (see appendixes G and I). The estimates for males and females may not  
add to the estimates for persons due to rounding. 
2. Data pertain to cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
3. Data for this figure are in online Table D7.1. 
Source: AIHW NMD. 
Figure 7.1: Estimated mortality from all cancers combined by age at death, Australia, 2014 
Risk of death from cancer 
In 2014, it is estimated that the risk of dying from cancer before the age of 75 is 1 in 9 for 
males and 1 in 13 for females. By the age of 85, the risk is estimated to increase to 1 in 4 for 
males and 1 in 6 for females (Table 7.3) (see Appendix H for an explanation of how these 
risks are calculated). 
The risk of dying from lung cancer before the age of 75 was estimated to be 1 in 40 for males 
and 1 in 59 for females. By the age of 85, the risk of dying from lung cancer doubled to 1 in 17 
for males and 1 in 29 for females. 
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Table 7.3: Estimated risk of death from all cancers combined(a), by sex, Australia, 2014 
Sex Risk to age 75  Risk to age 85 
Males 1 in 9 1 in 4 
Females  1 in 13 1 in 6 
Persons  1 in 11 1 in 5 
(a) The 2014 estimates are based on 2002–2012 mortality data (see appendixes G and I). Cancers coded in the 
 ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Source: AIHW NMD. 
Change over time 
In this section, trends in mortality from all cancers combined and selected cancer sites are 
presented for actual data for 1982–2012 and estimated for 2013 and 2014. 
Trends for all cancers combined  
The number of deaths from all cancers combined has steadily increased over time. In 2014, it 
is estimated that 45,780 Australians will die from cancer, compared with 24,922 in 1982, an 
increase of 84%. The number of deaths estimated for 2014 will be the largest number 
reported in any year to date. 
In contrast, it is estimated that there will be a decrease in the age-standardised mortality rate 
for cancer between 1982 and 2014. Over this time, it is estimated that the mortality rate from 
cancer will fall by 20%, from 209 to 168 per 100,000 (Figure 7.2)  
 
Notes 
1. Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based 
on revised and preliminary versions, respectively, and are subject to further revision by the ABS. 
2. The 2013 and 2014 estimates are based on 2002–2012 mortality data (see appendixes G and I). Estimates are displayed on the graph as  
a dotted line or as bars in a lighter shade. 
3. Actual mortality data from 1982 to 2011 are based on the year of occurrence of the death, and data for 2012 are based on the year of 
registration of the death (see Appendix I). 
4. The rates were age-standardised to the Australian population as at 30 June 2001. 
5. Data pertain to cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
6. Data for this figure are in online Table D7.2. 
Source: AIHW NMD. 
Figure 7.2: Trends in mortality from all cancers combined, Australia, 1982 to 2014 
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Males 
For males, after the mortality rate reached a peak in 1994, it is estimated that it will fall by 
26% over the period from 1994 to 2014 (from 285 to 212 per 100,000; see online Table D7.2). 
The trend of cancer mortality in males can be largely attributed to declines in mortality rates 
for lung cancer, prostate cancer and colorectal cancer, which accounted for most of the total 
decrease between 1994 and 2014. 
Females 
For females, the cancer mortality rate was consistently lower than that for males. The female 
mortality rate remained fairly steady before 1993 and decreased thereafter (online 
Table D7.2). The mortality rate among females is estimated to fall by 18% from 1993 (164 per 
100,000) to 2014 (134 per 100,000). The fall could be largely attributed to declines in mortality 
rates of breast cancer and colorectal cancer. 
Trends for specific cancers 
Between 1982 and 2014, the age-standardised mortality rate of many cancers decreased. 
Figure 7.3 summarises the estimated percentage change in age-standardised mortality rates. 
Cancers that showed the greatest decrease in the age-standardised mortality rate include: 
• stomach cancer (from 12.3 to 4.0 per 100,000 persons) 
• cervical cancer (5.2 to 1.8 per 100,000) 
• colorectal cancer (31.5 to 15.6 per 100,000)  
• breast cancer in females (30.4 to 20.9 per 100,000) 
• lung cancer (42.3 to 32.2 per 100,000)  
• ovarian cancer (8.8 to 6.9 per 100,000) 
• cancer of unknown primary site (10.1 to 8.1 per 100,000) 
• prostate cancer (34.5 to 28.2 per 100,000). 
Cancers that showed an increase in the age-standardised mortality rate include: 
• liver cancer (from 2.3 to 6.0 per 100,000) 
• melanoma of the skin (4.7 to 6.3 per 100,000) 
• myeloma (3.0 to 3.5 per 100,000) 
• oesophageal cancer (4.4 to 4.9 per 100,000) 
• brain cancer (5.0 to 5.1 per 100,000) (Figure 7.3). 
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Notes 
1. The 2014 estimates are based on 2002–2012 mortality data (see appendixes G and I). Estimates for 2015 and 2016 are also available 
 at Appendix B. 
2. The bars indicate the percentage change in mortality rates between1982 and 2014. 
3. The percentage change between 1982 and 2014 is a summary measure that allows the use of a single number to describe the change  
over a period of multiple years. However, it is not always reasonable to expect that a single measure can accurately describe the trend  
over the entire period. 
4. The rates were age-standardised to the Australian population as at 30 June 2001. 
5. Data for this figure are in online Table D7.3. 
Source: AIHW NMD. 
Figure 7.3: Estimated percentage change in age-standardised mortality rates between 1982 and 2014, 
Australia 
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8 Focus on key population groups 
Key findings  
Incidence 
In the 5 years from 2005 to 2009: 
• the age-standardised incidence rate was higher for Indigenous than for 
non-Indigenous Australians for liver cancer (2.8 times as high), cervical cancer (2.3), 
cancer of unknown primary site (1.8), lung cancer (1.7), uterine cancer (1.6), and 
pancreatic cancer (1.3) 
• the incidence rate for all cancers combined was highest in Tasmania (530 per 100,000) 
and lowest in the Northern Territory (456 per 100,000) 
• people living in Inner regional areas of Australia had the highest incidence rate in six of 
the selected cancers: prostate cancer (206 per 100,000), breast cancer in females (120 per 
100,000), colorectal cancer (70 per 100,000), melanoma of the skin (62 per 100,000), 
non-Hodgkin lymphoma (19 per 100,000) and kidney cancer (13 per 100,000). 
In the 4 years from 2006 to 2009 (2005 data were not included as some data were not 
available): 
• those living in the most disadvantaged areas of Australia accounted for the highest 
age-standardised incidence rate for six of the selected cancers: colorectal cancer (66 per 
100,000), lung cancer (52 per 100,000), cancer of unknown primary site (14 per 100,000), 
bladder cancer (11 per 100,000), pancreatic cancer (11 per 100,000) and cervical cancer 
(8 per 100,000). 
In 2014, the most common cancers diagnosed by life stage are estimated to be: 
• leukaemia for people aged 0–24 (315 new cases), breast cancer for people aged 25–49 
(3,300 new cases) prostate cancer for people aged 50–64 (6,090 new cases) and 
colorectal cancer for people aged 65 and over (11,490 new cases). 
Mortality 
In the 5 years from 2008 to 2012: 
• the age-standardised mortality rate was higher for Indigenous than for non-Indigenous 
Australians for cervical cancer (3.4 times as high), liver cancer (3.0), lung cancer (1.7), 
uterine cancer (1.6), cancer of unknown primary site (1.5), pancreatic cancer (1.2) and 
breast cancer in females (1.1) 
• the age-standardised mortality rate for all cancers combined was highest in the 
Northern Territory (217 per 100,000) followed by Tasmania (192 per 100,000); the 
lowest mortality rate was in the Australian Capital Territory (152 per 100,000) 
• the age-standardised mortality rate for all cancers combined was 15% higher in Remote 
and Very remote areas than in Major cities. 
In the 4 years from 2009 to 2012: 
• those living in the most disadvantaged areas of Australia accounted for the highest 
age-standardised mortality rate for nine of the selected cancers: lung cancer (40 per 
100,000), breast cancer in females (22 per 100,000), colorectal cancer (17 per 100,000), 
pancreatic cancer (11 per 100,000), cancer of unknown primary site (11 per 100,000), 
non-Hodgkin lymphoma (6 per 100,000), bladder cancer (5 per 100,000) kidney cancer 
(4 per 100,000) and cervical cancer (3 per 100,000).  
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Differences across population groups 
Cancer incidence and mortality data in this chapter are presented according to five 
population groups:  
• Aboriginal and Torres Strait Islander people 
• State and territory 
• Remoteness areas 
• Socioeconomic disadvantage 
• Life stages (represented by four broad age groups). 
Actual incidence and mortality data are presented in this chapter, except for the ‘Life stages’ 
section of the chapter, where incidence and mortality estimates for 2014 are presented. Data 
are presented for all cancers combined and for selected cancers for each of the focus 
population groups. 
The cancers discussed in the Aboriginal and Torres Strait Islander section have been selected, 
due to the higher diagnosis and mortality rates of certain cancers in this population group. 
For Aboriginal and Torres Strait Islander people, data are presented for the following 
cancers: breast cancer in females, cancer of unknown primary site, cervical cancer, colorectal 
cancer, liver cancer, lung cancer, non-Hodgkin lymphoma uterine cancer, pancreatic cancer 
and prostate cancer. 
For the population groups by state and territory, by remoteness area, and by socioeconomic 
disadvantage, data are presented for the following cancers: cervical cancer, colorectal cancer, 
bladder cancer, breast cancer in females, kidney cancer, lung cancer, melanoma of the skin, 
non-Hodgkin lymphoma, pancreatic cancer, prostate cancer, cancer of unknown primary 
site. 
Data have been presented for multiple years to reduce random variations in rates. This is 
especially important for small population groups. Apart from breast cancer in females, 
cervical cancer and prostate cancer, results are presented for males and females combined in 
a further attempt to reduce the random variation in the data. 
Life stages are presented according to four broad age groups: 0–24 years, 24–49 years,  
50–64 years, and 65 years and older. Data are presented as estimates for 2014 for all cancers 
combined and for the top five cancers for incidence and mortality. Incidence data are 
presented as an average over 5 years (2005 to 2009) for Indigenous, state and territory and 
remoteness areas sections of this report. Due to the unavailability of some data for 
socioeconomic disadvantage, 4 years of data (2006 to 2009) are used.Mortality data are 
presented as an average over 5 years (2008 to 2012) for Indigenous, state and territory, and 
remoteness areas sections of this report. For consistency, mortality data for socioeconomic 
disadvantage are also presented as the average of 4 years of data (2009 to 2012). Mortality 
data are based on the year of occurrence of the death, except for the most recent year (namely 
2012), where the number of people whose death was registered is used (see Appendix I). 
ASRs are provided for incidence and mortality to account for differences in the age structure 
and the size of the population groups. 
Observed differences by the characteristics examined in this section may result from a 
number of factors, including variations in:  
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• population characteristics (for example, a relatively greater proportion of Indigenous 
people living in remote areas) 
• the prevalence of risk and/or protective factors (for example, tobacco consumption, 
physical activity) 
• the availability and usage of diagnostic services. 
The main data source for this chapter was the 2011 Australian Cancer Database (ACD) and 
the National Mortality Database (NMD). The 5 years of incidence data from 2005 to 2009 
were used for this chapter because 2009 is the latest year for which actual data were available 
for all states and territories (see Appendix F). 
Care must be exercised when interpreting differences in rates based on small counts and/or 
population groups as such rates may be volatile. 
Due to the differences in data sources and analysis approaches, mortality data in this chapter 
are not directly comparable with those published by individual state and territory cancer 
registries (see Box 8.1). 
Box 8.1: Differences in reporting mortality data 
Mortality due to cancer shown in this report may not be comparable with data published by 
individual state and territory cancer registries for a number of reasons, including those 
below: 
• The mortality data in this chapter were derived using the place of a person’s residence 
at the time of death. In contrast, some state and territory cancer registries present 
mortality information based on a person’s place of residence at the time of diagnosis. In 
the latter data, the deaths may or may not have occurred in the state or territory 
indicated. 
• Different approaches were used to assign cause of death. In this report, data on 
mortality for each jurisdiction were derived from the NMD (see Appendix I). 
Information on cause of death in the NMD is coded by the ABS. This process uses an 
automated coding system which selects the underlying cause of death from all the 
information documented on the death certificate. In contrast, the state and territory 
cancer registries may use information from a number of different sources, including 
pathology reports and other notifications, to assign a cause of death. 
Aboriginal and Torres Strait Islander people  
Aboriginal and Torres Strait Islander people are disadvantaged across a range of 
health-related and socioeconomic indicators compared with other Australians. Many factors 
contribute to the gap between Indigenous and non-Indigenous health, including social 
disadvantage such as lower education and employment rates, as well as higher smoking 
rates, poor nutrition, physical inactivity and poor access to health services (AIHW 2014a). 
Aboriginal and Torres Strait Islander people are also more likely to live in remote areas of 
Australia than the non-Indigenous population. 
Note that rates presented in this report for Indigenous and non-Indigenous Australians are 
not comparable with rates presented in the previous report Cancer in Australia: an overview 
2012. Rates presented in this report are derived from population estimates from the ABS 2011 
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Census of Population and Housing, while the report Cancer in Australia: an overview 2012 
derived population estimates from the 2006 Census. 
Incidence by Indigenous status  
Reliable national data on the diagnosis of cancer for Indigenous Australians are not 
available. All state and territory cancer registries collect information on Indigenous status; 
however, in some jurisdictions the quality of Indigenous status data is insufficient for 
analyses. Information in the ACD on Indigenous status is considered to be of sufficient 
completeness for reporting for New South Wales, Queensland, Western Australia and the 
Northern Territory. Data for these four jurisdictions are used to examine the incidence of 
cancer by Indigenous status. While the majority (83%) of Australian Indigenous people live 
in these four jurisdictions, the degree to which data for these jurisdictions are representative 
of data for all Indigenous people is unknown (ABS 2012b). 
For the four jurisdictions analysed, the overall level of missing data on Indigenous status for 
all cancers combined that were diagnosed between 2005 and 2009 was 12%. It should be 
noted, however, that the level of missing data was particularly high for prostate cancer 
(15%). 
Between 2005 and 2009, an average of 840 Indigenous Australians were diagnosed with 
cancer each year—this comprised 1% of all cancer cases diagnosed in that period. 
Of the selected cancers, lung cancer (average of 130 cases per year) was the most commonly 
diagnosed cancer among Indigenous Australians, followed by breast cancer in females  
(95 cases per year), colorectal cancer (79 cases per year) and prostate cancer (66 cases per 
year). 
Between 2005 and 2009, the age-standardised incidence rate of all cancers combined was 
slightly lower for Indigenous Australians than for their non-Indigenous counterparts  
(421 and 443 per 100,000, respectively). This contrasts with findings in the 2012 edition of this 
report, where Indigenous Australians had a higher incidence rate for all cancers combined 
than non-Indigenous Australians (AIHW & AACR 2012). The reason for this reversal is that 
the ABS has revised upwards the estimated population of Indigenous Australians. This 
increase in population leads to an apparent decrease in incidence rate. 
The age-standardised incidence rate was significantly higher for Indigenous than for  
non-Indigenous Australians for: 
• liver cancer (2.8 times as high) 
• cervical cancer (2.3) 
• cancer of unknown primary site (1.8) 
• lung cancer (1.7) 
• uterine cancer (1.6). 
While the incidence rate of pancreatic cancer was also higher for Indigenous Australians 
than for non-Indigenous Australians (1.3 times as high), the difference was not significant. 
The higher incidence rates of lung cancer and liver cancer are consistent with Indigenous 
Australians’ higher rates of smoking and heavy alcohol consumption. The higher rate of 
cervical cancer diagnosed for Indigenous Australians may be partly attributed to lower 
levels of participation in cervical screening programs (Condon 2004; Condon et al. 2005) and 
to greater exposure to risk factors associated with cervical cancer (such as higher rates of 
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smoking and having more children) (Garland et al. 2011; Roder 2005). Indigenous 
Australians have poorer access to health-care services and are more likely to have cancers 
that are diagnosed at a later stage than non-Indigenous Australians, when the primary site is 
no longer apparent (Cunningham et al. 2008; Roder 2005). This contributes to an incidence 
rate of cancer of unknown primary site that is higher for Indigenous Australians than for 
non-Indigenous Australians. 
There are also some cancers for which the age-standardised incidence rate was lower for 
Indigenous than non-Indigenous Australians, namely: 
• colorectal cancer (rate ratio of 0.8) 
• breast cancer in females (0.7) 
• non-Hodgkin lymphoma (0.7)  
• prostate cancer (0.6) (Figure 8.1). 
In fact, these selected cancers with lower incidence rates for Indigenous Australians are the 
most commonly diagnosed cancers in non-Indigenous Australians. 
The reasons for the lower incidence rate of some cancers among Indigenous Australians are 
not clear. Indigenous Australians are more likely to have cancers that are diagnosed at a later 
stage than non-Indigenous Australians, when the primary site is no longer apparent 
(Cunningham et al. 2008; Roder 2005). This may contribute to lower incidence rates for 
specific primary sites. The uptake of screening and diagnostics testing (such as breast and 
bowel screening and PSA testing) is lower among Indigenous people (ABS 2014c; Condon et 
al. 2001; Roder 2005; Stumpers & Thomson 2009; Threlfall & Thompson 2009), which may 
also contribute to a lower rate of diagnosis.  
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Notes 
1. The rates were age-standardised to the Australian population as at 30 June 2001 and based on the total number of cases over the  
5 years from 2005 to 2009. 
2. Some states and territories use an imputation method to determine Indigenous cancers, which may lead to differences between  
these data and those shown in jurisdictional cancer incidence reports. 
3. UPS stands for cancer of unknown primary site. 
4. Data for this figure are in online tables D8.4, D8.7, D8.8, D8.11, D8.13 and D8.14. 
Source: AIHW ACD 2011. 
Figure 8.1: Incidence of lung cancer, uterine cancer, cancer of unknown primary site, cervical 
cancer, liver cancer and pancreatic cancer by Indigenous status, New South Wales,  
Queensland, Western Australia and the Northern Territory, 2005–2009 
Mortality by Indigenous status 
Information in the NMD on Indigenous status from 2008 to 2012 is considered to be of 
sufficient quality for use for five jurisdictions: New South Wales, Queensland, Western 
Australia, South Australia and the Northern Territory. Almost 9 in 10 (89%) Indigenous 
people live in these jurisdictions (ABS 2012b). In the NMD, the level of missing data on 
Indigenous status for all cancers combined was about 2% for these five jurisdictions (online 
Table D8.1). 
Between 2008 and 2012, Indigenous Australians accounted for an annual average of 
459 cancer deaths (1.5% of all deaths due to cancer).  
The age-standardised mortality rate of all cancers combined was significantly higher for 
Indigenous Australians than for their non-Indigenous counterparts (221 and 172 per 100,000, 
respectively). The higher mortality rate for Indigenous Australians may be partly explained 
by their greater likelihood of being diagnosed with cancers where the prospect of successful 
treatment and survival is poorer (for example, lung cancer and cancer of unknown primary 
site) (Condon et al. 2003; Threlfall & Thompson 2009) or by being diagnosed at an advanced 
stage, as well as their lesser likelihood of receiving adequate treatment (AIHW 2012a; 
Cunningham et al. 2008). 
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Between 2008 and 2012, lung cancer accounted for the highest average number of 
cancer-related deaths for Indigenous Australians, totalling 115 deaths per year (25% of all 
Indigenous deaths from cancer), followed by liver cancer with 34 deaths (7%), breast cancer 
in females with 30 deaths (6%) and cancer of unknown primary site with 27 deaths (6%). 
The age-standardised mortality rate was significantly higher for Indigenous than for 
non-Indigenous Australians for: 
• cervical cancer (3.4 times as high) 
• liver cancer (3.0) 
• lung cancer (1.7) 
• cancer of unknown primary site (1.5). 
Mortality rates for uterine cancer, pancreatic cancer and breast cancer in females were also 
higher for Indigenous Australians than for non-Indigenous Australians (1.6, 1.2 and 1.1 times 
as high, respectively), but the differences were not statistically significant (Figure 8.2).  
Conversely, mortality rates were lower for Indigenous Australians than non-Indigenous 
Australians for non-Hodgkin lymphoma (rate ratio of 0.9), colorectal cancer (0.8) and 
prostate cancer (0.8), but the differences were not statistically significant. 
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Notes 
1. The rates were age-standardised to the Australian population as at 30 June 2001 and based on the total number of deaths over  
the 5-year period from 2008 to 2012. 
2. Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 
are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. These data have not  
been adjusted for the additional deaths arising from outstanding registrations of deaths in Queensland in 2010. For more detail,  
refer to Technical note 3 in Causes of death, Australia, 2010 (ABS cat. no. 3303.0). 
3. Data for this figure are in online tables D8.3, D8.4, D8.7, D8.8, D8.11, D8.13 and D8.14. 
4. Breast cancer is for females only. UPS stands for cancer of unknown primary site. 
Source: AIHW NMD. 
Figure 8.2: Mortality from lung cancer, breast cancer in females, liver cancer, cancer of  
unknown primary site, pancreatic cancer, cervical cancer and uterine cancer, by Indigenous  
status, New South Wales, Queensland, Western Australia, South Australia and the Northern 
Territory, 2008–2012 
State and territory 
Incidence by state and territory  
Between 2005 and 2009, the annual average number of cancer cases diagnosed ranged from 
594 cases in the Northern Territory to 36,492 cases in New South Wales. 
When the size and age structure of the population in each state and territory is taken into 
account, the highest incidence rates of all cancers combined were in Tasmania (530 per 
100,000 persons) and Queensland (528 per 100,000). In contrast, the incidence rates were 
lowest in the Australian Capital Territory (458 per 100,000) and the Northern Territory 
(456 per 100,000) (Table 8.1). 
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Table 8.1: Incidence of all cancers combined(a) by state and territory, Australia, 2005–2009  
State or territory 
Average annual number of 
cases(b) 
Total number  
of cases 
Age-standardised  
rate(c) 
New South Wales 36,492 182,462 490.6 
Victoria 26,992 134,962 486.4 
Queensland 22,077 110,383 528.2 
Western Australia 10,182 50,912 483.6 
South Australia 8,964 44,820 482.9 
Tasmania 3,069 15,344 530.3 
Australian Capital Territory 1,405 7,025 457.6 
Northern Territory 594 2,969 456.0 
Total 109,775 548,877 495.7 
(a) Cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate a basal or  
squamous cell carcinoma of the skin. 
(b) Numbers may not sum to the total due to rounding. 
(c) The rates were age-standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population. 
The rates were based on the total number of cases over the 5 years from 2005 to 2009. 
Source: AIHW ACD 2011. 
Between 2005 and 2009, the highest age-standardised incidence rates for selected cancers 
were in: 
• South Australia for non-Hodgkin lymphoma (21 per 100,000) 
• Queensland for melanoma of the skin (67 per 100,000)  
• Tasmania for prostate cancer (212 per 100,000), colorectal cancer (75 per 100,000), bladder 
cancer (17 per 100,000) and kidney cancer (14 per 100,000) 
• Northern Territory for lung cancer (65 per 100,000), cancer of unknown primary site  
(20 per 100,000) and cervical cancer (14 per 100,000) 
• the Australian Capital Territory for breast cancer in females (127 per 100,000). 
New South Wales, Victoria and Western Australia all accounted for the highest 
age-standardised incidence rate for pancreatic cancer (11 per 100,000). 
Mortality by state and territory  
Between 2008 and 2012, the average annual number of deaths from cancer ranged from 253 
in the Northern Territory to 14,196 in New South Wales. 
After taking the size and age structure of the population in each state and territory into 
account, the mortality rate for all cancers combined was highest in the Northern Territory 
(217 per 100,000) followed by Tasmania (192 per 100,000) (Table 8.2). 
In contrast, the mortality rates of all cancers combined were lowest in the Australian Capital 
Territory (152 per 100,000), Western Australia (170 per 100,000) and Victoria (172 per 100,000) 
(Table 8.2). 
Note that mortality data by state and territory presented in this section are not directly 
comparable with those data published by individual state and territory cancer registries (see 
Box 8.1). 
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Table 8.2: Mortality from all cancers combined(a) by state and territory, Australia, 2008–2012(b)  
State or territory(c) 
Average annual number 
of deaths(d) 
Total number  
of deaths 
Age-standardised  
rate(e) 
New South Wales 14,196 70,981 172.4 
Victoria 10,591 52,953 172.0 
Queensland 8,163 40,816 179.8 
Western Australia 3,871 19,354 169.6 
South Australia 3,605 18,025 173.5 
Tasmania 1,218 6,091 191.8 
Australian Capital Territory 481 2,405 151.7 
Northern Territory 253 1,265 217.1 
Total 42,379 211,896 173.9 
(a) Cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate a basal or squamous cell 
carcinoma of the skin. 
(b) Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based 
on revised and preliminary versions, respectively, and are subject to further revision by the ABS. These data have not been adjusted for the 
additional deaths arising from outstanding registrations of deaths in Queensland in 2010. For more detail, refer to Technical note 3 in 
Causes of death, Australia, 2010 (ABS cat. no. 3303.0). 
(c) Mortality data may not be comparable with mortality data published in state and territory cancer reports since the data shown in this report 
relate to the place of residence at the time of death, not the place of residence at the time of diagnosis, as shown in some state and territory 
reports. Further, the state and territory cancer registries may use a different methodology from that used by the AIHW to determine the 
cause of death (see Box 8.1). 
(d) Numbers may not sum to the total due to rounding. 
(e) The rates were age-standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population. The rates 
were based on the total number of deaths over the 5 years from 2008 to 2012. 
Source: AIHW NMD. 
Between 2008 and 2012, the highest age-standardised mortality rates for selected cancers 
were in: 
• Northern Territory for lung cancer (51 per 100,000), cancer of unknown primary site  
(15 per 100,000), bladder cancer (5 per 100,000) and cervical cancer (4 per 100,000) 
• Tasmania for breast cancer in females (23 per 100,000), colorectal cancer (20 per 100,000), 
pancreatic cancer (10 per 100,000) and kidney cancer (4 per 100,000, equal with South 
Australia) 
• Queensland for prostate cancer (34 per 100,000) and melanoma of the skin (8 per 100,000) 
• South Australia for non-Hodgkin lymphoma (6 per 100,000). 
Remoteness area 
People living in remote areas of Australia are often disadvantaged in relation to access to 
primary health-care services, educational and employment opportunities, and income. 
Further, they are more likely to have higher rates of risky health behaviours, such as 
smoking, heavy alcohol use and poor nutrition (AIHW 2014a). 
Incidence and mortality rates were calculated according to the level of remoteness area of 
residence at diagnosis or death. The Remoteness Areas (RAs) divide Australia into broad 
geographic regions that share common characteristics of remoteness for statistical purposes. 
The Remoteness Structure divides each state and territory into several regions on the basis of 
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their relative access to services. More information about the RAs classification is at Appendix 
E. Incidence and mortality rates are presented by five categories: Major cities, Inner regional, 
Outer regional, Remote and Very remote. 
Incidence by remoteness area 
Between 2005 and 2009, the age-standardised incidence rate of all cancers combined was 
highest in Inner regional areas (540 per 100,000) and lowest in Very remote areas (398 per 
100,000) (Figure 8.3).  
 
Notes 
1. Remoteness was classified according to the Australian Standard Geographical Classification (ASGC) Remoteness Areas (see Appendix E). 
2. The rates were age-standardised to the Australian population as at 30 June 2001 and based on the total number of cases over  
the 5 years from 2005 to 2009. 
3. Data for this figure are in online Table D8.1. 
Source: AIHW ACD 2011. 
Figure 8.3: Incidence of all cancers combined by remoteness area, Australia, 2005–2009 
Between 2005 and 2009, Inner regional areas of Australia had the highest observed 
age-standardised incidence rate for: 
• prostate cancer (206 per 100,000) 
• breast cancer in females (120 per 100,000) 
• colorectal cancer (70 per 100,000) 
• melanoma of the skin (62 per 100,000) 
• non-Hodgkin lymphoma (19 per 100,000) 
• kidney cancer (13 per 100,000). 
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Remote areas of Australia had the highest observed age-standardised incidence rate for:  
• cancer of unknown primary site (16 per 100,000) 
• bladder cancer (13 per 100,000) 
• pancreatic cancer (12 per 100,000) 
• cervical cancer (10 per 100,000). 
Very remote areas accounted for the highest age-standardised incidence rate for lung cancer 
(57 per 100,000). 
Mortality by remoteness area 
Between 2008 and 2012, the age-standardised mortality rates of all cancers combined were 
higher in Very remote and Remote areas (both 192 per 100,000) and lower in Major cities (167 
per 100,000) (Figure 8.4).  
 
Notes 
1. Remoteness was classified according to the Australian Statistical Geography Standard (ASGS) Remoteness Areas (see Appendix E). 
2. Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are  
based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. 
3. The rates were age-standardised to the Australian population as at 30 June 2001 and based on the total number of deaths over  
the 5 years from 2008 to 2012. 
4.  The data for this figure are in online Table D8.1. 
Source: AIHW NMD. 
Figure 8.4: Mortality from all cancers combined by remoteness area, Australia, 2008–2012 
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Between 2008 and 2012, Very remote and Inner regional areas had the highest age-standardised 
mortality rate for: 
Very remote 
• lung cancer (43 per 100,000 persons) 
• prostate cancer (35 per 100,000, equal with Outer regional areas) 
• cancer of unknown primary site (14 per 100,000) 
• bladder cancer (5 per 100,000) 
• cervical cancer (5 per 100,000). 
Inner regional 
• colorectal cancer (17 per 100,000) 
• breast cancer in females (23 per 100,000) 
• melanoma of the skin (7 per 100,000) 
• non-Hodgkin lymphoma (6 per 100,000). 
Remote areas of Australia had the highest age-standardised mortality rate for kidney cancer 
(5 per 100,000), and Major cities and Outer regional areas of Australia had the highest 
mortality rates for pancreatic cancer (both 10 per 100,000). 
Socioeconomic disadvantage 
The Index of Relative Socio-economic Disadvantage (IRSD) is used to indicate socioeconomic 
disadvantage. The IRSD scores each area by summarising attributes of the population, such 
as low income, low educational attainment, high unemployment and jobs in relatively 
unskilled occupations. 
The distribution of cancer incidence (between 2006 and 2009) and mortality (between 2009 
and 2012) by quintile of relative socioeconomic disadvantage reflects the population 
distribution, with approximately 20% of records in each quintile. 
Note that the IRSD is an area-based measure of socioeconomic status rather than a 
person-based measure. It is used as a proxy for the socioeconomic status of people living in 
those areas and would not be correct for each person living in that area. 
Incidence by socioeconomic disadvantage 
In this report, the first socioeconomic status group (quintile 1) corresponds to geographical 
areas containing the 20% of the population living in the area with the most disadvantaged 
socioeconomic status according to the IRSD, and the fifth group (quintile 5) to the 20% of the 
population living in areas with the least disadvantaged socioeconomic status. More 
information is at Appendix E: Index of Relative Socio-economic Disadvantage. 
Between 2006 and 2009, the age-standardised incidence rate for all cancers combined was 
slightly higher for those living in the three most disadvantaged (quintile 1, 2 and 3) areas and 
slightly lower for those living in the least disadvantaged (quintile 4 and 5) areas (Figure 8.5). 
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Notes 
1. Socioeconomic status was classified using the ABS IRSD (see Appendix E). 
2. The rates were age-standardised to the Australian population as at 30 June 2001 and based on the total number of cases over the  
4-year period from 2006 to 2009. 
3. Data for this figure are in online Table D8.1. 
Source: AIHW ACD 2011. 
Figure 8.5: Incidence of all cancers combined by quintile of relative socioeconomic  
disadvantage, Australia, 2006–2009  
Of the selected cancers, those living in the most disadvantaged (quintile 1) areas accounted 
for the highest age-standardised incidence rate for: 
• colorectal cancer (66 per 100,000 persons) 
• lung cancer (52 per 100,000) 
• cancer of unknown primary site (14 per 100,000) 
• bladder cancer (11 per 100,000) 
• pancreatic cancer (11 per 100,000, equal with quintile 2) 
• cervical cancer (8 per 100,000). 
Those living in the second most disadvantaged (quintile 2) areas accounted for the highest 
incidence rate for: 
• melanoma of the skin (52 per 100,000, equal with quintile 5)  
• kidney cancer (13 per 100,000)  
• pancreatic cancer (11 per 100,000, equal with quintile 1). 
Those living in the least disadvantaged (quintile 5) areas accounted for the highest incidence 
rate for: 
• prostate cancer (205 per 100,000) 
• breast cancer in females (124 per 100,000) 
• melanoma of the skin (52 per 100,000, equal with quintile 2) 
• non-Hodgkin lymphoma (20 per 100,000). 
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Mortality by socioeconomic disadvantage 
Between 2009 and 2012, the age-standardised mortality rate for all cancers combined was  
highest among those living in the most disadvantaged (quintile 1) areas (190 per 100,000 
persons) and lowest among those living in the least disadvantaged (quintile 5) areas  
(149 per 100,000) (Figure 8.6). 
 
Notes 
1. Socioeconomic status was classified using the ABS IRSD (see Appendix E). 
2. Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are  
based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. 
3. The rates were age-standardised to the Australian population as at 30 June 2001 and based on the total number of deaths over the  
5 years from 2009 to 2012. 
4. Data for this figure are in online Table D8.1. 
Source: AIHW NMD. 
Figure 8.6: Mortality from all cancers combined, by quintile of relative socioeconomic 
disadvantage, Australia, 2009–2012 
Those living in the most disadvantaged (quintile 1) areas had the highest age-standardised 
mortality rate for: 
• lung cancer (40 per 100,000 persons) 
• breast cancer in females (22 per 100,000) 
• colorectal cancer (17 per 100,000) 
• pancreatic cancer (11 per 100,000) 
• cancer of unknown primary site (11 per 100,000) 
• non-Hodgkin lymphoma (6 per 100,000, equal with quintiles 2 and 3) 
• bladder cancer (5 per 100,000) 
• kidney cancer (4 per 100,000, equal with quintile 2)  
• cervical cancer (3 per 100,000). 
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Those living in the second most disadvantaged (quintile 2) areas had the highest 
age-standardised mortality rate for prostate cancer (32 per 100,000) and for melanoma of the 
skin (6 per 100,000, equal with quintile 3). 
Life stages 
This section focuses on the differences in cancer diagnoses and mortality according to the 
following four broad age groups (which are used to represent different life stages):  
0–24 years, 25–49 years, 50–64 years and 65 years and over. The incidence of cancer and 
deaths from cancer increases with age (Figure 8.7). While cancer cases and deaths are rare 
among younger people, the types of cancer and treatment options differ depending on age at 
diagnosis. 
 
Notes 
1. The 2014 incidence estimates are based on 2002–2011 incidence data (see Appendix G). The 2014 mortality estimates are based on 
2002–2012 mortality data (see Appendix G). The mortality estimates for males and females may not add to the estimates for persons  
due to rounding. 
2. Incidence data pertain to cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, except those C44 codes that indicate a  
basal or squamous cell carcinoma of the skin. 
3. Mortality data pertain to cancers coded in the ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
4. Data for this figure are in online Table D8.15. 
Source: AIHW ACD 2011. 
Figure 8.7: Estimated incidence rates of all cancers combined by age at diagnosis and estimated 
mortality from all cancers combined by age at death, Australia, 2014 
Incidence by life stage (broad age groups) 
This section focuses on estimated cancer incidence for 2014. Estimates are based on  
2002–2011 incidence data (see Appendix G). The estimated numbers of cancer cases 
diagnosed are rounded to the nearest 10 and the estimates for males and females may not 
add up to the estimates for persons due to rounding. 
Aged 0–24 
For people aged 0–24, it is estimated that 1,540 new cases of cancer will be diagnosed in 2014. 
People aged 0–24 tend to be diagnosed with different cancer types than older people. For this 
age group, leukaemia is estimated to be the most commonly diagnosed cancer, with 315 new 
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cases (21% of all cancers diagnosed in this age group). This is followed by lymphoma, with 
255 cases (17%) and brain cancer with 135 cases (9%).  
Males 
For males, it is estimated that 840 new cases of cancer will be diagnosed in 2014 (55% of all 
cancers diagnosed in this age group). Leukaemia is estimated to be the most commonly 
diagnosed cancer, with 180 new cases (22% of all cancers diagnosed for males in this age 
group). This is followed by lymphoma, with 150 cases (18%), and testicular cancer, with 
120 cases (14%). 
Females 
For females, it is estimated that 695 new cases of cancer will be diagnosed in 2014 (45% of all 
cancers diagnosed in this age group). Leukaemia is estimated to be the most commonly 
diagnosed cancer, with 135 new cases (19% of all cancers diagnosed for females in this age 
group). This is followed by lymphoma, with 106 cases (15%), and melanoma of the skin, with 
70 cases (10%). 
Aged 25–49 
For people aged 25–49, it is estimated that 14,590 new cases of cancer will be diagnosed in 
2014. Breast cancer is estimated to be the most commonly diagnosed cancer, with 3,300 new 
cases (23% of all cancers diagnosed in this age group). This is followed by melanoma of the 
skin, with 2,560 cases (18%), and colorectal cancer, with 1,100 cases (8%). 
Males 
For males, it is estimated that 5,810 new cases of cancer will be diagnosed in 2014 (40% of all 
cancers diagnosed in this age group). Melanoma of the skin is estimated to be the most 
commonly diagnosed cancer, with 1,170 new cases (20% of all cancers diagnosed for males in 
this age group). This is followed by colorectal cancer, with 590 cases (10%), and testicular 
cancer with 560 cases (10%). 
Females 
For females, it is estimated that 8,790 new cases of cancer will be diagnosed in 2014 (60% of 
all cancers diagnosed in this age group). For this age group, females represent a greater 
proportion of cancer diagnosis than males. This may be due to the high proportion of breast 
cancer diagnosis. Breast cancer is estimated to be the most commonly diagnosed cancer, with 
3,300 new cases (38% of all cancers diagnosed for females in this age group). This is followed 
by melanoma of the skin, with 1,380 cases (16%), and thyroid cancer, with 810 cases (9%). 
Aged 50–64 
For people aged 50–64, it is estimated that 35,720 new cases of cancer will be diagnosed in 
2014. Prostate cancer is the most commonly diagnosed cancer, with 6,090 new cases (17% of 
all cancers diagnosed in this age group). This is followed by breast cancer, with 5,880 cases 
(16%) and colorectal cancer with 4,020 cases (11%). National breast and bowel screening 
programs are targeted at people aged 50 and over, which could impact on the number of 
cancers diagnosed in this age group. 
Males 
For males, it is estimated that 19,480 new cases of cancer will be diagnosed in 2014 (55% of all 
cancers diagnosed in this age group). Prostate cancer is estimated to be the most commonly 
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diagnosed cancer, with 6,090 new cases (31% of all cancers diagnosed for males in this age 
group). This is followed by colorectal cancer, with 2,380 cases (12%), and melanoma of the 
skin, with 2,240 cases (11%). 
Females 
For females, it is estimated that 16,240 new cases of cancer will be diagnosed in 2014 (45% of 
all cancers diagnosed in this age group). Breast cancer is estimated to be the most commonly 
diagnosed cancer, with 5,840 new cases (36% of all cancers diagnosed for females in this age 
group). This is followed by colorectal cancer, with 1,640 cases (10%), and melanoma of the 
skin, with 1,570 cases (10%). 
Aged 65 and over 
For people aged 65 years and older, it is estimated that 72,070 new cases of cancer will be 
diagnosed in 2014. Colorectal cancer is estimated to be the most commonly diagnosed 
cancer, with 11,490 new cases (16% of all cancers diagnosed in this age group). This is 
followed by prostate cancer, with 10,520 cases (15%), and lung cancer, with 8,440 cases (12%). 
Population-based screening programs are targeted at people in this age group, which could 
have an impact on the number of cancers diagnosed. 
Males 
For males, it is estimated that 42,130 new cases of cancer will be diagnosed in 2014 (58% of all 
cancers diagnosed in this age group). Prostate cancer is estimated to be the most commonly 
diagnosed cancer, with 10,520 new cases (25% of all cancers diagnosed for males in this age 
group). This is followed by colorectal cancer, with 6,310 cases (15%), and melanoma of the 
skin, with 5,120 cases (12%). 
Females 
For females, it is estimated that 29,940 new cases of cancer will be diagnosed in 2014 (42% of 
all cancers diagnosed in this age group). Breast cancer is estimated to be the most commonly 
diagnosed cancer, with 6,120 new cases (20% of all cancers diagnosed for females in this age 
group). This is followed by colorectal cancer, with 5,180 cases (17%), and lung cancer, with 
3,320 cases (11%). 
 72 Cancer in Australia: an overview 2014 
 
Notes 
1. The 2014 incidence estimates are based on 2002–2011 incidence data (see Appendix G). 
2. Data for this figure are in online Table D8.16. 
Source: AIHW ACD 2011. 
Figure 8.8: Estimated most commonly diagnosed cancer at each age group, male, 2014 
 
 
Notes 
1. The 2014 incidence estimates are based on 2002–2011 incidence data (see Appendix G). 
2. Data for this figure are in online Table D8.16. 
Source: AIHW ACD 2011. 
Figure 8.9: The estimated most commonly diagnosed cancer at each age group, female, 2014 
Mortality by life stage (broad age groups) 
This section focuses on the estimated deaths from cancer for 2014. Estimates are based on 
2002–2012 mortality data (see Appendix G). Estimates are rounded to the nearest 10 and the 
estimates for males and females may not add to the estimates for persons due to rounding. 
Leukaemia
Lymphoma
Testis
Melanoma of the skin
Bowel
Prostate
Age group
0–4
5–9
10–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
80–84
85+
Leukaemia
Lymphoma
Melanoma
Breast
Bowel
Age group
0–4
5–9
10–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
80–84
85+
  Cancer in Australia: an overview 2014 73 
Aged 0–24 
For people aged 0–24, it is estimated that there will be 180 cancer-related deaths in 2014. 
While the number of cancer-related deaths is low compared with that for other age groups, 
cancer is the leading cause of death for people in this age group according to the most recent 
actual data (2012) (AIHW 2014). People aged 0–24 tend to die from different cancers types 
than those for older people. For this age group, brain cancer and leukaemia are estimated to 
be leading cause of death from cancer in 2014, both with 40 deaths (22% of all cancer deaths 
in this age group). This is followed by bone cancer, with 25 deaths (14%). 
Males 
For males, it is estimated that, in 2014, there will be 100 cancer-related deaths (56% of all 
cancers diagnosed in this age group) in 2014. Brain cancer and leukaemia are estimated to be 
the leading causes of death from cancer in 2014, both with 25 deaths (25% of all cancer deaths 
for males in this age group). This is followed by bone cancer, with 10 deaths (10%). 
Females 
For females, it is estimated that, in 2014, there will be 85 cancer-related deaths (47% of all 
cancers diagnosed in this age group). Brain cancer is estimated to be the leading cause of 
death from cancer in 2014, with 20 deaths (24% of all cancer deaths for females in this age 
group). This is followed by leukaemia, with 15 deaths (18%). 
Aged 25–49 
For people aged 25–49, it is estimated that there will be 2,140 cancer-related deaths in 2014. 
Breast cancer is estimated to be the leading cause of death from cancer in 2014, with 
405 deaths (19% of all cancer deaths in this age group). This is followed by lung cancer, with  
255 deaths (12%), and colorectal cancer, with 210 deaths (10%). 
Males 
For males, it is estimated that, in 2014, there will be 1,000 cancer-related deaths (47% of all 
cancers diagnosed in this age group). Lung cancer is estimated to be the leading cause of 
death from cancer in 2014, with 140 deaths (14% of all cancer deaths for males in this age 
group). This is followed by brain cancer, with 115 deaths (12%), and colorectal cancer, with 
100 deaths (10%). 
Females 
For females, it is estimated that, in 2014, there will be 1,130 cancer-related deaths (53% of all 
cancers diagnosed in this age group). For this age group, females represent a greater 
proportion of cancer-related deaths than males. This may be due to the high proportion of 
deaths related to breast cancer. Breast cancer is estimated to be the leading cause of death 
from cancer in 2014, with 325 deaths (29% of all cancer deaths for females in this age group). 
This is followed by lung cancer, with 130 deaths (12%), and colorectal cancer, with 
100 deaths (9%). 
Aged 50–64 
For people aged 50–64 years, it is estimated that there will be 8,290 cancer-related deaths in 
2014. Lung cancer is estimated to be the leading cause of death from cancer in 2014, with 
1,660 deaths (20%). This is followed by breast cancer, with 975 deaths (12%), and colorectal 
cancer, with 935 deaths (9%). 
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Males 
For males, it is estimated that, in 2014, there will be 4,570 cancer-related deaths (55% of all 
cancers diagnosed in this age group). Lung cancer is estimated to be the leading cause of 
death from cancer in 2014, with 970 deaths (21%). This is followed by colorectal cancer, with 
420 deaths (9%), and liver cancer, with 345 deaths (8%). 
Females 
For females, it is estimated that, in 2014, there will be 3,730 cancer-related deaths (45% of all 
cancers diagnosed in this age group). Breast cancer is estimated to be the leading cause of 
death from cancer in 2014, with 825 deaths (22% of all cancer deaths for females in this age 
group). This is followed by lung cancer, with 770 deaths (21%), and colorectal cancer, with 
340 deaths (9%). 
Aged 65 and over 
For people aged 65 and older, it is estimated that there will be 36,220 cancer-related deaths in 
2014. Lung cancer is estimated to be the leading cause of death from cancer in 2014, with 
6,860 deaths (19%). This is followed by prostate cancer, with 3,310 deaths (9%), and colorectal 
cancer, with 3,220 deaths (9%). 
Males 
For males, it is estimated that, in 2014, there will be 20,890 cancer-related deaths (58% of all 
cancers diagnosed in this age group). Lung cancer is estimated to be the leading cause of 
death from cancer in 2014, with 4,080 deaths (20%). This is followed by prostate cancer, with 
3,310 deaths (16%), and colorectal cancer, with 1,720 deaths (8%). 
Females 
For females, it is estimated that, in 2014, there will be 15,310 cancer-related deaths (42% of all 
cancers diagnosed in this age group). Lung cancer is estimated to be the leading cause of 
death from cancer in 2014, with 2,680 deaths (18% of all cancer deaths for females in this age 
group), followed by breast cancer with 1,900 deaths (12%) and colorectal cancer with 
1,430 deaths (9%). 
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Notes 
1. The 2014 mortality estimates are based on 2002–2012 mortality data (see Appendix G). The mortality estimates for males and females  
may not add to the estimates for persons due to rounding. 
2. Data for this figure are in online Table D8.17. 
Source: AIHW NMD. 
Figure 8.10: Estimated leading cause of death from cancer at each age group, male, 2014 
 
 
Notes 
1. The 2014 mortality estimates are based on 2002–2012 mortality data (see Appendix G). The mortality estimates for males and females  
may not add to the estimates for persons due to rounding. 
2. Data for this figure are in online Table D8.17. 
Source: AIHW NMD. 
Figure 8.11: Estimated leading cause of death from cancer at each age group, female, 2014 
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9 International comparisons 
Key findings 
In 2012, based on ASRs: 
• the incidence rate for all cancer combined in Australia (323 per 100,000) was higher 
than that for all other country groups (regions) 
• Australia had the world’s second highest incidence rate for melanoma of the skin  
(35 per 100,000), which was more than 11 times the average world rate (3.0 per 
100,000). New Zealand had a slightly higher incidence rate for melanoma of the skin, at 
36 per 100,000 
• the incidence rate of prostate cancer in Australia (115 per 100,000) was higher than that 
for all other regions 
• Australia had a slightly lower cancer mortality rate (96 per 100,000) than the average 
world rate (102 per 100,000) 
• cancer survival (as shown by the MIR) was higher in Australia than in all other 
regions. 
  
  Cancer in Australia: an overview 2014 77 
About international comparisons 
Comparing international cancer data—including for incidence, mortality and survival—is a 
valuable way to compare the Australian experience of cancer with that in other countries and 
regions. 
International cancer data are available from the GLOBOCAN database, which is prepared by 
the International Agency for Research on Cancer (IARC) (Ferlay et al. 2013). The most recent 
GLOBOCAN estimates are for 2012, and are based on cancer incidence and mortality rates 
from about 3 to 5 years earlier. The GLOBOCAN data for all cancers combined pertain to 
cancers coded in the ICD-10 as C00–C97, excluding those for C44 (that is, non-melanoma 
skin cancer). They thus encompass a narrower range of cancers than is generally considered 
in this report (see Appendix I). Australian estimates used in the international context are 
age-standardised to the World Standard Population and are therefore not comparable with 
national data presented elsewhere. 
For more information on international data and interpreting differences by countries and 
regions, see Box 9.1 and A working guide to international comparisons of health (AIHW 2012b). 
Box 9.1: Interpreting international comparisons 
Incidence and mortality 
Incidence and mortality estimates for international comparisons are derived from national 
data and standardised to the World Standard Population. Take care when comparing cancer 
data from different countries as observed differences may be influenced not only by the 
underlying number of cancer cases (or number of cancer deaths when considering mortality 
data), but also by differences in: 
• age distribution and composition of the populations 
• underlying differences in cancer risk and population exposure to modifiable risk 
factors 
• cancer detection and screening 
• cancer coding and registration practices (Ferlay et al. 2013) 
• features at diagnosis (for example, stage at diagnosis and cancer histology type) 
• availability and quality of treatment (CCS & NCIC 2007) 
• individual’s level of co-morbidity. 
In Australia, cancer is a notifiable disease and the completeness of cancer data is relatively 
high compared with that in a number of countries or regions (Curado et al. 2007). 
Mortality-to-incidence ratio 
The mortality-to-incidence ratio (MIR) is used as a proxy measure of survival in the 
international context. This ratio describes the number of cancer deaths in a given year, 
relative to the number of new cases of cancer diagnosed in the same year, using 
age-standardised data. It is a number between 0 and 1, although it can exceed 1 in certain 
circumstances. The MIR is a measure of the fatality of the cancer in question: if no-one ever 
died of the cancer, the MIR would be 0; if everyone died of the cancer on the same day they 
were diagnosed, the MIR would be 1. Therefore, low values of the MIR indicate longer 
survival while high ones indicate shorter survival.  Appendix H provides further 
information about interpreting MIRs. 
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Incidence 
In 2012, the estimated number of new cases of cancer diagnosed around the world was 
14.1 million. In the same year, it is estimated that 122,031 new cases of cancer were 
diagnosed in Australia, accounting for 0.9% of all cancers diagnosed worldwide. 
The incidence rate for all cancers combined in Australia (323 per 100,000) was higher than 
that for other country groups (regions) (Figure 9.1). This could be at least partly attributable 
to the introduction of national population screening programs in Australia (BreastScreen 
Australia, the National Bowel Cancer Screening Program and the National Cervical 
Screening Program) and increased PSA testing, contributing to increased diagnosis of these 
cancers. In Australia, cancer is a notifiable disease and the completeness of cancer data is 
relatively high compared with that of a number of countries or regions (Curado et al. 2007). 
Australia also has the world’s second highest rate of melanoma of the skin at 35 per 100,000, 
(slightly behind New Zealand at 36 per 100,000). Australia’s rate of melanoma of the skin 
was more than 11 times the average world rate (3.0 per 100,000). 
 
Notes 
1. Cancer coded in the ICD-10 as C00–C97, excluding C44 non-melanoma skin cancer. 
2. Data were estimated for 2012 by the IARC and are based on data from about 3 to 5 years earlier. 
3. The ASRs were standardised by the IARC using Doll et al. 1966 World Standard Population and are expressed per  
100,000 persons. Countries or regions are ordered in descending order according to the ASRs. 
4. Data for this figure are in online Table D9.1. 
Source: Ferlay et al. 2013. 
Figure 9.1: International comparison of estimated incidence for all cancers combined,  
persons, 2012 
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Mortality 
In 2012, the estimated number of deaths from cancer around the world was 8.2 million.  
The age-standardised mortality rate for Australia was 96 per 100,000, which was slightly 
lower than the average world rate (102 per 100,000) (Figure 9.2).  
The age-standardised mortality rate for cancer varied considerably between countries and 
regions. Compared with all other regions, the rate was highest in Central and Eastern Europe 
(123 per 100,000), and lowest in South-Central Asia (69 per 100,000). 
 
Notes 
1. Cancer coded in the ICD-10 as C00–C97, excluding C44 non-melanoma skin cancer. 
2. Data were estimated for 2012 by the IARC and are based on data from about 3 to 5 years earlier. 
3. The ASRs were standardised by the IARC using the Doll et al. (1966) World Standard Population and are expressed per  
100,000 persons. Countries or regions are ordered in descending order according to the ASRs. 
4. Data for this figure are in online Table D9.2. 
Source: Ferlay et al. 2013. 
Figure 9.2: International comparison of estimated mortality for all cancers combined,  
persons, 2012 
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Mortality-to-incidence ratio 
The MIR describes the number of cancer deaths in 2012, relative to the number of new cases 
of cancer diagnosed that year.  
Low values of the MIR indicate longer survival while high ones indicate shorter survival.  
A ratio approaching 1.0 suggests that survival is low, with similar numbers of deaths and 
incident cases. A ratio approaching zero suggests that survival is higher (see Box 9.1 and 
Appendix H for more information). 
The 2012 GLOBOCAN data suggest that the MIRs for all cancers varied markedly between 
countries and regions (Ferlay et al. 2013). The MIR for Australia was 0.3, suggesting that the 
survival of people in Australia who were diagnosed with cancer was higher than that of 
people in all other regions. By comparison, the MIR for the world was 0.6, indicating that 
Australia has higher survival from cancer than the world combined. The MIR for African 
regions and Melanesia was 0.7 or higher, suggesting relatively poorer survival (Figure 9.3). 
For more information on MIRs, see Box 9.1. 
 
Notes 
1. Cancer coded in the ICD-10 as C00–C97, excluding C44 non-melanoma skin cancer. 
2. The ratios are based on incidence and mortality data which were estimated for 2012 by the IARC and are based on data from  
about 3 to 5 years earlier. 
3. The MIR equals the age-standardised mortality rate divided by the age-standardised incidence rate. The ASRs were standardised  
by the IARC using the Doll et al. (1966) World Standard Population. Countries or regions are ordered in descending order  
according to the MIR. 
4. Data for this figure are in online Table D9.3. 
Source: Ferlay et al. 2013. 
Figure 9.3: International comparison of MIRs for all cancers combined, persons, 2012 
Australia
Northern America
Western Europe
New Zealand
Northern Europe
Southern Europe
Micronesia
South America
Polynesia
Caribbean
Central America
World
Central and Eastern Europe
Western Asia
Eastern Asia
Southern Africa
Northern Africa
South-Eastern Asia
South-Central Asia
Melanesia
Western Africa
Eastern Africa
Middle Africa
MIR
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
  Cancer in Australia: an overview 2014 81 
Appendix A: Cancer codes 
Table A1: Cancer codes 
Cancer site/type ICD-10 codes 
Lip, oral cavity and pharynx 
Lip C00 
Tongue C01–C02 
Mouth C03–C06 
Salivary glands C07–C08 
Oropharynx C09–C10 
Nasopharynx C11 
Hypopharynx C12–C13 
Other sites in pharynx, etc. C14 
Digestive organs 
Oesophagus  C15 
Stomach  C16 
Small intestine  C17 
Colorectal C18–C20 
Anus C21 
Liver C22 
Gallbladder and extrahepatic bile ducts  C23–C24 
Pancreas C25 
Other digestive organs C26 
Respiratory system and intrathoracic organs 
Nose, sinuses, etc. C30–C31 
Larynx C32 
Lung C33–C34 
Other thoracic and respiratory organs C37–C39 
Bone C40–C41 
Skin 
Melanoma of the skin C43 
Non-melanoma of the skin C44(a) 
Mesothelial and soft tissue 
Mesothelioma C45 
Kaposi sarcoma C46 
Peritoneum C48 
Other soft tissue C47, C49 
Breast C50 
 (continued) 
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Table A1 (continued): Cancer codes 
Cancer site/type ICD-10 codes 
Female genital organs 
Vulva C51 
Vagina C52 
Cervix C53 
Uterus C54–C55 
Ovary C56 
Other female genital organs and placenta C57–C58 
Male genital organs  
Penis C60 
Prostate C61 
Testis C62 
Other male genital organs C63 
Urinary tract  
Kidney C64 
Bladder C67 
Other urinary organs C65–C66, C68 
Eye, brain and other parts of the central nervous system  
Eye C69 
Brain  C71 
Other central nervous system C70, C72 
Thyroid and other endocrine glands  
Thyroid C73 
Other endocrine glands C74–C75 
Blood and lymphatic system  
Hodgkin lymphoma C81 
Non-Hodgkin lymphoma C82–C85  
Immunoproliferative cancers C88 
Myeloma C90 
Acute lymphoblastic leukaemia (ALL) C91.0 
Chronic lymphocytic leukaemia (CLL) C91.1 
Other and unspecified lymphoid leukaemia C91.2–C91.9 
Acute myeloid leukaemia (AML) C92.0, C92.3–C92.5, C93.0, C94.0, C94.2, C94.4, C94.5 
Chronic myelogenous leukaemia (CML) C92.1 
Other and unspecified myeloid leukaemia C92.2, C92.7, C92.9, C93.1–C93.9, C94.7 
Myeloproliferative cancers excluding CML C94.1, C94.3, C96.2, D45, D47.1, D47.3 
Myelodysplastic syndromes D46 
 (continued) 
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Table A1 (continued): Cancer codes 
Cancer site/type ICD-10 codes 
Other cancers of the blood and lymphatic system C95, C96.0, C96.1, C96.3–C96.9 
Other   
Other and ill-defined sites C76 
Unknown primary site C80(b) 
Multiple primary C97(c) 
All cancers combined C00–C97(a,c), D45, D46, D47.1, D47.3 
(a) For incidence data, those C44 codes that indicate basal or squamous cell carcinoma of the skin are not included. 
(b) For mortality data before 2008, the applicable codes are C77–C80. 
(c) C97 is of relevance for mortality data only. 
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Appendix B: Summary pages for selected 
cancers 
This appendix provides summary pages on the incidence, mortality, survival and prevalence 
statistics for selected cancers that were commonly diagnosed or were common causes of 
cancer deaths. 
Actual cancer incidence data for 1982–2011 and estimates for 2012–2016 (based on 2002–2011 
incidence data) are presented. Actual cancer mortality data for 1982–2012 and estimates for 
2013–2016 (based on 2002–2012 mortality data) are presented (see Appendix G). 
Data for the figures presented in this appendix are in online supplementary tables.  
  
 86 Cancer in Australia: an overview 2014 
All cancers combined (C00–C97, D45, D46, D47.1, 
D47.3) 
Risk factors(a):  
Table B1(a): Incidence and mortality of all cancers combined 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 67,117 51,594 118,711  24,341 18,698 43,039 
Crude rate 603.7 459.8 531.4  215.2 163.8 189.4 
ASR 579.7 403.6 484.1  210.6 133.0 166.8 
Risk to age 75 1 in 3 1 in 4 1 in 3  1 in 9 1 in 13 1 in 11 
Risk to age 85 1 in 2 1 in 3 1 in 2  1 in 4 1 in 6 1 in 5 
Mean age 67.0 65.0 66.1  73.1 73.1 73.1 
Estimated number for 2014, 2015 and 2016(c) 
2014 68,260 55,660 123,920  26,010 19,770 45,780 
2015 69,790 57,010 126,800  26,470 20,100 46,570 
2016 72,050 58,420 130,470  26,950 20,430 47,380 
 
  
Figure B1(a): Incidence and mortality ASRs(b,c) 
of all cancers combined, 1982–2016 
Figure B1(b): Incidence (2011) and mortality 
(2012) rates of all cancers combined, by age 
group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) For incidence data, ICD-10 C44 codes that indicate a basal or squamous cell carcinoma of the skin are not included. The 2011 incidence 
data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the ACT (see Appendix F). 
Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based 
on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were directly standardised to the 
Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B1(b): Survival and prevalence of all cancers combined(a) 
 Males Females Persons 
Prevalence as at the end of 2009(b) 
1-year prevalence 118,732 89,413 208,145 
5-year prevalence 258,639 206,377 465,016 
Relative survival in 2007–2011(c) 
1-year relative survival at diagnosis (%) 80.6 81.6 81.0 
95% confidence interval 80.4–80.7 81.5–81.8 80.9–81.2 
5-year relative survival at diagnosis (%) 66.1 67.5 66.7 
95% confidence interval 65.9–66.3 67.3–67.7 66.5–66.8 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 80.0 80.9 80.4 
95% confidence interval 79.8–80.3 80.7–81.2 80.3–80.6 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 89.9 92.1 91.0 
95% confidence interval 89.7–90.2 91.8–92.3 90.8–91.2 
 
 
Figure B1(c): Relative survival at diagnosis and 5-year conditional survival from all cancers 
combined, Australia, 2007–2011 
(a) For survival and prevalence data, those ICD-10 C44 codes that indicate a basal or squamous cell carcinoma of the skin are not included. 
(b) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(c) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Acute myeloid leukaemia (C92.0, C92.3–C92.5, C93.0, 
C94.0, C94.2, C94.4, C94.5) 
Risk factor(a):  
Table B2(a): Incidence and mortality of acute myeloid leukaemia 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 527 386 913  465 348 813 
Crude rate 4.7 3.4 4.1  4.1 3.0 3.6 
ASR 4.7 3.0 3.8  4.0 2.6 3.2 
Risk to age 75 1 in 328 1 in 478 1 in 390  1 in 444 1 in 608 1 in 514 
Risk to age 85 1 in 174 1 in 264 1 in 212  1 in 174 1 in 272 1 in 216 
Mean age 63.3 65.4 64.2  72.1 71.5 71.9 
Estimated number for 2014, 2015 and 2016(c) 
2014 580 440 1,020  545 375 920 
2015 595 450 1,050  565 385 950 
2016 610 460 1,070  585 395 980 
 
  
Figure B2(a): Incidence and mortality ASRs(b,c) of 
acute myeloid leukaemia, 1982–2016 
Figure B2(b): Incidence (2011) and mortality 
(2012) rates of acute myeloid leukaemia, by age 
group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to nearest 5. The 
estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD.  
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Table B2(b): Survival and prevalence of acute myeloid leukaemia 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 823 627 1,450 
5-year prevalence 1,358 1,051 2,409 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 40.1 42.0 40.9 
95% confidence interval 37.9–42.2 39.5–44.4 39.3–42.5 
5-year relative survival at diagnosis (%) 23.4 26.1 24.5 
95% confidence interval 21.6–25.2 24.0–28.2 23.2–25.9 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 55.7 60.1 57.7 
95% confidence interval 50.8–60.6 55.2–65.0 54.2–61.2 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 87.6 91.1 89.3 
95% confidence interval 84.2–91.0 88.3–93.9 87.1–91.5 
 
 
Figure B2(c): Relative survival at diagnosis and 5-year conditional survival from acute myeloid 
leukaemia, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Anal cancer (C21)  
Table B3(a): Incidence and mortality of anal cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(a) 
Number 151 218 369  32 39 71 
Crude rate 1.4 1.9 1.7  0.3 0.3 0.3 
ASR 1.3 1.7 1.5  0.3 0.3 0.3 
Risk to age 75 1 in 961 1 in 693 1 in 804  1 in 4,842 1 in 4,000 1 in 4,375 
Risk to age 85 1 in 618 1 in 479 1 in 538  1 in 3,465 1 in 3,071 1 in 3,243 
Mean age 64.7 64.7 64.7  66.1 63.8 64.8 
Estimated number for 2014, 2015 and 2016(b) 
2014 155 230 385  40 40 80 
2015 160 235 395  40 40 80 
2016 165 245 405  45 40 85 
 
  
Figure B3(a): Incidence and mortality ASRs(a,b) of 
anal cancer, 1982–2016 
Figure B3(b): Incidence (2011) and mortality 
(2012) rates of anal cancer, by age group 
(a) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(b) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to nearest 5. The 
estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B3(b): Survival and prevalence of anal cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 266 374 640 
5-year prevalence 587 851 1,438 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 86.4 89.6 88.3 
95% confidence interval 83.2–89.1 87.2–91.6 86.4–89.9 
5-year relative survival at diagnosis (%) 58.9 68.6 64.5 
95% confidence interval 54.4–63.2 65.0–72.1 61.7–67.3 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 65.1 74.4 70.6 
95% confidence interval 59.0–71.2 70.2–78.5 67.1–74.0 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 82.9 88.8 86.5 
95% confidence interval 77.0–88.8 84.7–93.0 83.0–89.9 
 
 
Figure B3(c): Relative survival at diagnosis and 5-year conditional survival from anal cancer, 
Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Bladder cancer (C67) 
Risk factors(a):  
Table B4(a): Incidence and mortality of bladder cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 1,806 598 2,404  707 331 1,038 
Crude rate 16.2 5.3 10.8  6.3 2.9 4.6 
ASR 16.2 4.3 9.6  6.3 2.1 3.9 
Risk to age 75 1 in 115 1 in 410 1 in 180  1 in 386 1 in 1,120 1 in 578 
Risk to age 85 1 in 43 1 in 166 1 in 71  1 in 125 1 in 347 1 in 191 
Mean age 74.4 76.1 74.8  77.9 80.3 78.6 
Estimated number for 2014, 2015 and 2016(c) 
2014 2,060 675 2,730  780 335 1,115 
2015 2,110 690 2,800  800 340 1,140 
2016 2,170 705 2,880  815 350 1,165 
 
  
Figure B4(a): Incidence and mortality ASRs(b,c) of 
bladder cancer, 1982–2016 
Figure B4(b): Incidence (2011) and mortality 
(2012) rates of bladder cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B4(b): Survival and prevalence of bladder cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 3,194 1,053 4,247 
5-year prevalence 6,880 2,068 8,948 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 78.8 68.9 76.4 
95% confidence interval 77.8–79.8 66.9–70.8 75.5–77.3 
5-year relative survival at diagnosis (%) 55.2 46.8 53.1 
95% confidence interval 53.8–56.5 44.5–49.0 51.9–54.3 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 66.9 66.6 66.8 
95% confidence interval 64.9–68.8 63.1–70.1 65.1–68.5 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 84.0 86.7 84.7 
95% confidence interval 82.1–86.0 83.6–89.9 83.0–86.3 
 
 
Figure B4(c): Relative survival at diagnosis and 5-year conditional survival from bladder  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Brain cancer (C71) 
Table B5(a): Incidence and mortality of brain cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(a) 
Number 1,010 714 1,724  737 504 1,241 
Crude rate 9.1 6.4 7.7  6.5 4.4 5.5 
ASR 8.8 5.8 7.3  6.2 3.9 5.0 
Risk to age 75 1 in 145 1 in 220 1 in 175  1 in 201 1 in 327 1 in 249 
Risk to age 85 1 in 96 1 in 149 1 in 118  1 in 127 1 in 206 1 in 159 
Mean age 58.7 58.7 58.7  62.3 64.3 63.1 
Estimated number for 2014, 2015 and 2016(b) 
2014 1,060 740 1,800  790 540 1,330 
2015 1,090 755 1,850  805 550 1,355 
2016 1,120 775 1,900  825 560 1,385 
 
  
Figure B5(a): Incidence and mortality ASRs(b,c) of 
brain cancer, 1982–2016 
Figure B5(b): Incidence (2011) and mortality 
(2012) rates of brain cancer, by age group 
(a) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(b) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to nearest 5. The 
estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B5(b): Survival and prevalence of brain cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,547 1,098 2,645 
5-year prevalence 2,409 1,767 4,176 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 49.4 47.8 48.7 
95% confidence interval 47.8–50.9 45.9–49.7 47.5–49.9 
5-year relative survival at diagnosis (%) 20.5 23.2 21.6 
95% confidence interval 19.2–21.7 21.7–24.8 20.7–22.6 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 38.7 47.4 42.3 
95% confidence interval 34.0–43.4 42.7–52.1 38.9–45.6 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 74.6 83.1 78.4 
95% confidence interval 70.9–78.3 79.8–86.4 75.9–80.9 
 
 
Figure B5(c): Relative survival at diagnosis and 5-year conditional survival from brain cancer, 
Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Breast cancer (C50) 
Risk factors(a):  
Table B6(a): Incidence and mortality of breast cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 103 14,465 14,568  24 2,795 2,819 
Crude rate 0.9 128.9 65.2  0.2 24.5 12.4 
ASR 0.9 116.0 60.2  0.2 20.6 11.0 
Risk to age 75 1 in 1,477 1 in 11 1 in 21  1 in 9,098 1 in 67 1 in 131 
Risk to age 85 1 in 917 1 in 8 1 in 15  1 in 3,255 1 in 40 1 in 75 
Mean age 66.4 61.3 61.3  71.8 68.8 68.8 
Estimated number for 2014, 2015 and 2016(c) 
2014 140 15,270 15,410  25 3,000 3,025 
2015 145 15,600 15,740  25 3,040 3,065 
2016 150 15,930 16,080  25 3,080 3,105 
 
  
Figure B6(a): Incidence and mortality ASRs(b,c) of 
breast cancer, 1982–2016 
Figure B6(b): Incidence (2011) and mortality 
(2012) rates of breast cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B6(b): Survival and prevalence of breast cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 221 26,970 27,191 
5-year prevalence 552 71,145 71,697 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 99.4 97.9 97.9 
95% confidence interval 97.1–
100.8 
97.7–98.0 97.7–98.0 
5-year relative survival at diagnosis (%) 86.4 89.6 89.6 
95% confidence interval 81.5–90.8 89.3–89.9 89.2–89.9 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 85.5 90.0 89.9 
95% confidence interval 80.7–90.3 89.7–90.3 89.6–90.2 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 90.0 93.2 93.2 
95% confidence interval 84.3–95.6 92.9–93.5 92.9–93.5 
 
 
Figure B6(c): Relative survival at diagnosis and 5-year conditional survival from breast cancer in 
females, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Cervical cancer (C53) 
Risk factors(a):  
Table B7(a): Incidence and mortality of cervical cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number . . 801 801  . . 226 226 
Crude rate . . 7.1 . .  . . 2.0 . . 
ASR . . 6.9 . .  . . 1.8 . . 
Risk to age 75 . . 1 in 193 . .  . . 1 in 828 . . 
Risk to age 85 . . 1 in 162 . .  . . 1 in 496 . . 
Mean age . . 48.7 . .  . . 63.0 . . 
Estimated number for 2014, 2015 and 2016(c) 
2014 . . 865 865  . . 245 245 
2015 . . 885 885  . . 250 250 
2016 . . 905 905  . . 255 255 
 
  
Figure B7(a): Incidence and mortality ASRs(b,c) of 
cervical cancer, 1982–2016 
Figure B7(b): Incidence (2011) and mortality 
(2012) rates of cervical cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B7(b): Survival and prevalence of cervical cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence . . 1,459 1,459 
5-year prevalence . . 3,643 3,643 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) . . 87.4 87.4 
95% confidence interval . . 86.2–88.5 86.2–88.5 
5-year relative survival at diagnosis (%) . . 71.9 71.9 
95% confidence interval . . 70.2–73.4 70.2–73.4 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) . . 80.8 80.8 
95% confidence interval . . 79.2–82.3 79.2–82.3 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) . . 94.6 94.6 
95% confidence interval . . 93.6–95.7 93.6–95.7 
 
 
Figure B7(c): Relative survival at diagnosis and 5-year conditional survival from cervical  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Chronic lymphocytic leukaemia (C91.1) 
Risk factors(a):  
Table B8(a): Incidence and mortality (2012) of chronic lymphocytic leukaemia 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 722 452 1,174  203 139 342 
Crude rate 6.5 4.0 5.3  1.8 1.2 1.5 
ASR 6.2 3.4 4.7  1.8 0.9 1.3 
Risk to age 75 1 in 211 1 in 386 1 in 273  1 in 1,461 1 in 3,843 1 in 2,128 
Risk to age 85 1 in 117 1 in 212 1 in 153  1 in 413 1 in 895 1 in 581 
Mean age 68.6 72.1 70.0  78.5 82.0 79.9 
Estimated number for 2014, 2015 and 2016(c) 
2014 790 510 1,300  230 145 375 
2015 805 520 1,330  240 145 385 
2016 825 535 1,360  245 150 395 
 
  
Figure B8(a): Incidence and mortality ASRs(b,c) of 
chronic lymphocytic leukaemia, 1982–2016 
Figure B8(b): Incidence (2011) and mortality 
(2012) rates of chronic lymphocytic leukaemia, 
by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B8(b): Survival and prevalence of chronic lymphocytic leukaemia 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,284 783 2,067 
5-year prevalence 3,255 1,985 5,240 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 93.1 93.7 93.3 
95% confidence interval 92.0–94.2 92.2–94.9 92.4–94.2 
5-year relative survival at diagnosis (%) 74.8 79.8 76.7 
95% confidence interval 72.8–76.8 77.3–82.2 75.1–78.2 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 75.8 81.6 78.0 
95% confidence interval 73.5–78.1 79.0–84.2 76.3–79.7 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 73.0 81.8 76.6 
95% confidence interval 69.8–76.2 78.5–85.1 74.3–78.9 
 
 
Figure B8(c): Relative survival at diagnosis and 5-year conditional survival from chronic 
lymphocytic leukaemia, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Colorectal cancer (C18–C20) 
Risk factors(a):  
Table B9(a): Incidence and mortality of colorectal cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 8,351 6,800 15,151  2,208 1,772 3,980 
Crude rate 75.1 60.6 67.8  19.5 15.5 17.5 
ASR 72.8 51.5 61.5  19.1 12.4 15.4 
Risk to age 75 1 in 19 1 in 28 1 in 23  1 in 91 1 in 145 1 in 112 
Risk to age 85 1 in 10 1 in 15 1 in 12  1 in 38 1 in 61 1 in 48 
Mean age 69.1 70.6 69.8  72.3 74.6 73.3 
Estimated number for 2014, 2015 and 2016(c) 
2014 9,290 7,340 16,640  2,210 1,910 4,120 
2015 9,550 7,520 17,070  2,190 1,930 4,120 
2016 9,810 7,710 17,520  2,170 1,950 4,120 
 
  
Figure B9(a): Incidence and mortality ASRs(b,c) of 
colorectal cancer, 1982–2016 
Figure B9(b): Incidence (2011) and mortality 
(2012) rates of colorectal cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD2011; AIHW NMD. 
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Table B9(b): Survival and prevalence of colorectal cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 9,153 8,521 17,674 
5-year prevalence 20,709 19,654 40,363 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 85.7 84.1 85.0 
95% confidence interval 85.3–86.1 83.6–84.6 84.7–85.3 
5-year relative survival at diagnosis (%) 66.4 67.4 66.9 
95% confidence interval 65.8–67.0 66.7–68.1 66.4–67.3 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 75.3 78.5 76.7 
95% confidence interval 74.6–76.0 77.8–79.3 76.2–77.3 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 90.1 92.7 91.3 
95% confidence interval 89.4–90.9 91.9–93.4 90.8–91.8 
 
 
Figure B9(c): Relative survival at diagnosis and 5-year conditional survival from colorectal  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Cancer of the gallbladder and extrahepatic bile ducts 
(C23–C24) 
Risk factors(a):  
Table B10(a): Incidence and mortality of cancer of the gallbladder and extrahepatic bile ducts 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 335 436 771  99 155 254 
Crude rate 3.0 3.9 3.5  0.9 1.4 1.1 
ASR 3.0 3.2 3.1  0.9 1.1 1.0 
Risk to age 75 1 in 523 1 in 499 1 in 511  1 in 2,654 1 in 1,755 1 in 2,107 
Risk to age 85 1 in 243 1 in 215 1 in 227  1 in 823 1 in 649 719 
Mean age 72.5 73.0 72.8  75.5 1 in 76.7 1 in 76.3 
Estimated number for 2014, 2015 and 2016(c) 
2014 355 440 795  110 150 260 
2015 365 450 815  115 145 260 
2016 380 460 840  120 145 265 
 
  
Figure B10(a): Incidence and mortality ASRs(b,c) 
of cancer of gallbladder and extrahepatic bile 
ducts, 1982–2016 
Figure B10(b): Incidence (2011) and mortality 
(2012) rates of cancer of gallbladder and 
extrahepatic bile ducts, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2).  
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding.  
Sources: AIHW ACD 2011 and AIHW NMD. 
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Table B10(b): Survival and prevalence of cancer of the gallbladder and extrahepatic bile ducts 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 522 601 1,123 
5-year prevalence 836 899 1,735 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 49.5 39.3 43.9 
95% confidence interval 46.8–52.2 36.9–41.7 42.1–45.8 
5-year relative survival at diagnosis (%) 20.3 17.0 18.5 
95% confidence interval 18.1–22.7 15.2–19.0 17.1–20.1 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 37.7 40.4 39.1 
95% confidence interval 28.6–46.9 31.9–48.9 32.9–45.3 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 81.0 82.9 82.0 
95% confidence interval 73.4–88.6 76.3–89.5 77.1–87.0 
 
 
Figure B10(c): Relative survival at diagnosis and 5-year conditional survival from cancer of the 
gallbladder and extrahepatic bile ducts, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Hodgkin lymphoma (C81) 
Risk factors(a):  
Table B11(a): Incidence and mortality of Hodgkin lymphoma 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 338 268 606  55 23 78 
Crude rate 3.0 2.4 2.7  0.5 0.2 0.3 
ASR 3.0 2.3 2.7  0.5 0.2 0.3 
Risk to age 75 1 in 437 1 in 596 1 in 505  1 in 3,791 1 in 11,785 1 in 5,784 
Risk to age 85 1 in 361 1 in 479 1 in 412  1 in 1,546 1 in 5,655 1 in 2,533 
Mean age 43.4 42.4 43.0  71.3 64.8 69.4 
Estimated number for 2014, 2015 and 2016(c) 
2014 335 265 605  15 15 30 
2015 345 270 615  15 15 30 
2016 350 275 630  15 15 30 
 
  
Figure B11(a): Incidence and mortality ASRs(b,c) 
of Hodgkin lymphoma, 1982–2016 
Figure B11(b): Incidence (2011) and mortality 
(2012) rates of Hodgkin lymphoma, by age 
group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD.  
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Table B11(b): Survival and prevalence of Hodgkin lymphoma 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 579 472 1,051 
5-year prevalence 1,521 1,323 2,844 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 93.8 92.9 93.4 
95% confidence interval 92.3–95.1 91.2–94.4 92.3–94.4 
5-year relative survival at diagnosis (%) 87.3 87.1 87.2 
95% confidence interval 85.1–89.2 84.8–89.1 85.7–88.6 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 91.9 92.9 92.4 
95% confidence interval 90.3–93.6 91.3–94.5 91.2–93.5 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 94.9 95.7 95.3 
95% confidence interval 93.4–96.4 94.2–97.1 94.2–96.3 
 
 
Figure B11(c): Relative survival at diagnosis and 5-year conditional survival from Hodgkin 
lymphoma, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Kidney cancer (C64) 
Risk factors(a):  
Table B12(a): Incidence and mortality of kidney cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 1,861 985 2,847  574 333 907 
Crude rate 16.7 8.8 12.7  5.1 2.9 4.0 
ASR 16.0 7.7 11.7  4.9 2.3 3.5 
Risk to age 75 1 in 78 1 in 159 1 in 105  1 in 318 1 in 855 1 in 466 
Risk to age 85 1 in 51 1 in 104 1 in 69  1 in 156 1 in 314 1 in 212 
Mean age 63.5 64.7 63.9  70.5 76.2 72.6 
Estimated number for 2014, 2015 and 2016(c) 
2014 2,000 1,060 3,060  625 355 980 
2015 2,060 1,080 3,150  635 360 995 
2016 2,120 1,110 3,230  650 365 1,015 
 
  
Figure B12(a): Incidence and mortality ASRs(b,c) 
of kidney cancer, 1982–2016 
Figure B12(b): Incidence (2011) and mortality 
(2012) rates of kidney cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B12(b): Survival and prevalence of kidney cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 3,302 1,794 5,096 
5-year prevalence 7,810 4,169 11,979 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 86.0 85.1 85.7 
95% confidence interval 85.1–86.8 83.9–86.2 85.0–86.3 
5-year relative survival at diagnosis (%) 72.9 74.2 73.4 
95% confidence interval 71.7–74.1 72.6–75.7 72.4–74.3 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 82.8 85.6 83.8 
95% confidence interval 81.6–84.1 84.1–87.1 82.8–84.8 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 88.3 91.3 89.4 
95% confidence interval 86.8–89.7 89.7–92.9 88.3–90.5 
 
 
Figure B12(c): Relative survival at diagnosis and 5-year conditional survival from kidney  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Laryngeal cancer (C32) 
Risk factors(a):  
Table B13(a): Incidence and mortality of laryngeal cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 526 64 590  184 24 208 
Crude rate 4.7 0.6 2.6  1.6 0.2 0.9 
ASR 4.5 0.5 2.4  1.6 0.2 0.8 
Risk to age 75 1 in 276 1 in 2,420 1 in 499  1 in 988 1 in 7,008 1 in 1,747 
Risk to age 85 1 in 166 1 in 1,482 1 in 310  1 in 419 1 in 3,984 1 in 802 
Mean age 67.2 67.6 67.2  71.5 72.9 71.6 
Estimated number for 2014, 2015 and 2016(c) 
2014 585 80 665  200 40 240 
2015 595 80 675  205 40 245 
2016 605 85 690  205 40 245 
 
  
Figure B13(a): Incidence and mortality ASRs(b,c) 
of laryngeal cancer, 1982–2016 
Figure B13(b): Incidence (2011) and mortality 
(2012) rates of laryngeal cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B13(b): Survival and prevalence of laryngeal cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 981 131 1,112 
5-year prevalence 2,421 290 2,711 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 84.7 81.9 84.4 
95% confidence interval 83.1–86.3 76.8–86.1 82.9–85.9 
5-year relative survival at diagnosis (%) 62.7 59.4 62.3 
95% confidence interval 60.4–64.9 53.1–65.4 60.2–64.4 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 71.0 69.7 70.8 
95% confidence interval 68.2–73.7 61.8–77.6 68.2–73.4 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 80.4 77.8 80.1 
95% confidence interval 77.4–83.3 69.3–86.3 77.3–82.9 
 
 
Figure B13(c): Relative survival at diagnosis and 5-year conditional survival from laryngeal  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Lip cancer (C00) 
Risk factors(a):  
Table B14(a): Incidence and mortality of lip cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 Incidence/2012 mortality(b) 
Number 677 235 912  11 1 12 
Crude rate 6.1 2.1 4.1  0.1 0.0 0.1 
ASR 5.9 1.8 3.8  0.1 0.0 0.1 
Risk to age 75 1 in 220 1 in 839 1 in 350  1 in 20,589 . .  1 in 41,555 
Risk to age 85 1 in 149 1 in 450 1 in 227  1 in 7,252 1 in 61,118 1 in 13,758 
Mean age 60.8 69.0 62.8  61.3 77.0 62.6 
Estimated number for 2014, 2015 and 2016(c) 
2014 740 265 1,010  10 5 15 
2015 750 270 1,020  10 5 15 
2016 760 270 1,030  10 5 15 
 
  
Figure B14(a): Incidence and mortality ASRs(b,c) 
of lip cancer, 1982–2016 
Figure B14(b): Incidence (2011) and mortality 
(2012) rates of lip cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: ABS 2014b; AIHW ACD 2011; AIHW NMD. 
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Table B14(b): Survival and prevalence of lip cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,250 486 1,736 
5-year prevalence 3,553 1,309 4,862 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 99.3 98.5 99.1 
95% confidence interval 98.6–99.8 97.0–99.6 98.5–99.6 
5-year relative survival at diagnosis (%) 93.3 93.8 93.4 
95% confidence interval 91.8–94.7 91.0–96.4 92.1–94.7 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 92.6 93.4 92.8 
95% confidence interval 91.2–93.9 90.9–95.8 91.6–94.0 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 94.8 93.9 94.6 
95% confidence interval 93.5–96.2 91.4–96.4 93.4–95.8 
 
 
Figure B14(c): Relative survival at diagnosis and 5-year conditional survival from lip cancer, 
Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Liver cancer (C22) 
Risk factors(a):  
Table B15(a): Incidence and mortality of liver cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 1,041 406 1,446  976 514 1,490 
Crude rate 9.4 3.6 6.5  8.6 4.5 6.6 
ASR 9.0 3.1 5.9  8.3 3.7 5.9 
Risk to age 75 1 in 150 1 in 451 1 in 226  1 in 171 1 in 417 1 in 244 
Risk to age 85 1 in 84 1 in 242 1 in 127  1 in 87 1 in 196 1 in 123 
Mean age 66.7 69.0 67.4  69.1 72.1 70.1 
Estimated number for 2014, 2015 and 2016(c) 
2014 1,260 430 1,690  1,080 535 1,615 
2015 1,320 445 1,760  1,150 565 1,715 
2016 1,380 460 1,840  1,210 595 1,805 
 
  
Figure B15(a): Incidence and mortality ASRs(b,c) 
of liver cancer, 1982–2016 
Figure B15(b): Incidence (2011) and mortality 
(2012) rates of liver cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B15(b): Survival and prevalence of liver cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,625 590 2,215 
5-year prevalence 2,349 865 3,214 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 41.0 37.4 40.0 
95% confidence interval 39.5–42.6 35.0–39.9 38.8–41.3 
5-year relative survival at diagnosis (%) 16.3 15.1 16.0 
95% confidence interval 15.2–17.6 13.4–17.0 15.0–17.0 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 35.6 37.5 36.1 
95% confidence interval 29.7–41.6 28.0–46.9 31.1–41.2 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 70.6 74.6 71.7 
95% confidence interval 64.6–76.6 65.5–83.6 66.7–76.7 
 
 
Figure B15(c): Relative survival at diagnosis and 5-year conditional survival from liver cancer, 
Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Lung cancer (C33–C34) 
Risk factors(a):  
Table B16(a): Incidence and mortality of lung cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 6,409 4,102 10,511  4,882 3,255 8,137 
Crude rate 57.6 36.6 47.1  43.2 28.5 35.8 
ASR 56.2 31.4 42.5  41.8 23.7 31.8 
Risk to age 75 1 in 26 1 in 41 1 in 32  1 in 38 1 in 58 1 in 46 
Risk to age 85 1 in 13 1 in 23 1 in 17  1 in 17 1 in 29 1 in 22 
Mean age 71.5 70.2 71.0  72.4 72.2 72.3 
Estimated number for 2014, 2015 and 2016(c) 
2014 6,860 4,720 11,580  5,150 3,480 8,630 
2015 6,990 4,890 11,880  5,190 3,600 8,790 
2016 7,130 5,070 12,200  5,240 3,720 8,960 
 
  
Figure B16(a): Incidence and mortality ASRs(b,c) 
of lung cancer, 1982–2016 
Figure B16(b): Incidence (2011) and mortality 
(2012) rates of lung cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B16(b): Survival and prevalence of lung cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 9,501 6,644 16,145 
5-year prevalence 13,704 9,834 23,538 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 36.0 43.6 39.0 
95% confidence interval 35.5–36.6 42.9–44.4 38.6–39.5 
5-year relative survival at diagnosis (%) 12.5 17.1 14.3 
95% confidence interval 12.1–13.0 16.5–17.7 14.0–14.7 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 31.6 36.4 33.6 
95% confidence interval 29.0–34.2 33.7–39.1 31.7–35.6 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 67.6 73.2 70.0 
95% confidence interval 64.9–70.3 70.6–75.8 68.1–71.9 
 
 
Figure B16(c): Relative survival at diagnosis and 5-year conditional survival from lung cancer, 
Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Melanoma of the skin (C43) 
Risk factors(a):  
Table B17(a): Incidence and mortality of melanoma of the skin 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 6,734 4,835 11,570  1,039 476 1,515 
Crude rate 60.6 43.1 51.8  9.2 4.2 6.7 
ASR 58.5 39.0 48.0  9.0 3.4 5.9 
Risk to age 75 1 in 23 1 in 33 1 in 27  1 in 187 1 in 456 1 in 266 
Risk to age 85 1 in 14 1 in 24 1 in 18  1 in 84 1 in 240 1 in 129 
Mean age 63.2 60.4 62.0  70.9 70.6 70.8 
Estimated number for 2014, 2015 and 2016(c) 
2014 7,440 5,210 12,640  1,120 505 1,625 
2015 7,640 5,320 12,960  1,160 515 1,675 
2016 7,850 5,440 13,280  1,210 530 1,740 
 
  
Figure B17(a): Incidence and mortality ASRs(b,c) 
of melanoma of the skin, 1982–2016 
Figure B17(b): Incidence (2011) and mortality 
(2012) rates for melanoma of the skin, by age 
group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B17(b): Survival and prevalence of melanoma of the skin 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 12,861 9,218 22,079 
5-year prevalence 33,138 25,309 58,447 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 96.3 98.3 97.1 
95% confidence interval 96.0–96.6 98.0–98.5 96.9–97.3 
5-year relative survival at diagnosis (%) 88.2 93.5 90.4 
95% confidence interval 87.6–88.7 92.9–94.0 90.0–90.8 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 90.4 94.5 92.2 
95% confidence interval 89.9–90.9 94.0–94.9 91.8–92.5 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 95.8 97.6 96.6 
95% confidence interval 95.3–96.3 97.2–98.1 96.3–97.0 
 
 
Figure B17(c): Relative survival at diagnosis and 5-year conditional survival from melanoma of the 
skin, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Mesothelioma (C45) 
Risk factors(a):  
Table B18(a): Incidence and mortality of mesothelioma 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 573 117 690  538 100 638 
Crude rate 5.2 1.0 3.1  4.8 0.9 2.8 
ASR 5.1 0.9 2.8  4.6 0.7 2.5 
Risk to age 75 1 in 302 1 in 1,505 1 in 507  1 in 382 1 in 2,057 1 in 650 
Risk to age 85 1 in 130 1 in 842 1 in 238  1 in 140 1 in 970 1 in 259 
Mean age 73.3 73.3 73.3  74.4 74.0 74.3 
Estimated number for 2014, 2015 and 2016(c) 
2014 640 145 780  575 125 700 
2015 655 150 805  595 130 725 
2016 675 155 830  620 135 755 
 
  
Figure B18(a): Incidence and mortality ASRs(b,c) 
of mesothelioma, 1982–2016 
Figure B18(b): Incidence (2011) and mortality 
(2012) rates of mesothelioma, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B18(b): Survival and prevalence of mesothelioma 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 908 203 1,111 
5-year prevalence 1,194 277 1,471 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 43.1 47.7 43.9 
95% confidence interval 41.1–45.1 43.3–51.9 42.1–45.7 
5-year relative survival at diagnosis (%) 5.2 8.4 5.8 
95% confidence interval 4.4–6.2 6.2–11.0 4.9–6.7 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) n.p.(c) n.p.(c) n.p.(c) 
95% confidence interval n.p.(c) n.p.(c) n.p.(c) 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 44.8 41.7 45.1 
95% confidence interval 21.5–68.2 10.5–72.9 27.4–62.8 
 
 
Figure B18(c): Relative survival at diagnosis and 5-year conditional survival from mesothelioma, 
Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
(c) Survival estimates and confidence interval are not presented due to the high standard error. 
Source: AIHW ACD 2011. 
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Mouth cancer (C03–C06) 
Risk factors(a):  
Table B19(a): Incidence and mortality of mouth cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 356 215 571  76 43 119 
Crude rate 3.2 1.9 2.6  0.7 0.4 0.5 
ASR 3.0 1.6 2.3  0.6 0.3 0.5 
Risk to age 75 1 in 392 1 in 760 1 in 518  1 in 1,714 1 in 6,239 1 in 2,707 
Risk to age 85 1 in 272 1 in 483 1 in 350  1 in 1,293 1 in 3,819 1 in 1,960 
Mean age 64.3 68.3 65.8  68.0 77.4 71.4 
Estimated number for 2014, 2015 and 2016(c) 
2014 360 230 595  75 55 130 
2015 370 235 605  75 55 130 
2016 380 245 620  75 55 130 
 
  
Figure B19(a): Incidence and mortality ASRs(b,c) 
of mouth cancer, 1982–2016 
Figure B19(b): Incidence (2011) and mortality 
(2012) rates of mouth cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B19(b): Survival and prevalence of mouth cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 590 380 970 
5-year prevalence 1,316 875 2,191 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 82.0 83.6 82.6 
95% confidence interval 79.8–84.0 80.8–86.1 80.9–84.2 
5-year relative survival at diagnosis (%) 57.0 63.7 59.6 
95% confidence interval 54.2–59.8 60.0–67.3 57.3–61.8 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 65.8 74.0 69.0 
95% confidence interval 61.8–69.8 69.7–78.3 66.0–71.9 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 72.1 81.8 76.1 
95% confidence interval 67.4–76.8 77.1–86.5 72.8–79.5 
 
 
Figure B19(c): Relative survival at diagnosis and 5-year conditional survival from mouth  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Multiple primary cancers (C97) 
Table B20(a): Mortality of multiple primary cancers 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2012 mortality(a) 
Number . . . . . .  312 194 506 
Crude rate . . . . . .  2.8 1.7 2.2 
ASR . . . . . .  2.8 1.3 1.9 
Risk to age 75 . . . . . .  1 in 990 1 in 1,259 1 in 1,110 
Risk to age 85 . . . . . .  1 in 259 1 in 589 1 in 376 
Mean age . . . . . .  78.1 75.9 77.2 
Estimated number for 2014, 2015 and 2016(b) 
2014 . . . . . .  415 230 645 
2015 . . . . . .  430 240 670 
2016 . . . . . .  445 245 690 
 
  
Figure B20(a): Mortality ASRs(a,b) of multiple 
primary cancers, 1982–2016 
Figure B20(b): Mortality (2012) rates of multiple 
primary cancers, by age group 
(a) Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based 
on revised and preliminary versions, respectively and are subject to further revision by the ABS. ASRs were directly standardised to the 
Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(b) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Although a person can have more than one primary cancer, a diagnosis of ‘multiple primary 
cancers’ (ICD-10 code C97) is not used by cancer registries; rather, each of the person’s 
cancers is coded separately. C97 only occurs in mortality data in cases when the certifying 
doctor cannot determine which of the cancers was the underlying cause of death. Because 
C97 is not a diagnosis used by cancer registries, prevalence and survival have not been 
calculated.  
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Myelodysplastic syndromes (D46) 
Table B21(a): Incidence and mortality of myelodysplastic syndromes 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(a) 
Number 829 480 1,309  268 156 424 
Crude rate 7.5 4.3 5.9  2.4 1.4 1.9 
ASR 7.6 3.4 5.2  2.4 1.0 1.6 
Risk to age 75 1 in 304 1 in 532 1 in 388  1 in 1,889 1 in 3,296 1 in 2,407 
Risk to age 85 1 in 95 1 in 203 1 in 134  1 in 323 1 in 942 1 in 506 
Mean age 76.8 76.5 76.7  81.3 83.5 82.1 
Estimated number for 2014, 2015 and 2016(b) 
2014 910 490 1,400  275 165 440 
2015 945 495 1,440  280 170 450 
2016 975 500 1,480  290 175 465 
 
  
Figure B21(a): Incidence and mortality ASRs(a,b) 
of myelodysplastic syndromes, 1982–2016 
Figure B21(b): Incidence (2011) and mortality 
(2012) rates of myelodysplastic syndromes, by 
age group 
(a) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(b) The 2012–2016 estimates for incidence are based on 2003–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B21(b): Survival and prevalence of myelodysplastic syndromes 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,239 819 2,058 
5-year prevalence 2,378 1,628 4,006 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 72.5 74.6 73.3 
95% confidence interval 70.7–74.2 72.4–76.6 71.9–74.6 
5-year relative survival at diagnosis (%) 36.5 40.3 38.0 
95% confidence interval 34.5–38.6 37.8–42.8 36.4–39.6 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 43.4 45.9 44.4 
95% confidence interval 38.2–48.5 40.3–51.6 40.6–48.2 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 49.7 57.6 53.4 
95% confidence interval 40.8–58.6 49.5–65.6 47.4–59.4 
 
 
Figure B21(c): Relative survival at diagnosis and 5-year conditional survival from  
myelodysplastic syndromes, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Myeloma (C90) 
Table B22(a): Incidence and mortality of myeloma 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(a) 
Number 886 647 1,533  470 364 834 
Crude rate 8.0 5.8 6.9  4.2 3.2 3.7 
ASR 7.7 4.9 6.2  4.1 2.5 3.2 
Risk to age 75 1 in 191 1 in 268 1 in 223  1 in 469 1 in 742 1 in 576 
Risk to age 85 1 in 96 1 in 149 1 in 118  1 in 162 1 in 275 1 in 209 
Mean age 70.1 71.3 70.6  74.3 77.5 75.7 
Estimated number for 2014, 2015 and 2016(b) 
2014 975 700 1,680  535 405 940 
2015 1,010 715 1,730  550 415 965 
2016 1,050 735 1,780  570 425 995 
 
  
Figure B22(a): Incidence and mortality ASRs(a,b) 
of myeloma, 1982–2016 
Figure B22(b): Incidence (2011) and mortality 
(2012) rates of myeloma, by age group 
(a) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(b) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B22(b): Survival and prevalence of myeloma 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,520 1,097 2,617 
5-year prevalence 3,047 2,236 5,283 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 80.5 78.5 79.6 
95% confidence interval 79.0–81.9 76.7–80.1 78.5–80.7 
5-year relative survival at diagnosis (%) 45.4 43.9 44.8 
95% confidence interval 43.5–47.3 41.8–46.0 43.4–46.2 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 48.9 48.5 48.8 
95% confidence interval 45.1–52.7 44.3–52.7 46.0–51.6 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 55.7 57.2 56.4 
95% confidence interval 50.5–61.0 51.6–62.8 52.6–60.2 
 
 
Figure B22(c): Relative survival at diagnosis and 5-year conditional survival from myeloma, 
Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Myeloproliferative cancers excluding CML (C94.1, 
C94.3, C96.2, D45, D47.1, D47.3) 
Table B23(a): Incidence and mortality of myeloproliferative cancers excluding CML 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(a) 
Number 359 293 651  80 81 161 
Crude rate 3.2 2.6 2.9  0.7 0.7 0.7 
ASR 3.2 2.3 2.7  0.7 0.5 0.6 
Risk to age 75 1 in 471 1 in 628 1 in 539  1 in 3,781 1 in 4,495 1 in 4,109 
Risk to age 85 1 in 246 1 in 352 1 in 293  1 in 1,158 1 in 1,658 1 in 1,385 
Mean age 65.1 65.6 65.3  77.4 82.4 79.9 
Estimated number for 2014, 2015 and 2016(b) 
2014 320 300 625  95 95 190 
2015 315 300 615  100 95 195 
2016 310 300 610  100 100 200 
 
  
Figure B23(a): Incidence and mortality ASRs(a,b) 
of myeloproliferative cancers excluding CML, 
1982–2016 
Figure B23(b): Incidence (2011) and mortality 
(2012) rates of other myeloproliferative cancers 
excluding CML, by age group 
(a) 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the ACT 
(see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 
and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were directly 
standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(b) The 2012–2016 estimates for incidence are based on 2003–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B23(b): Survival and prevalence of myeloproliferative cancers excluding CML 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 606 560 1,166 
5-year prevalence 1,805 1,644 3,449 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 91.5 93.7 92.5 
95% confidence interval 89.7–93.0 92.1–95.1 91.3–93.6 
5-year relative survival at diagnosis (%) 71.8 81.7 76.4 
95% confidence interval 69.2–74.3 79.0–84.1 74.5–78.2 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 74.6 82.7 78.4 
95% confidence interval 71.6–77.6 80.0–85.4 76.4–80.4 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 77.1 80.1 78.5 
95% confidence interval 73.2–80.9 76.3–83.8 75.8–81.2 
 
 
Figure B23(c): Relative survival at diagnosis and 5-year conditional survival from 
myeloproliferative cancers excluding CML, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Non-Hodgkin lymphoma (C82–C85) 
Risk factor(a):  
Table B24(a): Incidence and mortality of non–Hodgkin lymphoma 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 2,639 1,992 4,631  820 582 1,402 
Crude rate 23.7 17.8 20.7  7.2 5.1 6.2 
ASR 23.1 15.5 19.1  7.1 4.0 5.4 
Risk to age 75 1 in 59 1 in 88 1 in 71  1 in 262 1 in 514 1 in 348 
Risk to age 85 1 in 34 1 in 50 1 in 41  1 in 99 1 in 174 1 in 128 
Mean age 64.3 66.8 65.4  73.7 76.3 74.7 
Estimated number for 2014, 2015 and 2016(c) 
2014 2,780 2,170 4,940  830 605 1,435 
2015 2,850 2,220 5,070  840 600 1,440 
2016 2,930 2,270 5,200  850 595 1,445 
 
  
Figure B24(a): Incidence and mortality ASRs(b,c) 
of non-Hodgkin lymphoma, 1982–2016 
Figure B24(b): Incidence (2011) and mortality 
(2012) rates of non-Hodgkin lymphoma, by age 
group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B24(b): Survival and prevalence of non–Hodgkin lymphoma 
 Males Females Persons 
Prevalence as at the end of 2009(b) 
1-year prevalence 4,479 3,529 8,008 
5-year prevalence 10,528 8,513 19,041 
Relative survival in 2007–2011(c) 
1-year relative survival at diagnosis (%) 84.3 83.9 84.1 
95% confidence interval 83.6–85.1 83.0–84.7 83.6–84.7 
5-year relative survival at diagnosis (%) 71.4 72.9 72.1 
95% confidence interval 70.3–72.4 71.8–74.0 71.3–72.8 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 81.7 84.8 83.1 
95% confidence interval 80.6–82.8 83.7–85.9 82.3–83.9 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 86.9 89.0 87.9 
95% confidence interval 85.7–88.1 87.7–90.2 87.0–88.7 
 
 
Figure B24(c): Relative survival at diagnosis and 5-year conditional survival from non–Hodgkin 
lymphoma, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Non-melanoma skin cancer (C44) 
Risk factors(a):  
Table B25(a): Incidence and mortality of non-melanoma skin cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 487 282 769  362 159 521 
Crude rate 4.4 2.5 3.4  3.2 1.4 2.3 
ASR 4.4 2.1 3.1  3.2 1.0 1.9 
Risk to age 75 1 in 421 1 in 763 1 in 544  1 in 715 1 in 3,521 1 in 1,197 
Risk to age 85 1 in 170 1 in 368 1 in 239  1 in 265 1 in 889 1 in 424 
Mean age 70.7 70.8 70.8  76.3 84.0 78.7 
Estimated number for 2014, 2015 and 2016(c) 
2014 530 315 845  345 175 520 
2015 545 325 870  355 180 535 
2016 565 330 895  360 185 545 
 
  
Figure B25(a): Incidence and mortality ASRs(b,c) 
of non-melanoma skin cancer, 1982–2016 
Figure B25(b): Incidence (2011) and mortality 
(2012) rates of non-melanoma skin cancer, by 
age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) For incidence data, ICD-10 C44 codes that indicate a basal or squamous cell carcinoma of the skin are not included. The 2011 incidence 
data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the ACT (see Appendix F). 
Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based 
on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were directly standardised to the 
Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD.  
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Table B25(b): Survival and prevalence of non-melanoma skin cancer(a) 
 Males Females Persons 
Prevalence as at the end of 2009(b) 
1-year prevalence 860 524 1,384 
5-year prevalence 1,965 1,260 3,225 
Relative survival in 2007–2011(c) 
1-year relative survival at diagnosis (%) 89.3 88.2 88.9 
95% confidence interval 87.6–90.9 85.9–90.2 87.5–90.1 
5-year relative survival at diagnosis (%) 70.0 73.7 71.5 
95% confidence interval 67.2–72.7 70.4–76.9 69.4–73.5 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 77.5 81.7 79.2 
95% confidence interval 74.4–80.6 78.3–85.1 76.9–81.5 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 89.7 92.2 90.8 
95% confidence interval 86.5–92.8 89.0–95.4 88.6–93.1 
 
 
Figure B25(c):  Relative survival at diagnosis and 5-year conditional survival from  
non-melanoma skin cancer, Australia, 2007–2011 
(a) For survival and prevalence data, those ICD-10 C44 codes that indicate a basal or squamous cell carcinoma of the skin are not included.  
(b) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(c) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Oesophageal cancer (C15) 
Risk factors(a):  
Table B26(a): Incidence and mortality of oesophageal cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 991 404 1,395  879 324 1,203 
Crude rate 8.9 3.6 6.2  7.8 2.8 5.3 
ASR 8.6 3.0 5.6  7.4 2.2 4.7 
Risk to age 75 1 in 159 1 in 559 1 in 249  1 in 201 1 in 876 1 in 329 
Risk to age 85 1 in 85 1 in 230 1 in 127  1 in 97 1 in 339 1 in 155 
Mean age 69.5 74.8 71.0  70.5 76.4 72.1 
Estimated number for 2014, 2015 and 2016(c) 
2014 1,070 455 1,530  975 380 1,355 
2015 1,110 465 1,570  1,000 385 1,385 
2016 1,140 475 1,610  1,020 395 1,415 
 
  
Figure B26(a): Incidence and mortality ASRs(b,c) 
of oesophageal cancer, 1982–2016 
Figure B26(b): Incidence (2011) and mortality 
(2012) rates of oesophageal cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B26(b): Survival and prevalence of oesophageal cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,499 614 2,113 
5-year prevalence 2,216 947 3,163 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 47.3 44.9 46.6 
95% confidence interval 45.8–48.9 42.4–47.3 45.3–47.9 
5-year relative survival at diagnosis (%) 17.3 18.0 17.5 
95% confidence interval 16.1–18.6 16.1–20.0 16.5–18.6 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 34.3 38.4 35.6 
95% confidence interval 28.4–40.2 30.2–46.7 30.7–40.4 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 77.6 77.6 77.5 
95% confidence interval 72.4–82.7 70.8–84.5 73.4–81.7 
 
 
Figure B26(c):  Relative survival at diagnosis and 5-year conditional survival from oesophageal 
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Cancer of other digestive organs (C26) 
Table B27(a): Incidence and mortality of cancer of other digestive organs 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(a) 
Number 81 104 185  646 594 1,240 
Crude rate 0.7 0.9 0.8  5.7 5.2 5.5 
ASR 0.7 0.7 0.7  5.7 4.0 4.7 
Risk to age 75 1 in 2,917 1 in 4,390 1 in 3,514  1 in 375 1 in 569 1 in 453 
Risk to age 85 1 in 1,132 1 in 1,310 1 in 1,210  1 in 136 1 in 199 1 in 164 
Mean age 74.5 80.8 78.1  74.8 78.4 76.5 
Estimated number for 2014, 2015 and 2016(b) 
2014 85 110 195  740 680 1,420 
2015 90 110 200  765 695 1,460 
2016 95 115 205  790 715 1,505 
 
  
Figure B27(a): Incidence and mortality ASRs(a,b) 
of cancer of other digestive organs, 1982–2016 
Figure B27(b): Incidence (2011) and mortality 
(2012) rates of cancer of other digestive organs, 
by age group 
(a) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(b) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B27(b): Survival and prevalence of other digestive organs 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 101 114 215 
5-year prevalence 137 150 287 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 21.3 19.4 20.3 
95% confidence interval 16.4–26.7 15.1–24.3 17.0–23.8 
5-year relative survival at diagnosis (%) 12.9 11.3 12.1 
95% confidence interval 9.1–17.5 7.8–15.5 9.4–15.1 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 54.4 49.0 51.9 
95% confidence interval 32.3–76.5 24.2–73.8 35.3–68.4 
5-year conditional relative survival for those already survived 5 years after diagnosis 
(%) 
68.8 90.5 79.4 
95% confidence interval 45.0–92.5 74.7–106.3 65.2–93.6 
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Figure B27(c): Relative survival at diagnosis and 5-year conditional survival from other  
digestive organs, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Other soft tissue cancers (C47, C49) 
Table B28(a): Incidence and mortality of other soft tissue cancers 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(a) 
Number 372 270 641  133 132 265 
Crude rate 3.3 2.4 2.9  1.2 1.2 1.2 
ASR 3.3 2.2 2.7  1.2 1.0 1.1 
Risk to age 75 1 in 449 1 in 625 1 in 523  1 in 1,785 1 in 1,483 1 in 1,617 
Risk to age 85 1 in 270 1 in 412 1 in 330  1 in 578 1 in 784 1 in 682 
Mean age 58.8 60.5 59.5  66.6 68.2 67.4 
Estimated number for 2014, 2015 and 2016(b) 
2014 370 280 650  155 130 285 
2015 380 285 665  155 135 290 
2016 390 290 685  160 135 295 
 
  
Figure B28(a): Incidence and mortality ASRs(a,b) 
of other soft tissue cancers, 1982–2016 
Figure B28(b): Incidence (2011) and mortality 
(2012) rates of other soft tissue cancers, by age 
group 
(a) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(b) The 2012–2016 estimates for incidence are based on 2003–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B28(b): Survival and prevalence of other soft tissue cancers 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 592 472 1,064 
5-year prevalence 1,345 1,149 2,494 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 83.0 84.9 83.9 
95% confidence interval 80.8–85.0 82.6–87.0 82.3–85.4 
5-year relative survival at diagnosis (%) 65.0 67.7 66.2 
95% confidence interval 62.1–67.8 64.6–70.7 64.1–68.3 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 76.8 76.7 76.8 
95% confidence interval 73.6–80.0 73.3–80.1 74.5–79.1 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 90.5 90.2 90.4 
95% confidence interval 87.7–93.2 87.3–93.0 88.4–92.4 
 
 
Figure B28(c):  Relative survival at diagnosis and 5-year conditional survival from other soft  
tissue cancers, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Ovarian cancer (C56) 
Risk factors(a):  
Table B29(a): Incidence and mortality of ovarian cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number . . 1,330 1,330  . . 933 933 
Crude rate . . 11.9 . .  . . 8.2 . . 
ASR . . 10.4 . .  . . 6.7 . . 
Risk to age 75 . . 1 in 125 . .  . . 1 in 208 . . 
Risk to age 85 . . 1 in 81 . .  . . 1 in 111 . . 
Mean age . . 64.5 . .  . . 71.5 . . 
Estimated number for 2014, 2015 and 2016(c) 
2014 . . 1,430 1,430  . . 1,000 1,000 
2015 . . 1,460 1,460  . . 1,020 1,020 
2016 . . 1,480 1,480  . . 1,040 1,040 
 
  
Figure B29(a): Incidence and mortality ASRs(b,c) 
of ovarian cancer, 1982–2016 
Figure B29(b): Incidence (2011) and mortality 
(2012) rates of ovarian cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B29(b): Survival and prevalence of ovarian cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence . . 2,348 2,348 
5-year prevalence . . 4,997 4,997 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) . . 76.0 76.0 
95% confidence interval . . 74.8–77.1 74.8–77.1 
5-year relative survival at diagnosis (%) . . 43.0 43.0 
95% confidence interval . . 41.7–44.3 41.7–44.3 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) . . 52.5 52.5 
95% confidence interval . . 50.0–55.0 50.0–55.0 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) . . 78.1 78.1 
95% confidence interval . . 76.0–80.2 76.0–80.2 
 
 
Figure B29(c): Relative survival at diagnosis and 5-year conditional survival from ovarian  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Pancreatic cancer (C25) 
Risk factors(a):  
Table B30(a): Incidence and mortality of pancreatic cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 1,425 1,322 2,748  1,331 1,193 2,524 
Crude rate 12.8 11.8 12.3  11.8 10.5 11.1 
ASR 12.5 9.8 11.0  11.3 8.4 9.8 
Risk to age 75 1 in 116 1 in 158 1 in 134  1 in 135 1 in 202 1 in 162 
Risk to age 85 1 in 56 1 in 71 1 in 63  1 in 63 1 in 83 1 in 72 
Mean age 70.6 73.5 72.0  71.6 74.9 73.2 
Estimated number for 2014, 2015 and 2016(c) 
2014 1,530 1,410 2,940  1,360 1,280 2,640 
2015 1,570 1,460 3,030  1,400 1,310 2,710 
2016 1,620 1,500 3,120  1,450 1,350 2,800 
 
  
Figure B30(a): Incidence and mortality ASRs(b,c) 
of pancreatic cancer, 1982–2016 
Figure B30(b): Incidence (2011) and mortality 
(2012) rates of pancreatic cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B30(b): Survival and prevalence of pancreatic cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,932 1,741 3,673 
5-year prevalence 2,365 2,160 4,525 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 24.8 23.7 24.2 
95% confidence interval 23.7–25.8 22.6–24.8 23.5–25.0 
5-year relative survival at diagnosis (%) 6.0 6.2 6.1 
95% confidence interval 5.3–6.6 5.5–6.9 5.6–6.6 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 22.7 23.7 23.2 
95% confidence interval 14.1–31.3 15.0–32.5 17.0–29.3 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 75.6 75.4 75.5 
95% confidence interval 67.7–83.5 67.8–83.0 70.0–81.0 
 
 
Figure B30(c): Relative survival at diagnosis and 5-year conditional survival from pancreatic  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Prostate cancer (C61) 
Risk factors(a):  
Table B31(a): Incidence and mortality of prostate cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 19,993 . . 19,993  3,079 . . 3,079 
Crude rate 179.8 . . . .  27.2 . . . . 
ASR 167.3 . . . .  27.6 . . . . 
Risk to age 75 1 in 7 . . . .  1 in 119 . . . . 
Risk to age 85 1 in 5 . . . .  1 in 28 . . . . 
Mean age 68.2 . . . .  80.2 . . . . 
Estimated number for 2014, 2015 and 2016(c) 
2014 17,050 . . 17,050  3,390 . . 3,390 
2015 17,250 . . 17,250  3,440 . . 3,440 
2016 18,140 . . 18,140  3,500 . . 3,500 
 
  
Figure B31(a): Incidence and mortality ASRs(b,c) 
of prostate cancer, 1982–2016 
Figure B31(b): Incidence (2011) and mortality 
(2012) rates of prostate cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B31(b): Survival and prevalence of prostate cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 42,095 . . 42,095 
5-year prevalence 102,220 . . 102,220 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 98.3 . . 98.3 
95% confidence interval 98.1–98.4 . . 98.1–98.4 
5-year relative survival at diagnosis (%) 93.2 . . 93.2 
95% confidence interval 92.8–93.5 . . 92.8–93.5 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 93.6 . . 93.6 
95% confidence interval 93.4–93.9 . . 93.4–93.9 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 92.6 . . 92.6 
95% confidence interval 92.2–93.1 . . 92.2–93.1 
 
 
Figure B31(c): Relative survival at diagnosis and 5-year conditional survival from prostate  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Stomach cancer (C16) 
Risk factors(a):  
Table B32(a): Incidence and mortality of stomach cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 1,357 736 2,093  707 436 1,143 
Crude rate 12.2 6.6 9.4  6.3 3.8 5.0 
ASR 11.9 5.5 8.5  6.1 3.1 4.5 
Risk to age 75 1 in 125 1 in 268 1 in 171  1 in 261 1 in 610 1 in 367 
Risk to age 85 1 in 60 1 in 138 1 in 86  1 in 123 1 in 248 1 in 168 
Mean age 69.9 71.6 70.5  70.9 74.8 72.4 
Estimated number for 2014, 2015 and 2016(c) 
2014 1,460 785 2,240  700 415 1,115 
2015 1,480 800 2,280  695 415 1,110 
2016 1,510 815 2,330  690 410 1,100 
 
  
Figure B32(a): Incidence and mortality ASRs(b,c) 
of stomach cancer, 1982–2016 
Figure B32(b): Incidence (2011) and mortality 
(2012) rates of stomach cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B32(b): Survival and prevalence of stomach cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 2,221 1,126 3,347 
5-year prevalence 3,717 1,952 5,669 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 51.8 51.4 51.6 
95% confidence interval 50.4–53.1 49.5–53.3 50.6–52.7 
5-year relative survival at diagnosis (%) 26.4 28.3 27.0 
95% confidence interval 25.1–27.6 26.6–30.1 26.0–28.0 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 49.2 53.7 50.7 
95% confidence interval 45.7–52.7 49.3–58.0 48.0–53.5 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 87.4 90.7 88.6 
95% confidence interval 84.6–90.3 87.5–93.9 86.5–90.8 
 
 
Figure B32(c): Relative survival at diagnosis and 5-year conditional survival from stomach  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Testicular cancer (C62) 
Risk factor(a):  
Table B33(a): Incidence and mortality of testicular cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 732 . . 732  25 . . 25 
Crude rate 6.6 . . . .  0.2 . . . . 
ASR 6.7 . . . .  0.2 . . . . 
Risk to age 75 1 in 215 . . . .  1 in 6,334 . . . . 
Risk to age 85 1 in 208 . . . .  1 in 5,440 . . . . 
Mean age 36.2 . . . .  41.2 . . . . 
Estimated number for 2014, 2015 and 2016(c) 
2014 770 . . 770  5 . . 5 
2015 780 . . 780  5 . . 5 
2016 795 . . 795  5 . . 5 
 
  
Figure B33(a): Incidence and mortality ASRs(b,c) 
of testicular cancer, 1982–2016 
Figure B33(b): Incidence (2011) and mortality 
(2012) rates of testicular cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
 
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
2010
2012
2014
2016
0
1
2
3
4
5
6
7
8
Rate (per 100,000)
Incidence—males Mortality—males
0–4
10–14
20–24
30–34
40–44
50–54
60–64
70–74
80–84
0
2
4
6
8
10
12
14
16
18
Rate (per 100,000)
Incidence—males Mortality—males
  Cancer in Australia: an overview 2014 151 
Table B33(b): Survival and prevalence of testicular cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,441  1,441 
5-year prevalence 4,048  4,048 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 99.1 . . 99.1 
95% confidence interval 98.6–99.4 . . 98.6–99.4 
5-year relative survival at diagnosis (%) 97.9 . . 97.9 
95% confidence interval 97.2–98.4 . . 97.2–98.4 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 98.8 . . 98.8 
95% confidence interval 98.3–99.2 . . 98.3–99.2 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 99.7 . . 99.7 
95% confidence interval 99.3–100.1 . . 99.3–100.1 
 
 
Figure B33(c): Relative survival at diagnosis and 5-year conditional survival from testicular  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Thyroid cancer (C73) 
Risk factors(a):  
Table B34(a): Incidence and mortality of thyroid cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 580 1,518 2,098  67 59 126 
Crude rate 5.2 13.5 9.4  0.6 0.5 0.6 
ASR 5.1 13.1 9.1  0.6 0.4 0.5 
Risk to age 75 1 in 246 1 in 97 1 in 139  1 in 3,311 1 in 4,750 1 in 3,909 
Risk to age 85 1 in 190 1 in 85 1 in 117  1 in 1,215 1 in 1,801 1 in 1,469 
Mean age 54.4 50.9 51.9  71.7 77.1 74.3 
Estimated number for 2014, 2015 and 2016(c) 
2014 630 1,890 2,520  55 70 125 
2015 660 1,980 2,640  55 70 125 
2016 690 2,070 2,760  60 75 135 
 
  
Figure B34(a): Incidence and mortality ASRs(b,c) 
of thyroid cancer, 1982–2016 
Figure B34(b): Incidence (2011) and mortality 
(2012) rates of thyroid cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B34(b): Survival and prevalence of thyroid cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,030 2,956 3,986 
5-year prevalence 2,445 7,630 10,075 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 95.8 97.9 97.3 
95% confidence interval 94.8–96.7 97.4–98.2 96.9–97.7 
5-year relative survival at diagnosis (%) 92.1 97.0 95.8 
95% confidence interval 90.5–93.6 96.3–97.5 95.2–96.3 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 95.1 98.9 98.0 
95% confidence interval 93.8–96.4 98.5–99.4 97.6–98.5 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 96.0 99.4 98.6 
95% confidence interval 94.5–97.6 98.8–99.9 98.1–99.1 
 
 
Figure B34(c): Relative survival at diagnosis and 5-year conditional survival from thyroid  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Tongue cancer (C01–C02) 
Risk factors(a):  
Table B35(a): Incidence and mortality of tongue cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 474 215 689  128 82 210 
Crude rate 4.3 1.9 3.1  1.1 0.7 0.9 
ASR 4.0 1.7 2.8  1.1 0.6 0.8 
Risk to age 75 1 in 288 1 in 859 1 in 433  1 in 1,201 1 in 2,405 1 in 1,608 
Risk to age 85 1 in 210 1 in 474 1 in 293  1 in 646 1 in 1,201 1 in 850 
Mean age 62.2 65.4 63.1  68.9 71.2 69.8 
Estimated number for 2014, 2015 and 2016(c) 
2014 480 220 695  130 70 200 
2015 490 225 715  135 75 210 
2016 505 230 735  135 75 210 
 
  
Figure B35(a): Incidence and mortality ASRs(b,c) 
of tongue cancer, 1982–2016 
Figure B35(b): Incidence (2011) and mortality 
(2012) rates of tongue cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B35(b): Survival and prevalence of tongue cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 784 368 1,152 
5-year prevalence 1,706 828 2,534 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 82.0 84.3 82.8 
95% confidence interval 80.1–83.8 81.6–86.7 81.2–84.2 
5-year relative survival at diagnosis (%) 61.9 66.0 63.2 
95% confidence interval 59.4–64.4 62.3–69.5 61.2–65.2 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 72.8 74.6 73.4 
95% confidence interval 69.6–75.9 70.3–78.9 70.8–75.9 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 80.8 85.4 82.4 
95% confidence interval 77.2–84.5 80.9–89.8 79.6–85.2 
 
 
Figure B35(c): Relative survival at diagnosis and 5-year conditional survival from tongue  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Cancer of unknown primary site (C80)(a) 
Table B36(a): Incidence and mortality of cancer of unknown primary site 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 incidence/2012 mortality(b) 
Number 1,495 1,307 2,802  1,089 1,044 2,133 
Crude rate 13.4 11.6 12.5  9.6 9.1 9.4 
ASR 13.4 9.2 11.1  9.4 7.0 8.1 
Risk to age 75 1 in 142 1 in 216 1 in 172  1 in 221 1 in 311 1 in 259 
Risk to age 85 1 in 57 1 in 82 1 in 68  1 in 79 1 in 112 1 in 94 
Mean age 74.1 76.2 75.1  75.2 77.9 76.5 
Estimated number for 2014, 2015 and 2016(c) 
2014 1,430 1,210 2,640  1,160 1,180 2,340 
2015 1,430 1,190 2,620  1,140 1,190 2,330 
2016 1,430 1,180 2,610  1,130 1,200 2,330 
 
  
Figure B36(a): Incidence and mortality ASRs(b,c) 
of cancer of unknown primary site, 1982–2016 
Figure B36(b): Incidence (2011) and mortality 
(2012) rates for cancer of unknown primary site, 
by age group 
(a) For mortality data before 2008, the applicable codes are C77–C80. 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B36(b): Survival and prevalence of unknown primary site 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence 1,932 1,693 3,625 
5-year prevalence 3,034 2,515 5,549 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) 24.6 18.8 21.8 
95% confidence interval 23.5–25.7 17.7–19.8 21.1–22.6 
5-year relative survival at diagnosis (%) 16.3 11.2 13.8 
95% confidence interval 15.4–17.3 10.4–12.0 13.2–14.5 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 64.8 57.4 61.6 
95% confidence interval 61.3–68.2 53.0–61.7 58.9–64.2 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 84.8 83.7 84.3 
95% confidence interval 81.3–88.3 79.6–87.7 81.7–87.0 
 
 
Figure B36(c): Relative survival at diagnosis and 5-year conditional survival from unknown 
primary site, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
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Uterine cancer (C54–C55) 
Risk factor(a):  
Table B37(a): Incidence and mortality of uterine cancer 
 Incidence  Mortality 
 Males Females Persons  Males Females Persons 
2011 Incidence/2012 mortality(b) 
Number . . 2,238 2,238  . . 421 421 
Crude rate . . 19.9 . .  . . 3.7 . . 
ASR . . 17.4 . .  . . 3.1 . . 
Risk to age 75 . . 1 in 65 . .  . . 1 in 495 . . 
Risk to age 85 . . 1 in 47 . .  . . 1 in 232 . . 
Mean age . . 65.0 . .  . . 72.4 . . 
Estimated number for 2014, 2015 and 2016(c) 
2014 . . 2,490 2,490  . . 405 405 
2015 . . 2,570 2,570  . . 415 415 
2016 . . 2,650 2,650  . . 425 425 
 
  
Figure B37(a): Incidence and mortality ASRs(b,c) 
of uterine cancer, 1982–2016 
Figure B37(b): Incidence (2011) and mortality 
(2012) rates of uterine cancer, by age group 
(a) Based on IARC (2014) and WCRF & AICR (2007) (See Chapter 2). 
(b) The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the 
ACT (see Appendix F). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 
2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were 
directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population. 
(c) The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 
2002–2012 mortality data (see Appendix G). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. 
The estimates for males and females may not add to estimates for persons due to rounding. 
Sources: AIHW ACD 2011; AIHW NMD. 
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Table B37(b): Survival and prevalence of uterine cancer 
 Males Females Persons 
Prevalence as at the end of 2009(a) 
1-year prevalence . . 4,062 4,062 
5-year prevalence . . 10,099 10,099 
Relative survival in 2007–2011(b) 
1-year relative survival at diagnosis (%) . . 93.6 93.6 
95% confidence interval . . 93.0–94.1 93.0–94.1 
5-year relative survival at diagnosis (%) . . 82.5 82.5 
95% confidence interval . . 81.5–83.4 81.5–83.4 
5-year conditional relative survival for those already survived 1 year after diagnosis (%) . . 87.3 87.3 
95% confidence interval . . 86.4–88.2 86.4–88.2 
5-year conditional relative survival for those already survived 5 years after diagnosis (%) . . 95.4 95.4 
95% confidence interval . . 94.6–96.3 94.6–96.3 
 
 
Figure B37(c): Relative survival at diagnosis and 5-year conditional survival from uterine  
cancer, Australia, 2007–2011 
(a) Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases. 
(b) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
Source: AIHW ACD 2011. 
  
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
0
10
20
30
40
50
60
70
80
90
100
5-y ear conditional relativ e surv iv al
Relativ e surv iv al at diagnosis
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Years already survived
Years after diagnosis
Surv iv al (%)
 160 Cancer in Australia: an overview 2014 
Appendix C: Cancer incidence, mortality 
and survival for all cancer groupings 
Table C1: Incidence (2011), mortality (2012) and 5-year relative survival (2007–2011) by cancer type, 
persons, Australia 
 Incidence(a,b)  Mortality(c)  Survival(b,d) 
Cancer site/type (ICD-10 codes) Number ASR(e)  Number ASR(e)  RS (%)(f) 95% CI(g) 
Lip, oral cavity and pharynx 
Lip (C00) 912 3.8  12 0.1  93.4 92.1–94.7 
Tongue (C01–C02) 689 2.8  210 0.8  63.2 61.2–65.2 
Mouth (C03–C06) 571 2.3  119 0.5  59.6 57.3–61.8 
Salivary glands (C07–C08) 287 1.2  89 0.3  71.5 68.4–74.4 
Oropharynx (C09–C10) 456 1.9  144 0.6  61.3 58.9–63.6 
Nasopharynx (C11) 120 0.5  43 0.2  70.0 65.8–73.8 
Hypopharynx (C12–C13) 147 0.6  45 0.2  29.2 25.6–32.9 
Other sites in pharynx, etc. (C14) 83 0.3  85 0.3  33.1 27.8–38.6 
Digestive organs 
Oesophagus (C15) 1,395 5.6  1,203 4.7  17.5 16.5–18.6 
Stomach (C16) 2,093 8.5  1,143 4.5  27.0 26.0–28.0 
Small intestines (C17) 442 1.8  127 0.5  58.4 55.8–60.9 
Colorectal (C18–C20) 15,151 61.5  3,980 15.4  66.9 66.4–67.3 
Anus (C21) 369 1.5  71 0.3  64.5 61.7–67.3 
Liver (C22) 1,446 5.9  1,490 5.9  16.0 15.0–17.0 
Gallbladder and extrahepatic bile ducts  
(C23–C24) 771 3.1  254 1.0  18.5 17.1–20.1 
Pancreas (C25) 2,748 11.0  2,524 9.8  6.1 5.6–6.6 
Other digestive organs (C26) 185 0.7  1,240 4.7  12.1 9.4–15.1 
Respiratory system and intrathoracic organs 
Nose, sinuses, etc. (C30–C31) 177 0.7  30 0.1  56.5 52.5–60.4 
Larynx (C32) 590 2.4  208 0.8  62.3 60.2–64.4 
Lung (C33–C34) 10,511 42.5  8,137 31.8  14.3 14.0–14.7 
Other thoracic and respiratory organs (C37–C39) 102 0.4  58 0.2  52.8 47.6–57.8 
Bone (C40–C41) 229 1.0  112 0.5  66.9 63.6–70.1 
Skin 
Melanoma of the skin (C43) 11,570 48.0  1,515 5.9  90.4 90.0–90.8 
Non-melanoma of the skin (C44)(b) 769 3.1  521 1.9  71.5 69.4–73.5 
Mesothelial and soft tissue 
Mesothelioma (C45) 690 2.8  638 2.5  5.8 4.9–6.7 
Kaposi sarcoma (C46) 69 0.3  2 0.0  85.3 78.9–90.8 
Peritoneum (C48) 203 0.8  96 0.4  39.7 36.4–43.0 
 (continued) 
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 Incidence(a,b)  Mortality(c)  Survival(b,d) 
Cancer site/type (ICD-10 codes) Number ASR(e)  Number ASR(e)  RS (%)(f) 95% CI(g) 
Other soft tissue (C47, C49) 641 2.7  265 1.1  66.2 64.1–68.3 
Breast in females (C50) 14,465 116.0  2,795 20.6  89.6 89.3–89.9 
Female genital organs 
Vulva (C51) 318 1.3  90 0.3  74.2 71.1–77.2 
Vagina (C52) 77 0.3  20 0.1  46.7 40.6–52.7 
Cervix (C53) 801 3.5  226 0.9  71.9 70.2–73.4 
Uterus (C54–C55) 2,238 9.0  421 1.6  82.5 81.5–83.4 
Ovary (C56) 1,330 5.4  933 3.6  43.0 41.7–44.3 
Other female genital organs and placenta (C57–
C58) 155 0.6  44 0.2  58.0 53.1–62.7 
Male genital organs 
Penis (C60) 108 0.4  14 0.1  70.6 64.4–76.2 
Prostate (C61) 19,993 79.7  3,079 11.6  93.2 92.8–93.5 
Testis (C62) 732 3.3  25 0.1  97.9 97.2–98.4 
Other male genital organs (C63) 28 0.1  2 0.0  82.6 71.6–91.4 
Urinary tract 
Kidney (C64) 2,847 11.7  907 3.5  73.4 72.4–74.3 
Bladder (C67) 2,404 9.6  1,038 3.9  53.1 51.9–54.3 
Other urinary organs (C65–C66, C68) 455 1.8  195 0.8  42.6 40.1–45.2 
Eye, brain and other parts of the central nervous system 
Eye (C69) 266 1.1  30 0.1  79.1 76.3–81.8 
Brain (C71) 1,724 7.3  1,241 5.0  21.6 20.7–22.6 
Other central nervous system (C70, C72) 90 0.4  14 0.1  67.1 61.6–72.2 
Thyroid and other endocrine glands 
Thyroid (C73) 2,098 9.1  126 0.5  95.8 95.2–96.3 
Other endocrine glands (C74–C75) 99 0.4  51 0.2  60.1 55.4–64.5 
Blood and lymphatic system 
Hodgkin lymphoma (C81) 606 2.7  78 0.3  87.2 85.7–88.6 
Non-Hodgkin lymphoma (C82–C85) 4,631 19.1  1,402 5.4  72.1 71.3–72.8 
Immunoproliferative cancers (C88) 89 0.4  33 0.1  74.0 68.1–79.5 
Myeloma (C90) 1,533 6.2  834 3.2  44.8 43.4–46.2 
Acute lymphoblastic leukaemia (ALL)(C91.0) 353 1.6  111 0.5  71.0 68.6–73.3 
Chronic lymphocytic leukaemia (CLL)(C91.1) 1,174 4.7  342 1.3  76.7 75.1–78.2 
Other and unspecified lymphoid leukaemia 
(C91.2–C91.9) 126 0.5  45 0.2  82.3 77.6–86.5 
Acute myeloid leukaemia (AML)(C92.0, 
C92.3–C92.5, C93.0, C94.0, C94.2, C94.4, 
C94.5) 913 3.8  813 3.2  24.5 23.2–25.9 
Chronic myelogenous leukaemia (CML)(C92.1) 334 1.4  102 0.4  76.1 73.2–78.8 
Other and unspecified myeloid leukaemia (C92.2, 
C92.7, C92.9, C93.1–C93.9, C94.7) 315 1.3  95 0.4  35.9 32.7–39.2 
(continued) 
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 Incidence(a,b)  Mortality(c)  Survival(b,d) 
Cancer site/type (ICD-10 codes) Number ASR(e)  Number ASR(e)  RS (%)(f) 95% CI(g) 
Myeloproliferative cancers excluding CML (C94.1, 
C94.3, C96.2, D45, D47.1, D47.3) 651 2.7  161 0.6  76.4 74.5–78.2 
Myelodysplastic syndromes (D46) 1,309 5.2  424 1.6  38.0 36.4–39.6 
Other cancers of blood and lymphatic system 
(C95, C96.0, C96.1, C96.3–C96.9) 90 0.4  143 0.5  30.5 25.1–36.2 
Other 
Other and ill-defined sites (C76) 35 0.1  181 0.7  39.7 31.1–48.5 
Unknown primary site (C80)(h) 2,802 11.1  2,133 8.1  13.8 13.2–14.5 
Multiple primary (C97)(i) . . . .  506 1.9  . . . . 
All cancers combined (C00–C97(b, i), D45, D46, 
D47.1, D47.3) 118,711 484.1  43,039 166.8  66.7 66.5–66.8 
(a) The 2011 incidence data include estimates for NSW and the ACT. See Appendix F for more details. 
(b) For incidence and survival data, those C44 codes that indicate basal or squamous cell carcinoma of the skin are not included. 
(c) Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based 
on revised and preliminary versions, respectively, and are subject to further revision by the ABS. 
(d) Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does 
not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F). 
(e) The rates were age-standardised to the Australian population as at 30 June 2001 and expressed by 100,000 population. 
(f) RS = relative survival. 
(g) CI = confidence interval. 
(h) For mortality data before 2008, the applicable codes are C77–C80. 
(i) C97 is of relevance for mortality data only. 
Sources: ABS 2014b; AIHW ACD 2011; AIHW NMD. 
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Appendix D: Guide to online 
supplementary tables 
Additional tables are available as online Excel tables at <www.aihw.gov.au>. These tables 
contain detailed statistics, some of which are presented in summary form in the body of the 
report. Throughout the report, online additional tables are referred to with a prefix ‘D’; for 
example, ‘See online Table D3.1’. 
There are 9 Excel files, each representing a chapter (or appendix) from the report: 
• Chapter 2—Risk factors, early detection and prevention 
• Chapter 3—Incidence of cancer 
• Chapter 4—Hospitalisations and palliative care for cancer 
• Chapter 5—Survival after a diagnosis of cancer 
• Chapter 6—Prevalence of cancer 
• Chapter 7—Mortality from cancer 
• Chapter 8—Focus on key population groups 
• Chapter 9—International comparisons 
• Appendix B—Summary pages for selected cancers 
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Appendix E: Classifications 
Remoteness Areas 
The Remoteness Areas (RAs) divide Australia into broad geographic regions that share 
common characteristics of remoteness for statistical purposes. The Remoteness Structure 
divides each state and territory into several regions on the basis of their relative access to 
services. There are six classes of RA in the Remoteness Structure: Major cities, Inner regional, 
Outer regional, Remote Australia, Very remote and Migratory. The category Major cities includes 
Australia’s capital cities, except for Hobart and Darwin, which are classified as Inner 
regional. RAs are based on the Accessibility and Remoteness Index of Australia (ARIA) 
produced by the Australian Population and Migration Research Centre at the University of 
Adelaide (ABS 2014a). 
Each unit record in the ACD contains the 2006 Statistical Local Area (SLA) and 2011 
Statistical Area Level 2 (SA2) but not the RA. In order to calculate the cancer incidence rates 
by RA discussed in Chapter 8, a correspondence was used to map the 2006 SLA to the 2006 
RA (ABS 2011a). Similarly, the cancer mortality rates by RA in Chapter 8 were calculated by 
applying a correspondence from the 2011 SA2 to the 2011 RA (ABS 2012a). 
Index of Relative Socio-economic Disadvantage 
The Index of Relative Socio-economic Disadvantage (IRSD) is one of four Socio-Economic 
Indexes for Areas (SEIFAs) developed by the ABS (ABS 2011b). This index is based on factors 
such as average household income, education levels and unemployment rates. The IRSD is 
not a person-based measure; rather, it is an area-based measure of socioeconomic 
disadvantage in which small areas of Australia are classified on a continuum from 
disadvantaged to affluent. This information is used as a proxy for the socioeconomic 
disadvantage of people living in those areas and may not be correct for each person in that 
area. 
Socioeconomic disadvantage quintiles were assigned to cancer cases according to the IRSD of 
the Statistical Local Area of residence at the time of diagnosis, and to deaths according to the 
Statistical Area Level 2 (SA2) of residence at the time of death. 
In this report, the first socioeconomic status group (quintile 1) corresponds to geographical 
areas containing the 20% of the population with the greatest socioeconomic disadvantage 
according to the IRSD, and the fifth group (quintile 5) corresponds to the 20% of the 
population with the least socioeconomic disadvantage. 
International Classification of Diseases for Oncology 
Cancers were originally classified solely under the ICD classification system, based on 
topographic site and behaviour. However, during the creation of the Ninth Revision of the 
ICD in the late 1960s, working parties suggested creating a separate classification for cancers 
that included improved morphological information. The first edition of the ICD-O was 
subsequently released in 1976 and, in this classification, cancers were coded by both 
morphology (histology type and behaviour) and topography (site). 
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Since the first edition of the ICD-O, a number of revisions have been made, mainly in the 
area of lymphomas and leukaemias. The current edition, the Third Edition (ICD-O-3), was 
released in 2000 and is used by most state and territory cancer registries in Australia, as well 
as by the AIHW in regard to the ACD. 
International Statistical Classification of Diseases 
and Related Health Problems 
The International Statistical Classification of Diseases and Related Health Problems (ICD) is 
used to classify diseases and other health problems (including symptoms and injuries) in 
clinical and administrative records. The use of a standard classification system enables the 
storage and retrieval of diagnostic information for clinical and epidemiological purposes that 
is comparable between different service providers, across countries and over time. 
In 1903, Australia adopted the ICD to classify causes of death and it was fully phased in by 
1906. Since 1906, the ICD has been revised nine times in response to the recognition of new 
diseases (for example, Acquired Immunodeficiency Syndrome, or AIDS), increased 
knowledge of diseases, and changing terminology in the description of diseases. The version 
currently in use, the ICD-10 (WHO 1992), was endorsed by the 43rd World Health Assembly 
in May 1990 and officially came into use in WHO member states from 1994. 
International Statistical Classification of Diseases 
and Related Health Problems, Australian 
Modification 
The Australian modification of the ICD-10, referred to as the ICD-10-AM (NCCH 2010), is 
based on the ICD-10. The ICD-10 was modified for the Australian setting by the National 
Centre for Classification in Health, with assistance from clinicians and clinical coders. 
Despite the modifications, compatibility with the ICD-10 at the higher levels of the 
classification (that is, up to 4 character codes) has been maintained. The ICD-10-AM has been 
used to classify diagnoses in hospital records in all states and territories since 1999–00 
(AIHW 2000). 
Australian Classification of Health Interventions 
The current version of the ICD does not incorporate a classification system for coding health 
interventions (that is, procedures). In Australia, a health intervention classification system 
was designed to be implemented at the same time as the ICD-10-AM in July 1998. The 
system was based on the Medicare Benefits Schedule (MBS) coding system and originally 
called MBS-Extended. The name was changed to the Australian Classification of Health 
Interventions (ACHI) with the release of the Third Revision of the ICD-10-AM in July 2002 
(NCCH 2010). The ACHI and the ICD-10-AM are used together to classify morbidity, 
surgical procedures and other health interventions in Australian hospital records. 
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Appendix F: How estimated data in the 
2011 Australian Cancer Database were 
calculated 
The 2010 and 2011 incidence data for NSW and the ACT were not available for inclusion in 
the 2011 version of the ACD. The development of the new NSW Cancer Registries system 
has resulted in a delay in processing incidence data for 2010 onwards and therefore the most 
recent NSW data available for inclusion in the ACD are for 2009. Full details about this 
situation are given on the following web page: <http://www.cancerinstitute.org.au/data-
and-statistics/accessing-our-data/availability-of-nsw-central-cancer-registry-data>. 
As the coding of ACT cancer notifications is contracted to the NSW Cancer Registry, the 
most recent data available for the ACT are also for 2009. The 2010 and 2011 incidence data 
for NSW and the ACT were estimated by the AIHW (see below for detail of procedure). 
These estimates were combined with the actual data supplied by the other six state and 
territory cancer registries to form the 2011 ACD. 
Estimating 2010 and 2011 cancer incidence for NSW 
and the ACT, excluding prostate cancer 
To estimate 2010 and 2011 cancer incidence for NSW and the ACT, except for prostate cancer 
(detailed below), the most recent 10 years of incidence count data, from 2000 to 2009, were 
divided into time series, stratified as follows: 
• jurisdiction: NSW, ACT 
• sex: male, female 
• age group: 5-year age groups, 0–4, …, 80–84, and 85+ 
• 4-character ICD-O-3 topography code: C00.0, …, C80.9 
• 4-digit ICD-O-3 histology code: 8000, …, 9989. 
For each series, the following steps were undertaken to estimate cancer incidence: 
• The incidence numbers were divided by the sex- and age-specific mid-year populations 
to obtain the age-specific incidence rates from 2000 to 2009. 
• If any of the rates in the series was zero (0), the mean of the 10 rates was used as the 
estimate of the 2010 and 2011 rates. 
• If none of the rates were zero (0), least squares linear regression was used to find the 
straight line of best fit through the time series. 
• A 5% level of significance was used to test the hypothesis that the slope of the line was 
different from zero (0). 
• If the slope was not found to be significantly different from zero (0), the mean of the 
10 rates was used as the estimate of the 2010 and 2011 rates. 
• If the slope was found to be positive, the straight line of best fit was extrapolated to 
obtain the estimates of the 2010 and 2011 rates. 
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• If the slope was negative, the time series was fitted with a log-linear model (that is, the 
logs of the rates were fitted with a straight line) and the estimated rates for 2010 and 2011 
were found by extrapolating this line. 
• The estimated incidence rates for 2010 and 2011 were then multiplied by the Estimated 
Resident Populations for 2010 and 2011 to obtain the estimated incidence numbers. 
There were a small number of series that did not have a history of 10 years of incidence data. 
These were the non-melanoma skin cancers, for which the series begin at 2001, and the 
myelodysplastic and/or myeloproliferative cancers (histology codes 9950, 9960–9962 and 
9980–9989), for which the series begin at 2003. 
Estimating 2010 and 2011 prostate cancer incidence 
for NSW and the ACT 
Due to the effect of PSA testing, prostate cancer incidence rates have fluctuated considerably 
over time, making the above methodology unreliable for estimating the incidence of prostate 
cancer. Instead, the estimates of 2010 and 2011 prostate cancer incidence for NSW and the 
ACT were based on the actual data for 2010 and 2011 for the other six states and territories 
combined. 
Prostate cancer in those aged under 35 is very rare (just 12 cases in Australia in the period 
2000–2009). Therefore, the number of cases estimated for 2010 and 2011 for NSW and the 
ACT was zero (0). For those aged 35 and over, the time series for 2000–2009 of prostate 
cancer incidence counts were stratified as follows: 
• jurisdiction: NSW, ACT, SIX, where ‘SIX’ stands for the other six jurisdictions combined. 
Note that the series for SIX extends to 2011 
• age group: 5-year age groups, 35–39, …, 80–84, and 85+. 
The general procedure for calculating the estimates is illustrated by the following example 
for NSW and any fixed age group: 
• Convert the count data to age-specific incidence rates, using the relevant age- and 
jurisdiction-specific populations. 
• For each year from 2000 to 2009, divide the age-specific incidence rate for NSW by the 
corresponding age-specific incidence rate for SIX. 
• Calculate the average of the 10 ratios computed in the previous step. 
• Multiply the average ratio calculated in the previous step by the age-specific incidence 
rate for SIX in 2010, and likewise for 2011. This gives the estimated age-specific incidence 
rates for NSW for 2010 and 2011. 
• Convert these incidence rates to incidence counts by multiplying by the relevant 
populations. 
Estimating 2009 provisional death-certificate-only 
cases for NSW and the ACT 
The 2009 incidence data for NSW and the ACT provided to the AIHW excluded the 
provisional death-certificate-only cases. The reason the provisional death-certificate-only 
(DCO) cases were not available is explained on the following web page: 
<http://www.cancerinstitute.org.au/data-and-statistics/accessing-our-data/availability-of-
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nsw-central-cancer-registry-data>. The AIHW has estimated the number of provisional DCO 
cases in 2009 for each cancer, sex and age group based on the numbers observed for  
2004–2008. Overall, about 1.7% of NSW cases and 1.9% of ACT cases in 2009 are estimated 
provisional DCO cases. 
The procedure for estimating the number of provisional DCO cases for NSW and the ACT in 
2009 was as follows: 
• For each jurisdiction separately, divide the total number of provisional DCO cases in 
2004–2008 (years combined) by the total number of cases in 2004–2008 that were not 
provisional DCO. 
• Multiply the ratio computed in the previous step by the total number of cases in 2009 
that were not provisional DCO (which is simply the total number of cases supplied for 
2009). This gives the estimated total number of provisional DCO cases in 2009. 
• Allocate the estimated total computed in the previous step to each combination of sex, 
age group, topography code and histology code according to the same distribution as 
was observed in 2004–2008. 
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Appendix G: Methodology for cancer 
projections 
Incidence projections, excluding prostate cancer 
Estimates of incidence in 2012–2016 were calculated using the same approach as used to 
estimate 2010 and 2011 incidence for NSW and the ACT (Appendix F). Note the following:  
• Estimates were made for Australia as a whole, not for individual jurisdictions. 
• Instead of using the topography and histology codes to define the cancer groups, the 
‘Cancer in Australia’ reporting groups were used; that is, lip, tongue, mouth, and so on 
(see Appendix C). 
• The incidence estimates already made for 2009–2011 for NSW and the ACT were treated 
as real data for the purposes of estimating Australian incidence for 2012–2016. 
• The 10 years of incidence data used as the baseline were 2002–2011, except for the 
myelodysplastic and/or myeloproliferative cancers (histology codes 9950, 9960–9962 and 
9980–9989) for which there was only a 9-year series, 2003–2011. 
• For populations, the ABS preliminary Estimated Resident Populations were used for 
2012–2013, and the ABS population projection series 29(B) for 2014–2016 (ABS 2013). 
Estimating the incidence of prostate cancer 
As explained in Appendix F, MBS item 66655 (PSA test) enables testing activity for prostate 
cancer to be quantified. At the time this analysis was undertaken, the number of services of 
item 66655 was available up to and including June 2014. The total number of services for 
2014 was estimated using the following data: 
• year of test: 2004, …, 2013 
• MBS age group: 0–4, then 10-year age groups 5–14, …, 75–84, and 85+ 
• total number of services of item 66655 from January to June inclusive 
• total number of services of item 66655 from January to December inclusive. 
The ratio ‘January to June total’ divided by ‘January to December total’ was computed for 
each unit record in the above data set to form a time series from 2004 to 2013. The same 
approach as is described in Appendix F was used to estimate the ratios for 2014. Applying 
these ratios to the known ‘January to June’ totals for 2014 produced the estimated number of 
services for the whole of 2014. This number is used below. 
It has been noted previously that there is a positive correlation between the number of 
services of item 66655 and the incidence of prostate cancer (AIHW & AACR 2012). During 
the present analysis, it was noticed that this correlation is stronger when the reference year 
for the MBS data is 1 year behind that for the incidence data. This relationship is employed in 
the following explanation of how the estimates of prostate cancer incidence for 2012–2015 
were derived. The data used were: 
• year: 2003, …, 2011. Note that a 10-year time series would be preferable but 2002 cannot 
be used because the PSA data are incomplete for 2001 
• MBS age group: 0–4, then 10-year age groups 5–14, …, 75–84, and 85+ 
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• prostate cancer incidence: number of cases of prostate cancer in that year 
• PSA tests: number of services of item 66655 for the previous year, downloaded from 
<www.medicareaustralia.gov.au/statistics/mbs_item.shtml>. Thus, the years used for 
the PSA data were 2002–2010. 
The ratio ‘number of cases’ divided by ‘number of tests’ was computed for each stratum in 
the above data set to form a time series of ratios from 2003 to 2011. For each of these time 
series, the method explained in Appendix F was used to estimate the ratios for 2012–2015. 
The estimated incidence counts for 2012–2015 were then obtained by multiplying the 
estimated ratios for 2012–2015 by the number of services of item 66655 for 2011–2014, 
respectively. (Note that the method for estimating the number of services for 2014 is 
explained above.) 
The final step was to convert the estimated incidence counts for the 10-year MBS age groups 
to 5-year age groups, consistent with incidence data. The data used in this step were as 
follows: 
• year of diagnosis: 2002, …, 2011 
• MBS age group: 10-year age groups 5–14, …, 75–84 (0–4 and 85+ not required) 
• 5-year age group within the 10-year age group. For example, in the MBS age group 5–14 
there would be the ‘younger’ age group 5–9 and the ‘older’ age group 10–14 
• prostate cancer incidence: number of cases of prostate cancer in each 5-year age group. 
The ‘younger ratio’ is defined to be ‘number of cases of prostate cancer in younger age 
group’ divided by ‘number of cases of prostate cancer in corresponding 10-year age group’, 
and the ‘older ratio’ is the analogous ratio. Note that the older ratio can also be defined as 
1 minus the younger ratio. The following steps were then undertaken:  
• The younger ratios were computed for each stratum in the above data set to form a time 
series of ratios from 2002 to 2011. 
• If any of the ratios in the series was zero (0), the mean of the 10 ratios was used as the 
estimates of the 2012–2015 younger ratios. 
• If none of the ratios were zero (0), least squares linear regression was used to find the 
straight line of best fit through the time series. 
• A 5% level of significance was used to test the hypothesis that the slope of the line was 
different from zero (0). 
• If the slope was not found to be significantly different from zero (0), the mean of the 
ratios was used as the estimates of the 2012–2015 younger ratios. 
• If the slope was found to be significantly different from zero (0), note that the slope of 
the younger ratio time series will be equal in magnitude but of opposite sign to the slope 
of the older ratio time series. Therefore, one will have a negative slope and the other a 
positive slope. 
• The series with negative slope was fitted with a log-linear model and the estimated 
ratios for 2012–2015 were found by extrapolating this line. 
• For each 2012–2015 ratio that was determined above (by either the mean or a log-linear 
model), the other ratios for 2012–2015 were computed to be 1 minus the ratio 
determined. There is now a complete set of estimated younger and older ratios for  
2012–2015. 
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• The estimated number of cases for each 5-year age group for 2012–2015 were then 
obtained by multiplying the estimated number of cases for the corresponding 10-year 
age group by the appropriate ratio (that is, younger or older) for 2012–2015. 
At this point there are incidence estimates for each 5-year age group for each year from  
2012 to 2015. The estimates for 2016 cannot be obtained by the same method because there 
are no PSA data for 2015 yet. The 2016 prostate cancer incidence estimates were obtained by 
using the method explained in Appendix F on the 2006–2015 time series (treating the  
2012–2015 data as real). 
Mortality projections model 
Simple linear or log-linear ordinary least squares linear regression models of age-specific 
rates generally provide a good fit to the data while giving reasonably accurate predictions 
over a short to medium time span The accepted (conservative) approach among statisticians 
preparing projections of this nature is to assume a linear model for increasing rates, and a 
log-linear model for decreasing rates to prevent projecting incidence rates below zero (0). 
Where there is no significant trend, the mean rate over the most recent trend is used. 
Following this approach, a national model was developed for each cancer (by sex) using the 
following 4-step method:  
1. assess the historical trend in annual mortality for 1968 to 2012 
2. test the significance of the historical trend 
3. extrapolate that trend to predict annual rates for the years 2013 to 2024 
4. apply those rates to projected populations to derive projected mortality counts. 
These steps are described in more detail below. 
Step 1—assess the historical trend in annual mortality for 1968 to 2012 
Joinpoint analysis was used to assess the significance of the historical trend in annual cancer 
mortality for each cancer by sex and 5-year age group using national cancer mortality data. 
The most recent significant trend was used as the observation window from which to 
extrapolate the future trend (Step 2). The cancer- and sex-specific observation windows are 
presented in Table G1. 
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Table G1: Cancer- and sex-specific observation windows 
  Observation window (start year) 
 Cancer site/type Males Females Persons 
Acute myeloid leukaemia (AML) 1968 1993 1995 
Bladder 1985 1968 1985 
Brain 1996 1990 1994 
Breast 1968 1999 1968 
Cervix 2013 2004 2013 
Chronic lymphocytic leukaemia (CLL) 1994 1988 1994 
Chronic myelogenous leukaemia (CML) 1993 1992 1992 
Colorectal 1997 2006 2006 
Hodgkin lymphoma 1968 1968 1968 
Kidney 1999 1993 1995 
Liver 2004 1993 2004 
Lung 1994 1999 1989 
Melanoma of the skin 1987 1986 1998 
Mesothelioma 1997 1997 1997 
Non-Hodgkin lymphoma 1994 1998 2000 
Non-melanoma of the skin 1992 1994 1992 
Oesophagus 1998 1995 1997 
Ovary 2013 1994 2013 
Pancreas 1997 1968 1998 
Prostate 1993 2013 2013 
Stomach 1985 1993 1968 
Uterus 2013 1992 2013 
Anus 1968 1980 1982 
Gallbladder and extrahepatic bile ducts 2005 1997 2004 
Larynx 1991 1968 1991 
Lip 1979 1968 1984 
Mouth 1979 1991 1991 
Myeloma 1986 1988 1988 
Tongue 1987 1968 1988 
Unknown primary site 2005 1993 2006 
Leukaemias 1985 1992 1993 
Lymphomas 1997 1998 1997 
Bone 1968 1968 2000 
Step 2—test the significance of the historical trend 
An ordinary least squares (OLS) linear regression model was developed for each  
5-year age-sex group using national mortality rates from the most recent trend, as defined by 
the observation window derived in Step 1. The significance of each age-sex trend for each 
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cancer was tested, with one of three possible outcomes: significant increase, significant 
decrease, no significant trend. 
Step 3—extrapolate the trend to predict annual mortality rates for 2013 to 2016 
The historical trend within the observation window was extrapolated using one of three 
methods (see below), as determined by the outcome of the significance testing in Step 2: 
1. An OLS linear regression model was applied to significant increasing trends, so as not to 
overstate future mortality. 
2. An OLS linear regression model with log transformation (log-linear) was applied to 
significant decreasing trends, so as not to project mortality below zero (0). 
3. An intercept-only model (mean) was applied to non-significant trends. 
Step 4—derive projected mortality counts for 2013 to 2016 
The projected rates derived from Step 3 were applied to projected population data to 
estimate the future number of deaths for each cancer by age and sex. These projected counts 
were then summed to obtain the total number of deaths (and total ASR) for each cancer type. 
Assumptions 
It should be noted that there is a fundamental assumption in this approach that the factors 
that affect cancer mortality (for example, risk factors, cancer detection, and treatment) evolve 
in an approximately linear or log-linear way with time for each age group. This assumption 
should hold as long as there are no major quantitative changes in trends, as might occur, for 
example, from increased risk factors, or from treatment or screening breakthroughs. 
These assumptions are as follows: 
• Trends in age-sex-cancer specific mortality rates are the same across Australia. 
• The most recent trend will continue into the future. 
• The trend for the 5-year age group is representative of the trends of each single year of 
age within that group. 
• An appropriate model is chosen to describe both the historical data and expected future 
trend. 
• Projected populations, based on current trends in fertility, life expectancy at birth and 
net overseas migration, are indicative of future populations. 
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Appendix H: Statistical methods and 
technical notes 
Age-specific rates 
Age-specific rates provide information on the incidence of a particular event in an age group 
relative to the total number of people at risk of that event in the same age group. It is 
calculated by dividing the number of events occurring in each specified age group by the 
corresponding ‘at-risk’ population in the same age group and then multiplying the result by 
a constant (for example, 100,000) to derive the rate. Age-specific rates are often expressed per 
100,000 population. 
Age-standardised rates 
A crude rate provides information on the number of, for example, new cases of cancer or 
deaths from cancer by the population at risk in a specified period. No age adjustments are 
made when calculating a crude rate. Since the risk of cancer is heavily dependent on age, 
crude rates are not suitable for looking at trends or making comparisons across groups in 
cancer incidence and mortality. 
More meaningful comparisons can be made by the use of ASRs, with such rates adjusted for 
age in order to facilitate comparisons between populations that have different age 
structures—for example, between Indigenous people and other Australians. This 
standardisation process effectively removes the influence of age structure on the summary 
rate. 
There are two methods commonly used to adjust for age: direct and indirect standardisation. 
In this report, the direct standardisation approach presented by Jensen and colleagues (1991) 
is used. To age-standardise using the direct method, the first step is to obtain population 
numbers and numbers of cases (or deaths) in age ranges—typically 5-year age ranges. The 
next step is to multiply the age-specific population numbers for the standard population (in 
this case, the Australian population as at 30 June 2001) by the age-specific incidence rates (or 
death rates) for the population of interest (such as those in a certain socioeconomic status 
group or those who lived in Major cities). The next step is to sum across the age groups and 
divide this sum by the total of the standard population to give an ASR for the population of 
interest. Finally, this is expressed per 1,000 or 100,000 as appropriate. 
Mortality-to-incidence ratio 
Both mortality-to-incidence ratios (MIRs) and relative survival ratios can be used to estimate 
survival from a particular disease, such as cancer, for a population. Although MIRs are the 
cruder of the two ratios, they do not have the same comparability and interpretation 
problems associated with them when trying to make international comparisons (see Chapter 
9). Thus, the MIR is considered to be a better measure when comparing survival between 
countries. 
The MIR is the number of deaths in a given year divided by the number of new cases in the 
same year. It is a number between 0 and 1 although it can exceed 1 in certain circumstances. 
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The MIR is a measure of the fatality of the cancer in question: if no-one ever died of the 
cancer, the MIR would be 0; if everyone died on the same day they were diagnosed, the MIR 
would be 1. Low values of the MIR indicate longer survival while high values indicate 
shorter survival. In general, if the MIR is decreasing over time, we can conclude that survival 
is improving over time. 
The MIR gives a valid measure of the survival experience in a population only if: 
• cancer registration and death registration are complete or nearly so, and 
• the incidence rate, mortality rate and survival proportion are not undergoing rapid 
change. 
The incidence and mortality data used to calculate the MIRs in Chapter 9 were extracted 
from the 2012 GLOBOCAN database (Ferlay et al. 2013). 
Prevalence 
Limited-duration prevalence is expressed as N-year prevalence throughout this report. N-year 
prevalence on a given index date (31 December 2009)—where N is any number 1, 2, 3 and so 
on—is defined as the number of people alive at the end of that day who had been diagnosed 
with cancer in the past N years. For example: 
• 1-year prevalence is the number of living people who were diagnosed in the past year to 
31 December 2009 
• 5-year prevalence is the number of living people who were diagnosed in the past 5 years 
to 31 December 2009. This includes the people defined by 1-year prevalence. 
Note that prevalence is measured by the number of people diagnosed with cancer, not the 
number of cancer cases. An individual who was diagnosed with two separate cancers will 
contribute separately to the prevalence of each cancer. However, this individual will 
contribute only once to prevalence of all cancers combined. For this reason, the sum of 
prevalence for individual cancers will not equal the prevalence of all cancers combined. 
Prevalence can be expressed as a proportion of the total population as at the index date. In 
this report, the prevalence proportion is expressed per 10,000 population due to the relative 
size of the numerator and denominator. These are crude rates and have not been 
standardised. 
Differences in limited-duration prevalence are presented according to age in the report. Note 
that while age for survival and incidence statistics refers to the age at diagnosis, prevalence 
age refers to the age at the point in time from which prevalence was calculated, or 
31 December 2009 in this report. Therefore, a person diagnosed with cancer in 1982 when 
they turned 50 that year would be counted as age 75 in the prevalence statistics (as at the end 
of 2009). 
Relative survival 
Relative survival is a measure of the survival of people with cancer compared with that of 
the general population. It is the standard approach used by cancer registries to produce 
population-level survival statistics and is commonly used as it does not require information 
on cause of death. Instead, relative survival reflects the net survival (or excess mortality) 
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associated with cancer by adjusting the survival experience of those with cancer for the 
underlying mortality that they would have experienced in the general population. 
Relative survival is calculated by dividing observed survival by expected survival, where the 
numerator and denominator have been matched for age, sex and calendar year. 
Observed survival refers to the proportion of people alive for a given amount of time after a 
diagnosis of cancer; it is calculated from population-based cancer data. Expected survival 
refers to the proportion of people in the general population alive for a given amount of time 
and is calculated from life tables of the entire Australian population, assumed to be  
cancer free. 
A simplified example of how relative survival is interpreted is shown in Figure H1. Given 
that 6 in 10 people with cancer are alive 5 years after their diagnosis (observed survival of 
0.6) and that 9 in 10 people from the general population are alive after the same 5 years 
(expected survival of 0.9), the relative survival of people with cancer would be calculated as 
0.6 divided by 0.9, or 0.67. This means that individuals with cancer are 67% as likely to be 
alive for at least 5 years after their diagnosis compared with their counterparts in the general 
population. 
 
 
 
 
 
 
Figure H1: Simplified example of how relative survival is calculated 
All observed survival was calculated from data in the ACD. Expected survival was 
calculated from the life tables of the entire Australian population, as well as the Australian 
population stratified by remoteness area and socioeconomic status quintile. The Ederer II 
method was used to determine how long people in the general population are considered  
‘at risk’. It is the default approach, whereby matched people in the general population are 
considered to be at risk until the corresponding cancer patient dies or is censored (Ederer & 
Heise 1959). 
The survival analysis was based on records of primary and invasive cancers diagnosed 
between 1982 and 2011. At the time of analysis, these cases had been followed for deaths 
(from any cause) to the end of 2011. Therefore, the censor date selected for survival analysis 
was 31 December 2011. 
 
 
 
 
 
 
 
 
Observed survival = 0.6 
Individuals with cancer 
5 years after diagnosis 
General population 
Expected survival = 0.9 
Relative survival  
observed survival 
expected survival 
= 0.6 ÷ 0.9 
= 0.67 
= 67% 
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The period method was used to calculate the survival estimates in this report (Brenner & 
Gefeller 1996), in which estimates are based on the survival experience during a given at-risk 
or follow-up period. Time at risk is left truncated at the start of the period and right censored 
at the end so that anyone who is diagnosed before this period and whose survival experience 
overlaps with this period would be included in the analysis. 
The main follow-up period in this report was for the 5-year period 2007–2011, which was 
used for the most up-to-date estimates of survival by age, histological subtype, remoteness 
and socioeconomic status. 
Trends are also analysed by six periods of follow-up: 1982–1986, 1987–1991, 1992–1996,  
1997–2001, 2002–2006 and 2007–2011. In each period, 5 or 6 years of follow-up have been 
combined to draw upon a greater number of cases to produce more precise estimates. 
All survival statistics in this report were produced using SAS statistical software and 
calculated using software written by Dickman (2004). 
Calculation of conditional relative survival 
Conditional survival is the probability of surviving j more days, given that an individual has 
already survived i days. It was calculated using the formula 
𝑆(𝑗|𝑖) = 𝑆(𝑖 + 𝑗)
𝑆 (𝑖)  
where  
𝑆(𝑗|𝑖)  indicates the probability of surviving at least j more days given survival of at 
least i days 
𝑆(𝑖 + 𝑗)  indicates the probability of surviving at least i+j days   
𝑆 (𝑖)  indicates the probability of surviving at least i days. 
 
Confidence intervals for conditional survival were calculated using a variation of 
Greenwood’s (1926) formula for variance (Skuladottir & Olsen 2003): 
Var[𝑆(𝑗|𝑖)] = � 𝑑𝑘
𝑟𝑘(𝑟𝑘 − 𝑑𝑘)
𝑖+𝑗
𝑘=𝑖+1
 
where 
dk  is the number of deaths   
rk  is the number at risk during the kth interval. 
 
The 95% confidence intervals were constructed assuming that conditional survival estimates 
follow a normal distribution. 
Risk to age 75 or 85 
The calculations of risk shown in this report are measures that approximate the risk of 
developing (or dying from) cancer before the age of 75 or 85, assuming that the risks at the 
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time of estimation remained throughout life. It is based on a mathematical relationship with 
the cumulative rate. 
The cumulative rate is calculated by summing the age-specific rates for all specific age 
groups: 
 5 x (Sum of the age-specific rates) x 100 
100,000 
Cumulative rate = 
 
The factor of 5 is used to indicate the 5 years of life in each age group and the factor of 100 is 
used to present the result as a percentage. As age-specific rates are presented per 100,000 
population, the result is divided by 100,000 to return the age-specific rates to a division of 
cases by population. Cumulative risk is related to cumulative rate by the expression: 
 1 − e − rate 100   Cumulative risk      =  
 
Where the rate is expressed as a percentage. 
The risk is expressed as a ‘1 in n’ proportion by taking the inverse of the above formula: 
 
1 
1 − e − rate  100  (   ) 
 
n      =  
 
For example, if n equals 3, the risk of a person in the general population being diagnosed 
with cancer before the age of 75 (or 85) is 1 in 3. Note that these figures are average risks for 
the total Australian population. An individual person’s risk may be higher or lower than the 
estimated figures, depending on their particular risk factors. 
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Appendix I: Data sources 
To provide a comprehensive picture of national cancer statistics in this report, a range of data 
sources were used, including AIHW and external data sources. These data sources are 
described in this appendix. 
AIHW Australian Cancer Database 
All forms of cancer, except basal and squamous cell carcinomas of the skin, are notifiable 
diseases in each Australian state and territory. This means there is legislation in each 
jurisdiction that requires hospitals, pathology laboratories and various other institutions to 
report all cases of cancer to their central cancer registry. An agreed subset of the data 
collected by these cancer registries is supplied annually to the AIHW, where it is compiled 
into the ACD. The ACD currently contains data on all cases of cancer diagnosed from 1982 to 
2009 for all states and territories, and for 2010 and 2011 for all except NSW and the ACT (see 
Appendix F). 
Cancer reporting and registration is a dynamic process, and records in the state and territory 
cancer registries may be modified if new information is received. As a result, the number of 
cancer cases reported by the AIHW for any particular year may change slightly over time 
and may not always align with state and territory reporting for that same year. 
The Data Quality Statement for the ACD 2011 can be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/586979 >. 
AIHW National Mortality Database 
The AIHW National Mortality Database (NMD) contains information provided by the 
Registries of Births, Deaths and Marriages and the National Coronial Information System—
and coded by the ABS—for deaths from 1964 to 2012. Registration of deaths is the 
responsibility of the state and territory Registrars of Births, Deaths and Marriages. These 
data are then collated and coded by the ABS and are maintained at the AIHW in the NMD. 
In the NMD, both the year of occurrence of the death and the year in which the death was 
registered are provided. For the purposes of this report, actual mortality data are shown 
based on the year of occurrence of the death, except for the most recent year (namely 2012) 
where the number of people whose death was registered is used. Previous investigation has 
shown that the year of death and its registration coincide for the most part. However, in 
some instances, deaths at the end of each calendar year may not be registered until the 
following year. Thus, year of death information for the latest available year is generally an 
underestimate of the actual number of deaths that occurred in that year. 
In this report, deaths registered in 2010 and earlier are based on the final version of cause of 
death data; deaths registered in 2011 and 2012 are based on revised and preliminary 
versions, respectively, and are subject to further revision by the ABS. 
A statement on data quality relating to the AIHW NMD is available at the following ABS 
website: Quality declaration summary, Causes of death, 2012, ABS cat. no. 3303.0 
<http://www.abs.gov.au/AUSSTATS/abs@.nsf/Latestproducts/3303.0Quality%20Declarat
ion02012?opendocument&tabname=Notes&prodno=3303.0&issue=2012&num=&view=>. 
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AIHW National Hospital Morbidity Database 
The AIHW National Hospital Morbidity Database (NHMD) is compiled from data supplied 
by the state and territory health authorities. It is a collection of electronic confidentialised 
summary records for episodes of admitted patient care (separations or hospitalisations) in 
essentially all public and private hospitals in Australia. The data include demographic, 
administrative and clinical information, including patient diagnoses and other procedures. 
For more information on the specific use of the NHMD in cancer reporting, see Appendix J. 
The Data Quality Statement for the AIHW NHMD 2012–13 can be found at the AIHW 
website at <http://meteor.aihw.gov.au/content/index.phtml/itemId/568730>. 
National Death Index 
The National Death Index (NDI) is a database, housed at the AIHW, that contains records of 
all deaths occurring in Australia since 1980. The data are obtained from the Registrars of 
Births, Deaths and Marriages in each state and territory. The NDI is designed to facilitate the 
conduct of epidemiological studies and its use is strictly confined to medical research. 
Cancer incidence records from the ACD were linked to the NDI and used to calculate the 
survival and prevalence data presented in this report. 
The Data Quality Statement for the NDI can be found at the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/480010>. 
AIHW Disease Expenditure Database 
The AIHW Disease Expenditure Database contains estimates of expenditure by disease 
category, age group and sex for each of the following areas of expenditure: admitted patient 
hospital services, out-of-hospital medical services, prescription pharmaceuticals, 
optometrical and dental services, community mental health services and public health cancer 
screening. 
For more information on the AIHW Disease Expenditure Database, see Health system 
expenditures on cancer and other neoplasms in Australia: 2008–09 (AIHW 2013b). 
The Data Quality Statement for the Disease Expenditure Database can be found on the 
AIHW website at <http://meteor.aihw.gov.au/content/index.phtml/itemId/512599>. 
BreastScreen Australia Program data 
Data from BreastScreen Australia were used in Chapter 2 to indicate the number of women 
who had had a screening mammogram and the number of women with invasive breast 
cancer and DCIS (detected through BreastScreen Australia). These data are supplied 
annually to the AIHW by state and territory BreastScreen programs for monitoring purposes. 
They are compiled by the AIHW and reports are produced annually (AIHW 2014b). 
The latest Data Quality Statement for the BreastScreen Australia data can be found at the 
AIHW website at <http://meteor.aihw.gov.au/content/index.phtml/itemId/560075>. 
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National Bowel Cancer Screening Program data 
Data from the National Bowel Cancer Screening Register were used in Chapter 2 to indicate 
the number of persons who participated in the National Bowel Cancer Screening Program as 
well as to indicate the number of bowel cancers detected through the program. These data 
are supplied twice a year to the AIHW by the Department of Human Services (formerly 
Medicare Australia) for monitoring purposes. They are compiled by the AIHW and reports 
are produced annually (AIHW 2014c). 
The latest Data Quality Statement for the National Bowel Cancer Screening Program data can 
be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/569056>. 
National Cervical Screening Program data 
Data from the National Cervical Screening Program were used in Chapter 2 to indicate the 
number of women who participated in the program, and the number of women with a 
high-grade cervical abnormality detected through the program. These data are supplied 
annually to the AIHW by state and territory cervical screening programs for monitoring 
purposes. They are compiled by the AIHW and reports are produced annually 
(AIHW 2014b). 
The latest Data Quality Statement for the National Cervical Screening Program data can be 
found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/539449>. 
GLOBOCAN 
The GLOBOCAN database, prepared by the IARC, contains cancer incidence and mortality 
data from cancer registries around the world (Ferlay et al. 2013). The IARC uses these data to 
produce estimates for a ‘common year’. The most recent GLOBOCAN estimates are for 2012 
and are based on incidence data from 3 to 5 years earlier. 
Population data  
Throughout this report, population data were used to derive rates of, for example, cancer 
incidence and mortality. The population data were sourced from the ABS using the most  
up-to-date estimates available at the time of analysis. 
To derive their estimates of the resident populations, the ABS uses the 5-yearly Census of 
Population and Housing data and adjusts it as follows: 
• All respondents in the Census are placed in their state or territory, Statistical Local Area 
and postcode of usual residence; overseas visitors are excluded. 
• An adjustment is made for persons missed in the Census. 
• Australians temporarily overseas on Census night are added to the usual residence 
Census count. 
Estimated resident populations are then updated each year from the Census data, using 
indicators of population change such as births, deaths and net migration. More information 
is available from the ABS website at <www.abs.gov.au>. 
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For the Indigenous comparisons in this report (Chapter 8), the most recently released 
Indigenous experimental estimated resident populations as released by the ABS were used 
(ABS 2014c). Those estimates were based on the 2011 Census of Population and Housing. 
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Appendix J: Definition of cancer-related 
hospitalisations 
Data on hospitalisations include principal diagnosis—this is the reason determined to be 
chiefly responsible for the person’s hospitalisation. The principal diagnosis recorded is 
usually a disease (or health-related condition), but can also be a specific treatment of an 
already diagnosed condition, such as chemotherapy for cancer. These treatments are usually 
coded using Z-codes defined in the ICD-10-AM Chapter 21 ‘Factors influencing health status 
and contact with health services’ (NCCH 2010). 
Due to the method in which the principal diagnosis for hospitalisations of cancer patients is 
coded, it is insufficient to simply select those hospitalisations for which cancer was recorded 
as the principal diagnosis—it must also include those hospitalisations where a treatment 
relating to cancer was recorded as the principal diagnosis. 
Some cancer-related interventions recorded as a principal diagnosis (such as Z08 ‘Follow-up 
examination after treatment for malignant neoplasms) are specific only to the investigation 
for, or treatment of, cancer. However, some (such as Z51.0 ‘Radiotherapy session’) are not 
entirely cancer specific; that is, they may be provided to a small number of non-cancer 
patients, although the majority of these interventions are cancer related. Some (such as Z45.1 
‘Adjustment and management of infusion pump’ and Z45.2 ‘Adjustment and management of 
vascular access device’) apply to a number of disease types. 
For some cancer-related interventions (such as same-day chemotherapy), the Australian 
Coding Standards (NCCH 2010) stipulate that the principal diagnosis is to be coded to reflect 
the treatment, with the type(s) of cancer listed as an additional diagnosis. This standard does 
not apply, however, to all interventions that may be cancer related. Thus, for the purposes of 
examining the number of admitted patient hospitalisations that arose due to invasive cancer, 
or that were directly related to the investigation, treatment or care for cancer, ‘cancer-related 
hospitalisations’ were identified in this report as those hospitalisations in which:  
• the principal diagnosis was cancer (ICD-10 AM codes C00–C97, D45, D46, D47.1 and 
D47.3)  
or  
• the principal diagnosis was related to health services or treatment for cancer. This 
includes a principal diagnosis of one of the following cancer-specific ICD-10-AM 
Z codes: 
– Z08 Follow-up examination after treatment for malignant neoplasms  
– Z12 Special screening examination for neoplasm  
– Z40.0 Prophylactic surgery for risk-factors related to malignant neoplasms 
– Z51.0 Radiotherapy session  
– Z51.1 Pharmacotherapy session for neoplasm  
– Z54.1 Convalescence following radiotherapy  
– Z54.2 Convalescence following chemotherapy  
– Z80 Family history of malignant neoplasm  
– Z85 Personal history of malignant neoplasm 
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or  
• a principal diagnosis of one of the following non-cancer specific ICD-10-AM Z codes, 
with an additional diagnosis of cancer (ICD-10 AM codes C00–C97, D45, D46, D47.1 and 
D47.3): 
– Z29.1 Prophylactic immunotherapy  
– Z29.2 Other prophylactic chemotherapy  
– Z42.0 Follow-up care involving plastic surgery of head and neck  
– Z42.1 Follow-up care involving plastic surgery of breast  
– Z45.1 Adjustment and management of infusion pump  
– Z45.2 Adjustment and management of vascular access device. 
Note that, based on the definition of cancer-related hospitalisations, data presented in this 
report may have included a small number of some treatments and services provided to 
non-cancer patients. However, the proportion of these over counts is less than 0.01% of the 
data presented in this report. 
Identifying palliative care separations 
Information on the provision of palliative care is captured by two NHMD data items: ‘Care 
type’ and ‘Diagnoses’. If either (or both) has a code of Palliative care, that separation is 
included as being in scope. 
A ‘Care type’ is assigned for each admitted patient separation, with any one separation equal 
to either a total hospital stay (from admission to discharge, transfer or death) or to a portion 
of a hospital stay starting or ending in a change of care type (for example, from a ‘Care type’ 
of acute care to a ‘Care type’ of palliative care). 
In addition, information on palliative care is also recorded in the NHMD under the 
‘Diagnosis’ data items. While diagnosis codes usually describe a disease, injury or poisoning, 
they can also be used in certain instances to indicate the specific care or service provided for 
a current condition or other reasons for hospitalisation. This is the case when Palliative care is 
recorded as a diagnosis code ‘Z51.5’. 
For the purpose of this report, a palliative care separation is defined as a separation for 
which palliation was a substantial component of the care provided, and those in which the 
principal clinical intent of the care was palliation during part or all of the separation, as 
evidenced by a code of Palliative care for the ‘Care type’ and/or diagnosis data items in the 
NHMD. Further information on this can be found in the AIHW report Palliative care services 
in Australia 2014 (AIHW 2014d).  
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Glossary 
Aboriginal or Torres Strait Islander: A person of Aboriginal and/or Torres Strait Islander 
descent who identifies as an Aboriginal and/or Torres Strait Islander. See also Indigenous. 
Additional diagnosis: A condition or complaint either coexisting with the principal 
diagnosis or arising during the episode of care. 
Administrative databases: Observations about events that are routinely recorded or 
required by law to be recorded. Such events include births, deaths, hospital separations and 
cancer incidence. Administrative databases include the Australian Cancer Database, the 
National Mortality Database and the National Hospital Morbidity Database. 
Admitted patient: A person who undergoes a hospital’s formal admission process to receive 
treatment and/or care. Such treatment or care can occur in hospital and/or in the person’s 
home (as a ‘hospital-in-home’ patient). 
Age-specific rate: A rate for a specific age group. The numerator and denominator relate to 
the same age group. 
Age-standardisation: A method of removing the influence of age when comparing 
populations with different age structures. This is usually necessary because the rates of many 
diseases vary strongly (usually increasing) with age. The age structures of the different 
populations are converted to the same ‘standard’ structure; then the disease rates that would 
have occurred with that structure are calculated and compared. 
Asymptomatic: Without symptoms. 
Average length of stay: The average (mean) number of patient days for admitted patient 
episodes. Patients admitted and separated on the same date are allocated a length of stay of 
1 day. 
Benign: Term that describes non-cancerous tumours that may grow larger but do not spread 
to other parts of the body. 
Body Mass Index: The most commonly used method of assessing whether a person is 
normal weight, underweight, overweight or obese. It is calculated by dividing the person’s 
weight (in kilograms) by their height (in metres) squared; that is, kg/m2. For both men and 
women, underweight is a BMI below 18.5, acceptable weight is from 18.5 to less than 25, 
overweight is 25 and above (includes obese), and obese is 30 and over. 
Burden of disease and injury: Term referring to the quantified impact of a disease or injury 
on an individual or population, using the disability-adjusted life year measure. 
Cancer (malignant neoplasm): A large range of diseases in which some of the body’s cells 
become defective, begin to multiply out of control, can invade and damage the area around 
them, and can also spread to other parts of the body to cause further damage. 
Carcinoma: A cancer that begins in the lining layer (epithelial cells) of organs such as the 
ovaries. 
Chemotherapy: The use of drugs (chemicals) to prevent or treat disease, with the term being 
applied for treatment of cancer rather than for other uses. 
Cohort method: A method of calculating survival that is based on a cohort of people 
diagnosed with cancer in a previous time period and followed over time. 
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Colonoscopy: A procedure to examine the bowel using a special scope (colonoscope) usually 
carried out in a hospital or day clinic. 
Colorectal (bowel) cancer: Comprises cancer of the colon, cancer of the rectosigmoid 
junction and cancer of the rectum (ICD-10 codes C18–C20), collectively known as colorectal 
cancer. 
Confidence interval (CI): A statistical term describing a range (interval) of values within 
which we can be ‘confident’ that the true value lies, usually because it has a 95% or higher 
chance of doing so. 
Crude rate: The number of events in a given period divided by the size of the population at 
risk in a specified time period. 
Death due to cancer: A death where the underlying cause is indicated as cancer. 
Ductal carcinoma in situ (DCIS): A non-invasive tumour of the mammary gland (breast) 
arising from cells lining the ducts. 
Expected survival: A measure of survival that reflects the proportion of people in the general 
population alive for a given amount of time. Expected survival estimates are crude estimates 
calculated from life tables of the general population by age, sex and calendar year. 
FOBT (faecal occult blood test): A test used to detect tiny traces of blood in a person’s faeces 
that may be a sign of bowel cancer. The immunochemical FOBT is a central part of 
Australia’s National Bowel Cancer Screening Program. 
Heath system expenditure: Includes expenditure on health goods and services (for example, 
medications, aids and appliances, medical treatment, public health, research, collectively 
termed current expenditure) and on health-related investment (often referred to as capital 
expenditure). 
Histology: The microscopic characteristics of cellular structure and composition of tissue. 
Hospitalisation: See Separation. 
Incidence: The number of new cases (of an illness or event, and so on) in a given period. 
Indigenous: A person of Aboriginal and/or Torres Strait Islander descent who identifies as 
an Aboriginal and/or Torres Strait Islander. See also Aboriginal or Torres Strait Islander. 
International Statistical Classification of Diseases and Related Health Problems: The 
World Health Organization’s internationally accepted classification of death and disease. The 
Tenth Revision (ICD-10) is currently in use. The ICD-10-AM is the Australian modification of 
the ICD-10; it is used for diagnoses and procedures recorded for patients admitted to 
hospitals (see Appendix E). 
Invasive: See Malignant. 
Length of stay: Duration of hospital stay, calculated by subtracting the date the patient was 
admitted from the day of separation. All leave days, including the day the patient went on 
leave, are excluded. A same-day patient is allocated a length of stay of 1 day. 
Life tables: Tables of annual probabilities of death in the general population. 
Limited-duration prevalence: The number of people alive at a specific time who have been 
diagnosed with cancer over a specified period (such as the previous 5 or 25 years). 
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Malignant: A tumour with the capacity to spread to surrounding tissue or to other sites in 
the body. See Invasive. 
Mammogram: A radiographic depiction of the breast. 
Metastasis: See Secondary cancer. 
Mortality due to cancer: The number of deaths that occurred during a specified period 
(usually a year) for which the underlying cause of death was recorded as cancer. 
Mortality-to-incidence ratio: The ratio of the age-standardised mortality rate for cancer to 
the age-standardised incidence rate for cancer. 
Neoplasm: An abnormal (‘neo’ = new) growth of tissue. Can be benign (not a cancer) or 
malignant (a cancer) (see also Invasive). Also known as a tumour. 
New cancer case: See Incidence. 
Non-Indigenous: People who have declared that they are not of Aboriginal or Torres Strait 
Islander descent. 
Observed survival: A measure of survival that reflects the proportion of people alive for a 
given amount of time after a diagnosis of cancer. Observed survival estimates are crude 
estimates calculated from population-based cancer data. 
Other Australians: Includes people who have declared that they are not of Aboriginal or 
Torres Strait Islander descent as well as those who have not stated their Indigenous status. 
Overnight patient: An admitted patient who receives hospital treatment for a minimum of  
1 night (that is, is admitted to, and separates from, hospital on different dates). 
Palliative care hospitalisations: For the purposes of this report, those hospitalisations for 
which palliative care was a substantial component of the care provided. Such separations 
were identified as those for which the principal clinical intent of the care was palliation 
during part or all of the separation, as evidenced by a code of palliative care for the ‘Care type’ 
and/or ‘Diagnosis’ data items in the National Hospital Morbidity Database. 
Pap smear (Pap test): Papanicolaou smear, a procedure to detect cancer and pre-cancerous 
conditions of the female genital tract. 
Patient days: The number of full or partial days of stay for patients who were admitted for 
an episode of care and who underwent separation during the reporting period. A patient who 
is admitted and separated on the same day is allocated 1 patient day. 
Period method: A method of calculating survival that is based on the survival experience 
during a recent at-risk or follow-up time period. 
Population estimates: Official population numbers compiled by the Australian Bureau of 
Statistics at both state and territory and Statistical Local Area levels by age and sex, as at  
30 June each year. These estimates allow comparisons to be made between geographical 
areas of differing population sizes and age structures (see Appendix E). 
Prevalence (or complete prevalence): The total number of people alive at a specific date who 
have ever been diagnosed with a particular disease such as cancer. 
Primary cancer: A tumour that is at the site where it first formed (see also Secondary cancer). 
Principal diagnosis: The diagnosis listed in hospital records to describe the problem that 
was chiefly responsible for the patient’s episode of care in hospital. 
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Procedure: A clinical intervention that is surgical in nature, carries a procedural risk, carries 
an anaesthetic risk, requires specialised training and/or requires special facilities or 
equipment available only in the acute care setting. 
Projection: Longer-term extrapolation of recent trend data using unknown parameters such 
as expected future populations. 
Relative survival: The ratio of observed survival of a group of persons diagnosed with cancer 
to expected survival of those in the corresponding general population after a specified interval 
following diagnosis (such as 5 or 10 years). 
Risk factor: Any factor that represents a greater risk of a health disorder or other unwanted 
condition or event. Some risk factors are regarded as causes of disease, others are not 
necessarily so. Along with their opposites, namely protective factors, risk factors are known 
as ‘determinants’. 
Same-day patient: A patient who is admitted to, and separates from, hospital on the same 
date. 
Secondary site cancer: A tumour that originated from a cancer elsewhere in the body. Also 
referred to as a metastasis. 
Separation: An episode of care for an admitted patient which may include a total hospital stay 
(from admission to discharge, transfer or death) or a portion of a hospital stay that begins or 
ends in a change of type of care (for example, from acute to rehabilitation). In this report, 
separations are also referred to as hospitalisations. 
Stage: The extent of a cancer in the body. Staging is usually based on the size of the tumour, 
whether lymph nodes contain cancer, and whether the cancer has spread from the original 
site to other parts of the body. 
Statistical significance: An indication from a statistical test that an observed difference or 
association may be significant or ‘real’ because it is unlikely to be due just to chance. A 
statistical result is usually said to be ‘significant’ if it would occur by chance only once in 20 
times or less often (see Appendix B for more information about statistical significance). 
Survival: A general term indicating the probability of being alive for a given amount time 
after a particular event, such as a diagnosis of cancer. 
Symptom: Any indication of a disorder that is apparent to the person affected. 
Tumour: An abnormal growth of tissue. Can be benign (not a cancer) or malignant (a cancer). 
Underlying cause of death: The disease or injury that initiated the sequence of events 
leading directly to death. 
Valid FOBT test result: Faecal occult blood test result that is either positive or negative. 
Inconclusive results are excluded from analysis. 
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Cancer in Australia: an overview 2014 presents the latest 
available information on national population screening 
programs, cancer incidence, hospitalisations, survival, 
prevalence and mortality. It is estimated that the most 
commonly diagnosed cancers in 2014 will be prostate 
cancer, colorectal cancer and breast cancer (excluding basal 
and squamous cell carcinoma of the skin, as these cancers 
are not notifiable diseases in Australia). For all cancers 
combined, the incidence rate is expected to increase by 
22% from 1982 to 2014, but the mortality rate is estimated 
to decrease by 20%. Cancer survival has improved over 
time. Cancer outcomes differ by Aboriginal and Torres Strait 
Islander status and remoteness area.
